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ii. Abstract 
Identifying the sites and mechanisms involved in haematopoietic stem cells 
(HSCs) during development would improve our understanding of how to induce 
HSCs from alternative sources like embryonic stem cells, while offering insight into 
pathways involved in HSC-related diseases such as leukaemia. Adult-type HSC, or 
long-term reconstituting HSCs (LTR-HSCs), are widely defined as cells capable of 
reconstituting the entire haematopoietic system of a lethally irradiated adult recipient. 
The first LTR-HSCs emerge and expand in the aorta-gonad-mesonephros (AGM) 
region of the mid-gestation mouse embryo. Recently, the development of a novel 
reaggregate culture system has provided a valuable tool to identify key cell 
populations involved in LTR-HSC development. This system allows the mechanical 
dissociation of the E11.5 AGM region prior to culture whilst maintaining its ability 
to autonomously expand LTR-HSCs. Here, I show that reaggregate LTR-HSCs are 
CD45+Sca1+c-kit+CD31med and that IL-3, SCF, and Flt3l are required in order to 
achieve an optimal 150 fold LTR-HSC expansion. I also characterise the pattern of 
Runx1 expression in the adult and E11.5 AGM region of our novel Runx1EGFP 
reporter mouse and identify a population of EGFP+CD45-VE-cadherin- cells in the 
E11.5 AGM region that disappears during reaggregate culture. Finally, using the 
E11.5 AGM reaggregate culture, I show that while uro-genital ridges are potentially 
required for optimal LTR-HSC expansion, most LTR-HSCs are derived from the 
dorsal aorta (Ao) region, and that the dorsal aspect of the dorsal aorta (AoD) can 
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1. Introduction 
 
1.1. General Introduction 
1.1.1. On stem cells… 
The future of regenerative medicine, which promises treatments for complex 
diseases such as neurological disorders or cancers, relies mainly on the advances of 
stem cell research. A stem cell is widely defined as an undifferentiated cell that 
undergoes the processes of self-renewal and differentiation into mature cell types.  
Embryonic stem (ES) cells, isolated from the inner cell mass of the pre-
implantation embryo, are the only pluripotent cells with the capacity for in vivo and 
in vitro differentiation into cell lineages from all three germ layers (endoderm, 
mesoderm and, ectoderm)(Beddington and Robertson, 1989; Bradley et al., 1984).  
Undifferentiated ES cell lines can be maintained and expanded when either co-
cultured on fibroblast feeder cells (Evans and Kaufman, 1981; Martin, 1981) or in 
the presence of leukaemia inhibitory factor and bone morphogenic protein 4 (Smith 
et al., 1988; Williams et al., 1988; Ying et al., 2003).  
During embryonic development, and in the adult organism, tissue specific 
stem cells can be isolated (Figure 1.1). Contrary to ES cells, tissue specific stem cells 
can only give rise to cell lineages that are from the same germ layer and sometimes 
from the same tissue only.  
 
1.1.2. On haematopoietic stem cells… 
 Elucidating the mechanisms by which haematopoietic stem cells (HSC) can 
be generated is of major scientific interest as it will improve our understanding of 
how to induce HSCs from alternative sources such as ES cells, while offering 
important insights into pathways involved in HSC-related diseases such as 
leukaemia. Because it is believed that long-term repopulating haematopoietic stem  
Figure 1.1: Sources and types of stem cells during development.
ES cells are the most primitive stem cells that are isolated from the inner cell mass of pre-
implantation embryos and can give rise to all embryonic and extra-embryonic lineages.
Further along development, only tissue specific stem cells are present in the organism and
they can be isolated from most tissues of the endodermal, mesodermal, and ectodermal
germ layers.
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cells (LTR-HSCs) arise de novo during ontogeny only, the study of embryonic LTR-
HSCs is under a great scrutiny. The study of embryonic LTR-HSCs is a challenge 
because, contrary to the adult, embryonic haematopoiesis involves a complex spatial 
and temporal chain of events which are characterised by successive appearance of 
haematopoietic progenitors in extra-embryonic tissues followed by the emergence of 
LTR-HSCs in intra-embryonic organs (Cumano et al., 1996; Cumano et al., 2001; 
Gekas et al., 2005; Medvinsky and Dzierzak, 1996; Moore and Metcalf, 1970; 
Muller et al., 1994; Ottersbach and Dzierzak, 2005; Yoder and Hiatt, 1997; Yoder et 
al., 1997b). This is further complicated by the possible existence of two 
ontogenetically distinct haematopoietic hierarchies during development: the 
primitive (embryonic) and definitive (adult) haematopoietic hierarchies. 
 In this introduction, current knowledge and issues associated with the 
ontogeny of LTR-HSCs in the murine embryo are discussed. The complex spatial 
and temporal emergence of the primitive and definitive waves of haematopoiesis will 
be extensively described with a particular focus on theories about the ancestry of 
LTR-HSC and their supporting evidence. After a brief overview on molecular 
mechanisms involved in LTR-HSCs biology, the essential role of the transcription 
factor Runx1 in haematopoiesis will be discussed.  
 
1.2. The adult haematopoietic hierarchy 
 The adult (definitive) haematopoietic hierarchy is represented by the steady-
state haematopoiesis that exists within the organism1. Haematopoiesis is the process 
by which a small number of LTR-HSCs, located in the bone marrow, is able to 
support and provide sufficient progeny that will progressively restrict differentiation 
potential and differentiate into mature blood cells (Figure 1.2).  
 
                                                 
1 Unless stated otherwise, all discussions are presented in the context of the murine organism.  
Figure 1.2: Schematic representation of the definitive haematopoietic hierarchy.
The definitive haematopoietic hierarchy is described by the LTR-HSCs compartment giving
rise to progeny that sequentially loose self-renewal capacity (STR-HSC) and commit to
specific lineages (CMP and CLP) before undergoing terminal differentiation and giving rise
to mature blood cells.
LTR-HSC: long-term repopulating haematopoietic stem cell; STR-HSC: short term
repopulating haematopoietic stem cell; MPP: multipotent progenitor; CLP: common
lymphoid progenitor; CMP: common myeloid progenitor; MEP: common erythroid
progenitor; GMP: granulocyte macrophage progenitor.
(adapted from Larsson and Karlsson, 2005)
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1.2.1. The haematopoietic stem cell compartment 
 HSCs are the cells capable of simultaneously self-renewing and 
differentiating into more committed progeny. These cells subsequently proliferate 
and further differentiate into all blood cell types. In the adult bone marrow, there are 
two types of multipotent2 cells with the capacity to home and engraft in adult 
haematopoietic organs upon transplantation, the LTR-HSCs and the short-term 
repopulating (STR) progenitors. STR progenitors lack life-long self-renewal capacity 
and thus can only provide haematopoietic reconstitution for a limited period (Zhao et 
al., 2000; Zhong et al., 1996). LTR-HSCs however, are capable of undergoing life-
long self-renewal and robustly support haematopoiesis throughout life. 
Experimentally, LTR-HSCs are detected and assessed functionally by the in vivo 
competitive long-term repopulation assay and are defined by their ability to 
repopulate the haematopoietic system of a lethally irradiated adult recipient mouse 
upon serial transplantations (Szilvassy et al., 1990).  
 
1.2.1.1. The bone marrow HSC identity 
 The bone marrow of an adult mouse (CBA x C57/Bl6) contains LTR-HSC at 
a frequency of 1 in 10, 000 nucleated cells (Kumaravelu et al., 2002). Flow 
cytometry have allowed the purification of bone marrow LTR-HSCs: they can either 
be identified by their ability to efflux the nuclear dye Hoechst 33342 (Goodell et al., 
1996) or by a complex immunophenotype based on the absent/low expression of cell 
surface proteins expressed on mature cell lineages (Lin-)(includes Ter119, Mac-1, 
Gr-1, B220, CD3ε, CD4 and CD8 lineage markers) and the expression of Sca1, c-kit, 
Thy1.1 and CD34 (Berman and Basch, 1985; Ikuta and Weissman, 1992; Osawa et 
al., 1996; Spangrude et al., 1988). An LTR-HSC enrichment of 1 in 5 cells can be 
achieved by fluorescent assisted cell sorting (FACS) of Lin-Sca1+c-kit+Thy1.1lo or 
                                                 
2 Property to give rise to multiple, yet limited, number of cell lineages. For example, haematopoietic 
stem cells can differentiate into blood cells but not into brain cells.  
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Lin-Sca1+c-kit+CD34lo/- cell fractions (Osawa et al., 1996; Wagers et al., 2002). A 
more recent study has achieved very high levels of LTR-HSC purity using a simple 
combination of antibodies against the signalling lymphocyte activation molecule 
(SLAM) family markers CD48 and CD150 (frequency of 1 in 5 in CD48-CD150+ 
cells and 1 in 2 in CD48-CD150+CD41- cells)(Kiel et al., 2005).  
 Four weeks after birth, postnatal HSCs switch from a predominantly 
proliferating state to a more quiescent state (Bowie et al., 2007b; Bowie et al., 2006). 
In the adult bone marrow, elegant experiments combining flow cytometry with 
bromodeoxyuridine (BrdU) label-retaining assay have identified a rarely dividing 
(once every 36 days) HSC population and a highly dormant HSC population (once 
every 145 days) containing the majority of the LTR-HSC activity (Wilson et al., 
2008). It is thought that quiescence prevents HSC exhaustion and limits the 
occurrence of mutations that could lead to transformation into cancer stem cells 
(Orford and Scadden, 2008; Warner et al., 2004). Even if the majority of LTR-HSC 
are in a quiescent state in the bone marrow, they are readily capable of reversibly 
switching from dormancy to self-renewal under conditions of injury and stress 
(Wilson et al., 2008). 
 
1.2.1.2. The bone marrow HSC niche 
The majority of adult LTR-HSC are located in the trabecular zone of the bone 
marrow but can also be found in much smaller numbers in the liver and the spleen 
(Calvi et al., 2003; Kiel and Morrison, 2008; Kiel et al., 2005; Taniguchi et al., 1996; 
Wolber et al., 2002; Zhang et al., 2003). Understanding the nature of the HSC niche3 
is almost as important as understanding the HSC intrinsic properties because niche 
elements can regulate HSC migration, quiescence and differentiation (Arai et al., 
2004; Calvi et al., 2003; Nilsson et al., 2001; Orford and Scadden, 2008; Warner et 
al., 2004; Zhang et al., 2003). Genetic studies have shown that factors secreted by 
                                                 
3 Specialized microenvironment made of supporting cells influencing HSC behaviour. 
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endosteal cells (osteoblasts and osteoclasts) can promote HSC maintenance (Kiel and 
Morrison, 2008). However, further characterisation of the endosteum as well as 
conditional inactivation of factors of interest, in particular endosteal cell types, 
remain to be performed to elucidate major niche-mediated mechanisms involved in 
HSC biology (Kiel and Morrison, 2008). Additionally, a growing body of evidence 
highlights the possible roles of sinusoid vascular cells and the wider perivascular 
environment (Kiel and Morrison, 2008). Possible mechanisms by which niche 
components can influence HSCs are complex and are likely to involve a wide range 
of surrounding cells (Figure 1.3).  
 
1.2.2. The colony-forming unit spleen 
Downstream of the HSC compartment in the definitive haematopoietic 
hierarchy are the colony-forming unit spleen (CFU-S) which are defined as cells 
capable of homing to the spleen and forming macroscopic colonies (Till and Mc, 
1961). CFU-S can be divided into early CFU-S that can generate colonies 7-9 days 
after transplantations (and recede by day 10) and late CFU-S that generate colonies 
after 9-12 days post transplantation and remain until day 14 (Magli et al., 1982). 
These two CFU-S types have accordingly been named CFU-S8 and CFU-S12. CFU-
S12 are more primitive progenitors than CFU-S8 because of their capacity for self-
renewal (Magli et al., 1982; Siminovitch et al., 1963). 
CFU-S12 were considered to be HSCs for a long time because cell separation 
techniques based on expression of cell surface markers failed to separate CFU-S 
from HSCs. Evidence against this hypothesis came much later by allowing the 
separation of CFU-S and HSCs using counterflow centrifugal elutriation, a technique 
that separates cells according to their size and density (Jones et al., 1990).  
 
1.2.3. Common myeloid and common lymphoid progenitors 
 Downstream of the CFU-S are the lineage-committed progenitors, the 





















Figure 1.3: Diversity and complexity of the bone marrow LTR-HSC niche.
Contributions of cells near the endosteum (osteoblasts and osteoclasts) and at perivascular
sites (vessels endothelial cells and associated reticular cells, megakaryocytes and
mesenchymal progenitors). LTR-HSCs in the niche can be regulated either by cell-cell
contacts, soluble factors, or by intermediate cells.
(Reviewed and adapted from Kiel and Morrison, 2008)
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Similarly to HSCs, CLP and CMP are Lin- but express low levels of Sca1 and c-kit 
(Akashi et al., 2000; Kondo et al., 1997). They can be isolated based on their 
differential expression of interleukin 7 receptor α-chain (IL7-R), CLP being Lin-
Thy1.1loSca1loc-kitloIL-7Rα+ and CMP being Lin-Thy1.1loSca1-c-kit+IL-7Rα- 
(Akashi et al., 2000; Kondo et al., 1997).  
 CLP differentiation potential is limited to lymphoid lineages. The CLPs are 
capable of transient in vivo reconstitution of the lymphoid compartment (B cells, T 
cells, and natural killer cells) and can only give rise to B lymphoid colonies in vitro 
even when exposed to cytokines used for myeloid differentiation (Kondo et al., 
1997).  
 CMP differentiation potential is limited to myeloid lineages and can also 
provide transient in vivo reconstitution of the myeloid compartment (Akashi et al., 
2000). The CMP population can be further divided by flow cytometry based on the 
differential expression of Fcγ receptor II-III (FcγR) and CD34; three functionally 
distinct populations with different differentiation potential can be identified. First, 
the CMP (FcγRloCD34+) can give rise to all types of myeloid colony forming unit-
culture (CFU-Cs), the progenitors to fully differentiated lineages (Akashi et al., 
2000).  Myeloid CFU-Cs include Burst Forming Unit-Erythroid (BFU-E), CFU-
Mast, CFU-Macrophage (CFU-mac), CFU-Megakaryocyte (CFU-Meg), CFU-
Granulocyte/Macrophage (CFU-GM), and CFU-
Granulocyte/Erythrocyte/Macrophage/Megakaryocyte (CFU-GEMM).  Second, the 
granulocyte macrophage lineage-restricted progenitor (GMP)(FcγRhiCD34+) can only 
give rise to both CFU-mac and CFU-GM (Akashi et al., 2000). Finally; the 
megakaryocyte erythrocyte lineage-restricted progenitor (MEP)(FcγRloCD34-) can 
only give rise to CFU-Meg, BFU-E (Akashi et al., 2000).  Experiments in which 
CMP were serially cultured in methylcellulose determined that the CMP gave rise to 
the more committed lineage restricted progenitors GMP and MEP (Akashi et al., 
2000). 
 
  20 
1.2.4. Terminally differentiated haematopoietic lineages  
 All cells from the leucocytic4 lineages express the plasma membrane protein 
CD45 (Lagasse et al., 2000; Ledbetter and Herzenberg, 1979; Thomas, 1989). As 
previously mentioned, fully differentiated lineages can be divided into myeloid 
lineages (granulocytes, monocytes/macrophages, mast cells, 
magakaryocytes/platelets, erythrocytes) and lymphoid lineages (B cells, T cells, and 
natural killer cells).   
 Erythrocytes function to facilitate gaseous exchange in tissues of the 
organism; enucleation occurs as part of their terminal differentiation, a process that 
can be followed by the differential expression of the plasma membrane proteins 
CD71 and Ter119 (Kina et al., 2000).  
 Apart from having a very different array of functions (which will not be 
discussed here), fully differentiated haematopoietic cell lineages express different 
plasma membrane proteins. Development of monoclonal antibodies against these 
proteins has allowed the identification of these cell types by fluorescent microscopy 
and flow cytometry. The most commonly used lineage specific markers were 
summarised in Table 1.1.  
 
1.3. The development of the haematopoietic system 
 Understanding the emergence of LTR-HSCs during embryonic development 
is of major interest because it is believed to be the only time during the mammalian 
organism life when LTR-HSCs can arise de novo. Haematopoiesis during 
development is very different to the steady state haematopoiesis happening in the 
adult and is far more complex as it occurs in various organs at various developmental 
times. 
                                                 
4 Nucleated cells belonging to the immune system (also called white blood cells). Main types include 
neutrophils, eosinophils, basophils, lymphocytes (B cells, T cells, and natural killer cells), monocytes, 
macrophages and dendritic cells. 
Myeloid
Drew et al, 2002CD34Mast cell
Drew et al, 2002c-Kit/CD117
Drew et al, 2002Sca-1
Ishizaka and Ishizaka, 1984; Dombrowicz
et al, 1993; Turner et al, 1999
FcåRI
Nieswandt et al, 1999; Phillips et al, 1991 CD41Megakaryocyte/platelet
Springer et al, 1979; Leenen et al, 1994; 
Lagasse and Weissman, 1996
Mac-1/CD11bMonocyte/Macrophage
Hestdal et al, 1991; Fleming et al, 1993; 
Lagasse and Weissman, 1996
Gr-1
Lagasse and Weissman, 1996Mac-1/CD11bNeutrophil
Hestdal et al, 1991; Fleming et al, 1993; 
Lagasse and Weissman, 1996
Gr-1
Koo and Peppard, 1984; Yokoyama and 
Seaman, 1993
NK1.1Natural killer
Ledbetter et al, 1980; van Ewijk et al, 
1981
CD8á
Pierres et al, 1984CD4
Leo et al, 1987; Nakano et al, 1996CD3åT-cell
Hardy et al, 1991CD43
Krop et al, 1996; Tedder et al, 1994CD19
Hardy et al, 1991; Allman et al, 1992; 
Rolink et al, 1996
B220B-cell
Lymphoid
Kemp et al, 1987; Zhang et al, 2003CD71
Kina et al, 2000; Zhang et al, 2003Ter119Erythroid
Ledbetter and Herzenberg, 1979; Thomas, 
1989; Lagasse et al, 2000
CD45/Ly-5Leucocyte
ReferencesPlasma membrane proteinHaematopoietic lineage
 
Table 1.1: Erythroid, lymphoid and myeloid lineage specific cell surface markers
expressed on fully differentiated cells
(taken from Taoudi, 2006)
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 During development, the dynamics of LTR-HSC emergence, migration and 
expansion have been linked to four major haematopoietic organs: the aorta-gonad 
mesonephros (AGM region), the yolk sac (YS), the fetal liver and the placenta 
(Gekas et al., 2005; Kumaravelu et al., 2002; Muller et al., 1994; Ottersbach and 
Dzierzak, 2005; Yoder et al., 1997b). 
 
1.3.1. The embryonic origin of LTR-HSCs: the beginnings of 
a controversy 
 The first haematopoietic cells to appear in the developing embryo are 
observed in the YS blood islands from embryonic day (E) 7.5, approximately two 
days before the onset of blood circulation5 (Moore and Metcalf, 1970). Blood islands 
first produce nucleated erythrocytes cells that express embryonic globins in a process 
called primitive erythropoiesis. The detection of CFU-S and CFU-C in early YS 
explants (Moore and Metcalf, 1970; Palis et al., 1999) led to the hypothesis that 
LTR-HSCs originate in situ in the early YS before migrating via peripheral 
circulation and colonising to the fetal liver (Moore and Metcalf, 1970). Such 
hypothesis was supported by experiments in avian models (Moore and Owen, 1965; 
Moore and Owen, 1967). Two studies in the mouse reported repopulation activity in 
the YS prior to E11 when donor cells were microinjected in utero into recipient 
embryos.  Contribution to the adult haematopoietic system was either limited to the 
erythroid lineage (Toles et al., 1989) or to almost undetectable lymphoid lineages 
(Weissman IL, 1978).   
 The extra-embryonic source of LTR-HSC hypothesis was challenged when a 
series of elegant experiments with chicken-quail chimeras (quail embryos and 
haematopoietic organs were grafted onto chick YS) revealed that all blood cell types 
were of quail origin, thus proving the intra-embryonic origin for the adult 
                                                 
5 which begins at E8.5 with the completion of the omphalomesenteric artery and is completed at E10.5 
with a beating heart that drives haematopoietic circulation (McGrath et al, 2003). 
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haematopoietic system (Dieterlen-Lievre, 1975). Further experiments by the same 
group showed that while the YS was capable of generating a transient wave of 
erythroid cells, the site of HSC generation was predominantly intra-embryonic 
(Lassila et al., 1978; Lassila et al., 1982).  
 
1.3.2. Primitive erythropoiesis in the early yolk sac 
 Defining primitive and definitive haematopoiesis has been subject to a long 
debate among scientists and is discussed further in Section 1.3.6. Here, primitive 
haematopoiesis will be defined as the process by which mature erythroid cells and 
some macrophages are formed by the early YS. After their initial formation in the 
E7.5 YS, the outer layer of the blood islands differentiate into endothelial cells while 
the inner cells loose their intercellular attachments and differentiate into primitive 
erythroblasts (McGrath and Palis, 2005). After their formation, primitive 
erythroblasts enter the embryonic vasculature where they proliferate, hence 
providing the embryo with an immediate supply of oxygen carrying cells necessary 
to fill in the gap between maternal passive oxygen diffusion and the start of 
erythrocytes production by E11 fetal liver. Contrary to adult type erythrocytes (as 
formed by the E11 fetal liver), primitive erythroblasts (also called megaloblasts due 
to their size) are nucleated and express the embryonic forms of hemoglobin (βH1 and 
ε)(McGrath and Palis, 2005; Palis et al., 1999). YS derived primitive erythroid cells 
are no longer found in the bloodstream after E16 (McGrath and Palis, 2005).  
 
1.3.3. Identifying the intra-embryonic source of LTR-HSCs 
 The presence of CFU-S8 and CFU-S11 in the E10.0 AGM region but not YS 
provided the first evidence of an intra-embryonic source of multilineage progenitors 
(Medvinsky et al., 1993). Because this activity reaches a maximum in the AGM 
region at E11.0, shortly before similar haematopoietic activity can be found in the 
fetal liver, it was speculated that the AGM region was the source of hepatic 
multilineage progenitors (Medvinsky et al., 1993). Proper assessment of LTR-HSC 
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content in the E10 embryo by serial long-term multilineage engraftment into 
irradiated adult recipients confirmed the AGM region as the first site in the embryo 
to harbour LTR-HSC activity (Muller et al., 1994). While these results indicated that 
the AGM region was the most potent pre-liver site of definitive haematopoiesis, this 
did not address the issue of the site of origin of the LTR-HSCs because of the active 
interchange of cells via circulation and interstitial migration that could have 
happened prior to E10.5 (Medvinsky and Dzierzak, 1996). The development of an ex 
vivo organ culture system, preventing possible cellular interchanges and thus 
revealing the autonomous and intrinsic capacity of the haematopoietic organs to 
generate LTR-HSCs, finally confirmed the E10.0 AGM as the first site of LTR-HSC 
emergence and expansion (from 1 to 12 LTR-HSCs) in the murine embryo 
(Kumaravelu et al., 2002; Medvinsky and Dzierzak, 1996). This was further 
supported by studies performed before the onset of circulation showing that E8 para-
aortic spanchnopleura (P-Sp)6, but not the YS, contained multipotent lymphomyeloid 
progenitors, although they were not capable of high level reconstitution of adult 
recipients (Cumano et al., 1996; Cumano et al., 2001).  
 
1.3.4. The extra-embryonic sources of LTR-HSCs  
1.3.4.1. The controversial role of the early yolk sac 
 A controversial body of evidence has indicated that the E8.0 YS was capable 
of generating LTR-HSCs when cells were transplanted in utero (Toles et al., 1989; 
Weissman IL, 1978). However, various studies failed to detect early YS cells with 
the capacity to engraft adult irradiated recipients or display multilineage 
differentiation prior to E11.0 (Cumano et al., 1996; Cumano et al., 2001; Medvinsky 
and Dzierzak, 1996; Medvinsky et al., 1993; Muller et al., 1994).  
                                                 
6 Region including the splanchnic mesoderm surrounding the endoderm of the developing gut and the 
endothelium of arteries, it is a transient structure which develops into the AGM region at late E9 
(Cumano et al, 1996). 
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It was hypothesised by Yoder and colleagues that the failure of ≤E11.0 YS cells to 
demonstrate LTR-HSC activity was a result of the failure of these cells either to 
home to haematopoietic microenvironments or to respond appropriately to such 
microenvironments (Yoder and Hiatt, 1997). Intravenous and intrahepatic injections 
into conditioned newborn pups confirmed this idea and showed that intrahepatic 
injections of E9-10 YS could give rise to high level long-term multilineage 
reconstitution in the adult haematopoietic system (Yoder and Hiatt, 1997; Yoder et 
al., 1997a; Yoder et al., 1997b).  
 
1.3.4.2. The placenta as a haematopoietic organ 
Recent studies have revived the idea that the placenta is a significant 
embryonic haematopoietic organ because it harbours high frequencies of committed 
lymphoid (pre-B cells) and myeloid progenitors (CFU-GM, CFU-GEMM, and BFU-
E) from E8.5 onwards (Alvarez-Silva et al., 2003; Melchers, 1979). More recently, 
two research groups independently confirmed that the placenta is a reservoir for a 
large pool of LTR-HSCs from E11 until E13.5 when it dramatically reduces, 
concomitantly with the extensive hepatic pool expansion (Gekas et al., 2005; 
Ottersbach and Dzierzak, 2005). Placental LTR-HSCs can be enriched in the 
CD34+c-kit+Sca1+ fraction, similarly to LTR-HSCs isolated in the AGM region and 
YS (Gekas et al., 2005; Ottersbach and Dzierzak, 2005; Sanchez et al., 1996; Yoder 
et al., 1997a), and are located within the endothelial layer of embryonic vessels in 
chorionic and labyrinth regions (Ottersbach and Dzierzak, 2005; Rhodes et al., 
2008). However, the actual number of LTR-HSCs in the E12.5 placenta is still 
unclear because Gekas and colleagues counted approximately 50 LTR-HSCs per 
placenta while Ottersbach and colleagues counted approximately 12 (Gekas et al., 
2005; Ottersbach and Dzierzak, 2005). 
Unlike the E10.5 AGM, the E10.5 placenta is not able to autonomously 
initiate LTR-HSC formation when cultured as organ explant (Ottersbach and 
Dzierzak, 2005). The presence of haematopoietic progenitors in the allantois and the 
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chorion (whose fusion forms the placenta) in the early headfold embryo suggests an 
autonomous potential of the placenta (Zeigler et al., 2006). Additional experiments 
with embryos lacking a heartbeat, thus having no peripheral circulation (Ncx1-/- 
embryos7), also suggest that the placenta contains multipotent haematopoietic cells as 
early as E8.5, prior to the onset of circulation (Rhodes et al., 2008). However, the 
lack of transplantation experiments did not provide evidence in favour of 
autonomous LTR-HSC generation in the placenta, leaving this question unanswered.  
 
1.3.5. Quantitative analysis of LTR-HSCs during embryonic 
development: a model for haematopoietic hepatic 
colonisation 
 Studies that quantified LTR-HSCs in the murine embryo from E10.5, at the 
onset of LTR-HSC emergence, have proven that LTR-HSCs are detected in the fetal 
liver by E11.5 and that this pool undergoes massive expansion (from 3.3 LTR-HSCs 
at early E11 up to 250 at E13)(Ema and Nakauchi, 2000; Gekas et al., 2005; 
Kumaravelu et al., 2002; Morrison et al., 1995). Such rapid expansion within the 
fetal liver cannot possibly be explained by mitotic divisions of a small number of 
LTR-HSCs that had previously colonised the fetal liver (Kumaravelu et al., 2002). 
Proper quantification of the LTR-HSCs within the haematopoietic organs from the 
onset of their emergence until their expansion in the liver have suggested that the 
fetal liver is seeded by consecutive waves of LTR-HSCs migrating from the AGM 
region first and subsequently from the YS and the placenta (Gekas et al., 2005; 
Kumaravelu et al., 2002; Moore and Metcalf, 1970). Such model is based on the 
following evidence and summarised in Figure 1.4:  
 
 
                                                 
7 Ncx1-/- embryos lack heartbeat due to a defect in the sodium-calcium exchange pump 1 and thus do 
not survive beyond E10.5 (Koushik et al, 2001).  
Figure 1.4: Embryonic haematopoietic sites and LTR-HSCs journey during
development.
LTR-HSCs in the developing mouse embryo can be isolated first from the AGM region, the
YS, and the placenta. The site where LTR-HSCs emerge is still controversial and their
trafficking between these 3 embryonic sites is still unclear. After they emerge, LTR-HSC
are thought to migrate to the fetal liver where they expand and migrate to the bone marrow
post-natally. They reside in the bone marrow throughout life.
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- The expansion of LTR-HSCs in the liver occurs concomitantly with 
increasing numbers of LTR-HSCs in the circulation (Kumaravelu et al., 
2002). 
- Although the AGM is capable of significant LTR-HSC expansion ex vivo 
(Kumaravelu et al., 2002; Medvinsky and Dzierzak, 1996), the numbers of 
progenitors and LTR-HSCs found in situ in the AGM are low at all times 
(between 1 and 2 LTR-HSCs)(Gekas et al., 2005; Kumaravelu et al., 2002; 
Muller et al., 1994).  
- The YS contains similar numbers of LTR-HSCs as the AGM from E11 
onwards but becomes competent to generate LTR-HSCs at E12 (7 LTR-
HSCs)(Kumaravelu et al., 2002). 
- The placenta contains large amount of LTR-HSCs from E10.5 but placental 
LTR-HSCs number dramatically decreases after E13.5 (Gekas et al., 2005; 
Ottersbach and Dzierzak, 2005). 
- The lineage tracing of vascular endothelial (VE) cadherin positive cells 
suggests that haematopoietic cells in the fetal liver originate from endothelial 
cells in the AGM region (Zovein et al., 2008)(see Section 1.4.2.3 for more 
details).  
Mapping LTR-HSCs numbers in developing embryos has given fundamental 
information about the origins of LTR-HSCs seeding the fetal liver, but one must 
keep in mind that the precise sites of LTR-HSC emergence are still subject to 
extensive debate as LTR-HSCs are first detected after the onset of circulation. 
Specific genetic marking of YS, AGM, and placental cells would empirically 
determine the extent by which each organ contributes to the LTR-HSC pool as well 
as whether fetal liver LTR-HSCs even originate from these sites.   
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1.3.6. Primitive and definitive haematopoiesis and their 
ontogenetical connections  
1.3.6.1. Defining primitive and definitive haematopoiesis 
 Distinguishing between primitive (embryonic) and definitive (adult) 
haematopoiesis has been another great subject of debate in the HSC field. If 
definitive haematopoiesis was defined as adult haematopoiesis, with a hierarchy 
sequentially evolving from the LTR-HSCs and giving rise to CFU-S, CLP and CMP, 
the presence of such progenitors in the embryo prior to E10.5 would indicate that 
LTR-HSCs have already developed by this stage (Jaffredo et al., 2005). This would 
mean that LTR-HSCs are present in extra-embryonic tissues but the niche in which 
they reside limits their properties and differentiation potential to erythroid and 
macrophage lineages (Taoudi, 2006; Yoder and Hiatt, 1997). Evidently, this argues 
against the hypothesis of an independent mid-gestation emergence of LTR-HSCs in 
the AGM region. 
 Another possibility is that haematopoiesis during embryogenesis occurs in 
two waves: the first transitory wave is initiated in the E7.5 YS and generates 
nucleated erythrocytes and macrophages to meet the organism’s immediate need for 
oxygen (discussed in Section 1.3.2). The second definitive wave is initiated perhaps 
in the E10.5 AGM region with the emergence of the first detectable LTR-HSCs and 
from then on it is possible that haematopoiesis occurs in an adult-like manner (ie: 
restricted progeny arise from LTR-HSCs)(Medvinsky and Dzierzak, 1996; Muller et 
al., 1994; Taoudi, 2006).  In the context of this discussion, primitive 
haematopoiesis will refer to primitive erythropoiesis and the emergence of early 
progenitors, and definitive haematopoiesis will refer to the emergence and 
differentiation of the first LTR-HSCs in the E10.5 AGM region (Godin and Cumano, 
2002).   
 
1.3.6.2.  The distinct origin of primitive and definitive haematopoiesis  
1.3.6.2.1. CD41 expression as a candidate marker of definitive haematopoiesis 
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 The platelet glycoprotein receptor IIb/IIIa (CD41) is a protein composed of 
two subunits that interact with CD61 to form a functional adhesive protein receptor 
in the presence of calcium (Phillips et al., 1988). It has long been used as a 
phenotypic marker for megakaryocyte-platelet lineage and is required for its normal 
function (Phillips et al., 1988). Additionally, CD41 expression has been reported in 
E10.5 AGM progenitors and in E9.5 primitive and definitive haematopoietic 
progenitors (Ferkowicz et al., 2003; Mikkola et al., 2003a; Mitjavila-Garcia et al., 
2002). Because haematopoietic activity of YS CD45- cells could be enriched on the 
basis of CD41, it was hypothesized that CD41 may be an early marker for the 
initiation of definitive haematopoiesis (Mikkola et al., 2003a). Later during 
ontogeny, definitive progenitors in the E12.5-13.5 fetal liver become heterogeneous 
for CD41 expression (Ferkowicz et al., 2003; Mitjavila-Garcia et al., 2002). 
Interestingly, most E12.5 fetal and adult bone marrow LTR-HSCs are CD41-, which 
might indicate that CD41 expression is lost upon “pre-HSC” maturation (Ferkowicz 
et al., 2003). The crossing of CD41 promoter driven Cre recombinase mice with a 
reporter mouse strain showed that CD41 is expressed in progenitors in the YS, AGM 
region and fetal liver in vivo (Emambokus and Frampton, 2003). However, the 
limited expression of β-galactosidase in adult bone marrow suggested that two waves 
of progenitors arise in the fetus and that the majority of bone marrow HSC might not 
emerge from a CD41+ precursor (Emambokus and Frampton, 2003). 
 The evidence presented so far indicate that CD41 expression is the earliest 
haematopoietic marker (pre-CD45) as CD41 cells are committed to haematopoietic 
differentiation (Mikkola et al., 2003a) but fail to prove that CD41 is expressed in 
founder cells of the adult haematopoietic hierarchy. 
 
1.3.6.2.2. Insights from amphibian studies 
 A clear model for the in vivo dissection of the origins of primitive and 
definitive haematopoiesis came from amphibian models. The ability to perform 
orthotopical transplantations with differentially marked cells have allowed the 
reliable tracing of cells that contribute to primitive and definitive haematopoiesis 
(Chen and Turpen, 1995; Ciau-Uitz et al., 2000; Turpen et al., 1997). In Xenopus 
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laevis, the ventral blood island (VBI), a region analogous to the mammalian YS, 
generates the primitive haematopoietic supply and also contributes to definitive 
haematopoiesis but at a later stage (Chen and Turpen, 1995; Turpen et al., 1997). The 
dorso-lateral plate (DLP), the region analogous to the mammalian AGM region, is 
only capable of definitive haematopoiesis and contributes to the majority of the 
hepatic haematopoietic pool and the earliest stage of liver colonization (Chen and 
Turpen, 1995). While this study was consistent with the hypothesis of a dual intra 
and extra-embryonic contribution to the hepatic LTR-HSCs pool, fate tracing 
experiments performed by the same group, in which the ventral marginal zone 
(VMZ) was differentially labelled, indicated a common origin of both primitive and 
definitive haematopoietic cells within the VBI and the DLP (Chen and Turpen, 
1995). However, improved resolution of individual blastomeres within the VMZ and 
the dorsal marginal zone (DMZ) demonstrated that primitive and definitive 
haematopoietic lineages originate from different regions within the 32 blastomeres 
stage (Ciau-Uitz et al., 2000). Intriguingly, the same study by Ciau Uitz et al 
confirmed that the VBI is able to produce both primitive and definitive blood cells 
but is derived from two independent blastomeres, suggesting that primitive and 
definitive haematopoietic activity might be ontogenetically independent (Ciau-Uitz 
et al., 2000). 
 
1.3.6.3. Molecular resolution of primitive and definitive haematopoiesis  
 The clearest functional resolution of primitive and definitive haematopoiesis 
in the murine embryo has come from gene inactivation studies. Inactivation of 
certain genes such as stem cell leukemia (SCL) gene, LIM domain only 2 (lmo2) or 
the GATA factors has been shown to disrupt both primitive and definitive 
haematopoiesis. Another set of genes, including notch, c-kit, c-myb, Runx1, and 
core-binding factor β (CBFβ), when inactivated have been shown to disrupt 
definitive haematopoietic specifically. A third set of genes, including β1-, α4- 
integrins, and CXCR4, has been shown to affect HSC migration and homing to the 
fetal haematopoieitic organs. As discussing the roles of each gene in detail is beyond 
the scope of this introduction, Table 1.2 summarises a list of the major genes 
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involved in governing the processes of primitive and definitive haematopoiesis 
(Godin and Cumano, 2002). A more detailed discussion about a few relevant genes 
of interest is provided.   
 
1.3.6.3.1. The role of stem cell leukaemia  (SCL) gene  
The SCL gene is a member of the basic-helix-loop-helix (bHLH) class of 
transcription factors, and has been termed a master regulator of haematopoiesis 
because of the dramatic haematopoietic phenotype observed in SCL-/- murine model 
(Porcher et al., 1996; Robb et al., 1995; Shivdasani et al., 1995). SCL null embryos, 
which die in utero between E8.5 and E10.5, fail to initiate both primitive and 
definitive haematopoiesis as evidenced by the absence of YS blood islands and 
primitive nucleated erythrocytes, the absence of CFU-Cs, and the failure of SCL-/- ES 
cells to contribute to adult haematopoiesis in chimaeric mice (Porcher et al., 1996; 
Robb et al., 1995; Shivdasani et al., 1995).  
Conditional inactivation of SCL in the adult organism revealed that SCL was 
dispensable for maintenance, engraftment, self-renewal and multilineage 
differentiation of LTR-HSCs (Mikkola et al., 2003b). Interestingly however, a recent 
study by Souroullas and colleagues has shown that adult “HSCs” in lyl1/SCL-
conditional double knockout fail to repopulate irradiated recipients and undergo 
rapid apoptosis, indicating that lyl1 is essential for HSC function in the absence of 
SCL. Lyl1 is a bHLH transcription factor that is highly related (80%) to SCL with a 
similar expression pattern (Giroux et al., 2007). Despite the inability of lyl1 to rescue 
SCL deficient phenotype during development (Chan et al., 2007), these results 
indicate a functional overlap between these two proteins in the adult LTR-HSC 
compartment (Souroullas et al., 2009). This example illustrates functional 
redundancy between related proteins and brings to attention the care with which 
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1.3.6.3.2. The role of LIM domain only 2 (lmo2) 
 Lmo2/Rbtn2 encodes a LIM-domain nuclear protein that directly interacts 
with SCL and GATA-1 as a bridging molecule and is largely expressed in primitive 
and definitive erythroid cells during development (Warren et al., 1994). Lmo2 null 
embryos die in utero between E10.5 and E11.5 with a failure to develop YS blood 
islands and a complete absence of primitive erythrocytes (Warren et al., 1994). 
However, the ability of Lmo2-/- ES cells and E9.5 YS cells to form macrophages 
colonies in vitro indicate that haematopoiesis is not completely ablated (Warren et 
al., 1994), a similar phenotype as GATA-1 null embryos (see Section1.3.6.3.3). The 
generation of chimeric mice, in which Lmo2-/- ES cells were microinjected into wild 
type (WT) blastocysts, revealed that Lmo2 deficient cells do not contribute to adult 
haematopoiesis (Yamada et al., 1998). This study indicated that Lmo2 was essential 
for the development of the definitive haematopoietic system but the stage at which 
Lmo2 plays a role is yet to be determined. The only circumstantial evidence of a role 
for Lmo2 at the stage of LTR-HSC emergence came from the in situ hybridisation 
detection of Lmo2 in midgestation aortic endothelium, intra-aortic haematopoietic 
clusters (IAHC), and possibly sub-aortic patches (SAP)(Bertrand et al., 2005; Manaia 
et al., 2000)(see Section 1.4).  
 
1.3.6.3.3. The roles of GATA transcription factors  
 The GATA family of transcription factors is composed of 6 members of zinc 
finger proteins that recognize a GATA consensus motif, and can be divided into two 
groups: GATA-4, GATA-5, and GATA-6 which are mainly expressed in cardiac cells 
and lineages derived from the endoderm (Peterkin et al., 2005), and GATA-1, GATA-
2, and GATA-3 which are mainly expressed in the central nervous system and various 
ectodermal lineages as well as haematopoietic lineages (Evans and Felsenfeld, 1989; 
Pandolfi et al., 1995; Pevny et al., 1991; Tsai et al., 1994; Yu et al., 2002).  
 GATA-1 target sites are found in the regulatory elements of virtually all 
genes expressed by erythroid cells and is also expressed in mast, megakaryocyte and 
eosinophil lineages (Evans and Felsenfeld, 1989; Tsai et al., 1989; Yu et al., 2002). 
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Insights into the differential role of GATA-1 in primitive and definitive 
haematopoiesis have come from embryoid bodies (EB) differentiation models in 
which temporal appearance of precursors resembles that in the early embryo8. 
GATA-1 loss and gain of function studies have revealed the essential requirement of 
GATA-1 for normal definitive erythroid development both in vitro and in vivo 
(Fujiwara et al., 1996; Pevny et al., 1991; Simon et al., 1992). The loss of functional 
GATA-1 in ES cells leads to impaired primitive erythropoiesis whereas definitive 
erythroid progenitors are present in normal numbers yet display a severe 
developmental arrest and death at the pro-erythroblast stage (Weiss et al., 1994). In 
vivo however, both primitive and definitive erythroid precursors are present but 
experience a developmental arrest at the pro-erythroblast stage (Fujiwara et al., 
1996).  
 GATA-2 is expressed in various haematopoietic lineages including the adult 
bone marrow LTR-HSC pool (Orlic et al., 1995). GATA-2-/- embryos die at E11.5 
and exhibit marked anaemia (Tsai et al., 1994). In the midgestation embryo, GATA-
2 is expressed in the E9.5-11.5 AGM region but not in the YS as assessed by in situ 
hybridisation in a reporter mouse model (Minegishi et al., 1999; Zhou et al., 1998), 
suggesting a predominant role in definitive rather than primitive haematopoiesis. The 
presence of normal primitive erythroid cells in knockout embryos, and the failure of 
GATA-2-/- cells to contribute to definitive haematopoiesis in embryonic or adult 
haematopoietic organs, functionally confirms the requirement of GATA-2 for 
definitive haematopoiesis (Tsai et al., 1994). Interestingly, GATA-2 
haploinsufficient embryos failed to facilitate the LTR-HSC expansion in the E11.5-
12.5 AGM region whereas YS-derived LTR-HSCs expanded similarly to controls, 
suggesting that there are distinct pathways governing extra and intra embryonic 
haematopoiesis (Ling et al., 2004).  
 
                                                 
8 Primitive erythroid precursors arise at 6-7 days EBs whereas definitive erythroid precursors are 
found in E10-14 days EBs (Weiss et al, 1994).  
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 GATA-3 gene inactivation results in embryonic lethality around E11.75-12.5 
due to extensive internal haemorrhages, growth retardation and central nervous 
system malformations (Pandolfi et al., 1995). The numbers of YS progenitors in null 
E11.5 embryos are comparable to WT animals whereas the numbers of FL 
progenitors are markedly decreased; leading to the conclusion that GATA-3 
deficiency specifically affects definitive haematopoiesis (Pandolfi et al., 1995). 
However, analysis of chimaeric GATA-3-/-/RAG-2-/- adult mice revealed that GATA-
3-/- cells contribute to functional adult myeloid lineages (Mac-1+ and Gr-1+) and B 
cell lineage but fail to complete T-lymphocyte differentiation (Ting et al., 1996). 
While this highlights an important role of GATA-3 for T-lymphocyte differentiation, 
it also strongly suggests that GATA-3-/- cells contributes to definitive adult 
haematopoiesis (Ting et al., 1996). Additionally, GATA-3 expression was reported 
in SAPs (see Section 1.4.2.5) and aortic endothelium in the E10.5-11.5 AGM region, 
structures hypothesised to be associated with LTR-HSC emergence in the AGM 
region (see Section 1.4). However, the role of GATA-3 in definitive haematopoiesis 
is still unclear due to the lack of direct functional evidence showing a requirement of 
GATA-3 in the LTR-HSC compartment and linking SAPs to LTR-HSCs. 
 
1.3.6.3.4. The role of notch signalling 
 The Notch family of receptors, comprising the four members Notch-1, Notch-
2, Notch-3 and Notch-4, and their ligands (Delta-like-1, -3, -4, and Jagged-1 to 2) are 
expressed in various haematopoietic lineages and control cell fate decisions during 
haematopoietic lineage differentiation (Milner and Bigas, 1999). Conditional 
inactivation of Notch-1 in adult animals has demonstrated that it is dispensable for 
the maintenance of LTR-HSCs in vivo (Maillard et al., 2008; Mancini et al., 2005; 
Radtke et al., 1999), a finding confirmed and extended to all four members of the 
Notch family (Maillard et al., 2008).  
However, Notch-1 gene inactivation is embryonic lethal by E11.5, with null 
embryos showing severe vasculature defects in the dorsal aorta and the YS (Krebs et 
al., 2000), which may disturb LTR-HSC development. In vivo data have shown that 
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Notch-1 signalling is dispensable for normal primitive haematopoiesis (Hadland et 
al., 2004; Kumano et al., 2003). As Notch-1 deficient ES-cells contribute to YS 
derived haematopoiesis but not to adult haematopoiesis in chimaeras (Hadland et al., 
2004). Notch-1 in particular, specifically via activation by Jagged-1 (Robert-Moreno 
et al., 2008), seems to be essential for cell-autonomous emergence of LTR-HSC in 
the developing embryos as such observations were not made in Notch-2 or Notch-4 
deficient embryos (Kumano et al., 2003; Robert-Moreno et al., 2005).  
 The evidence available indicates that Notch signalling does not play a major 
role in primitive haematopoiesis; it acts at the step of LTR-HSC emergence but is 
dispensable for their expansion and maintenance in the adult (Maillard et al., 2008; 
Mancini et al., 2005; Radtke et al., 1999; Robert-Moreno et al., 2005; Robert-
Moreno et al., 2008).  
 
1.3.6.3.5. The role of runx1  
 Runx1 is a critical gene involved in human leukaemogenesis (Speck and 
Gilliland, 2002). Runx1 gene inactivation studies have shown that Runx1 is 
dispensable for primitive erythrocytes formation, although required for their final 
maturation and normal Ter119 and GATA-1 expression (Yokomizo et al., 2008). 
However, Runx1 is essential for the emergence of LTR-HSCs and the establishment 
of definitive haematopoiesis (Okuda et al., 1996; Wang et al., 1996a). Conditional 
Runx1 inactivation models, created to by-pass embryonic lethality, showed that 
Runx1 is essential for the normal maturation of lymphoid cells (B and T cells) and 
megakaryocytes (Growney et al., 2005; Ichikawa et al., 2004; Ichikawa et al., 2008; 
Putz et al., 2006). The role of Runx1 is extensively discussed in Section 1.5. 
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1.4. The ancestry of LTR-HSCs in developing 
embryos 
1.4.1. The spatial origin of LTR-HSCs in the E11.5 AGM 
region 
 At E11.5, the AGM region comprises the dorsal aorta (Ao), the urogenital 
ridges (UGR) and remnants of the ventral mesentery (see Figure 5.1). 
Transplantations of fresh Ao and UGR have demonstrated that LTR-HSCs first 
emerge in the Ao at E11.5 (de Bruijn et al., 2000b; Taoudi and Medvinsky, 2007). 
This axio-lateral polarity is still quantitatively observed at E12.5 but at this stage 
some LTR-HSCs can be experimentally detected in the UGR (de Bruijn et al., 
2000b). Interestingly however, the presence of LTR-HSCs in E11.5 Ao and UGR 
explants raises the possibilities that UGRs could autonomously induce/expand LTR-
HSCs or that pre-HSCs seed the UGR prior to E11.5 (de Bruijn et al., 2000b). In 
addition, co-culture of Ao and UGRs does not increase LTR-HSCs output from UGR 
or Ao, suggesting that there are no supportive/inhibitory interactions between these 
two tissues (de Bruijn et al., 2000b). 
 The hypothesis of a dorso-ventral polarity in the Ao came from the 
identification of IAHCs on the ventral wall of the Ao in vertebrate species (avian, 
mouse, human)(Figure 1.5). IAHC are structures hypothesised to mature into LTR-
HSCs. This theory relies on the expression of various haematopoietic markers in 
IAHCs (CD34, PECAM-1, CD45 in the 5-week old human and CD45, CD34, 
PECAM-1, AA4.1, Runx1, Notch1, and Lmo2 in the E10.5-11.5 Ao)(Bertrand et al., 
2005; Garcia-Porrero et al., 1995; Garcia-Porrero et al., 1998; Kumano et al., 2003; 
Manaia et al., 2000; North et al., 1999; Robert-Moreno et al., 2008). The absence of 
IAHC upon inactivation of genes involved in definitive haematopoiesis and the 
presence IAHC concomitantly with the presence of LTR-HSCs in the AGM, have 





Figure 1.5: Presence of intra-aortic haematopoietic clusters on the ventral aspect of
the dorsal aorta in vertebrate species of midgestation embryos.
A: transverse section through murine E11.5 AGM region, a CD34+ IAHC is lying on the
ventral part of the dorsal aorta (arrow head), scale bar = 57 µm (taken from Garcia-Porrero
et al, 1998).
B: transverse section through avian E3 dorsal aorta, QH1+ IAHC is lying on the ventral part
of the dorsal aorta (square), scale bar = 75 µm (taken from Jaffredo et al, 1998) .
C: transverse section through day 32 human dorsal aorta, two CD34+ IAHCs are lying on
the ventral part of the dorsal aorta (arrow heads), scale bar = 100 µm (taken from Tavian et
al, 1999) .
D: Transverse section through murine E11.5 AGM region, GATA-3+ IAHC (arrow) and
SAP (arrowheads) are ventrally located, scale bar = 100 µm  (taken from Manaia et al,
2000).
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 The ventral localisation of LTR-HSC development was further hinted by the 
observation of SAPs in the ventral para-aortic mesenchyme, and the expression of 
high-levels of GATA-2, GATA-3, and Lmo2 within this region (Bertrand et al., 
2005; Manaia et al., 2000).  
However, to date, only one study in the mouse embryo has provided 
functional evidence of ventral localisation of LTR-HSCs in the E11.5 AGM region 
(Taoudi and Medvinsky, 2007). In this study, sub-dissection of the dorsal aorta into 
dorsal (AoD) and ventral (AoV) domains demonstrated that only the AoV harbours 
LTR-HSCs and is capable of autonomous LTR-HSC induction/expansion (Taoudi 
and Medvinsky, 2007). See Section 5.1 for more details.  
Despite the functional evidence of dorso-ventral polarity of LTR-HSC 
development in the E11.5 AGM region and the large amount of circumstantial 
evidence linking IAHC and SAP to LTR-HSC emergence, no group to date has been 
able to functionally attribute LTR-HSC activity to any of these morphological 
structures.  
 
1.4.2. The ancestry of LTR-HSCs in the developing embryo 
 As previously described, the first blood cells appear in the YS blood islands 
as a compact group of cells which are initially identical. As development proceeds, 
the cells at the exterior of the clusters adopt endothelial identity while the cells 
within the clusters progressively lose inter-cellular connections and differentiate into 
haematopoietic cells and primitive erythrocytes (McGrath and Palis, 2005). This 
close association of endothelial and haematopoietic cells that develop from cells that 
are originally identical have led to the hypothesis of a common precursor of both 
lineages: the haemangioblast (Sabin, 1920). The close developmental link between 
endothelial and haematopoietic cells is also illustrated by the close association of the 
IAHCs with the endothelial lining of the Ao as well as the common expression of 
various cell surface markers such as PECAM-1, CD34, c-kit, Tie-2, Flk-1, CD45, 
and VE-cadherin (Baumann et al., 2004; Bernex et al., 1996; Nishikawa et al., 1998a; 
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Takakura et al., 1998; Taoudi et al., 2008; Taoudi et al., 2005; Wood et al., 1997; 
Yoshida et al., 1998).  
While there is some evidence in favour of the endothelial ancestry of LTR-
HSCs, alternative theories have arisen in the past few years (schematically 
summarised in Figure 1.6).  
 
1.4.2.1. The endothelial origins of LTR-HSCs 
 To successfully demonstrate the endothelial origin of LTR-HSCs in the 
embryo, it is necessary to specifically label endothelial cells and accurately trace 
their fate in vivo or evaluate their haematopoietic potential in vitro (Taoudi, 2006). 
This relies on the assumption that endothelial cells can be specifically identified 
based on their surface markers and/or their properties (summarized in Table 1.3). To 
date, the expression of VE-cadherin is the most effective single surface marker that 
immunophenotypically identifies endothelial cells (Breier et al., 1996; Matsuyoshi et 
al., 1997; Nishikawa et al., 1998b).  
 The only reported instance in which VE-cadherin is expressed in non-
endothelial cells is in the first LTR-HSCs that reside in the E11.5 AGM region 
(CD45+VE-cadherin+)(North et al., 2002; Taoudi et al., 2005). Based on these 
results, basic immunophenotypes were defined for endothelial cells (CD45-VE-
cadherin+), haematopoietic cells (CD45+VE-cadherin-), and a purified population of 
LTR-HSCs (CD45+VE-cadherin+)(Fraser et al., 2003; Nishikawa et al., 1998b; North 
et al., 2002; Taoudi et al., 2005).   
 
1.4.2.2. Concept of the haemangioblast 
 The haemangioblast is defined as a precursor that is restricted to differentiate 
into endothelial and haematopoietic cells exclusively (Sabin, 1920). Experimentally, 
the isolation of Flk-1 positive precursors capable of differentiating into both 
endothelial and haematopoietic cells has been postulated to be putative 
haemangioblasts in avian and murine embryos (Eichmann et al., 1997; Huber et al.,  
Figure 1.6: Models of candidate LTR-HSCs ancestry in the AGM region.
The haemangioblast theory implies that there is one common progenitor to endothelium and
LTR-HSCs.
The haemogenic endothelium theory implies that LTR-HSCs are derived from endothelial
cells that are already primed to a haematopoietic fate.
The pre-HSC theory implies that LTR-HSCs are derived from mesodermal cells that can
mature into LTR-HSCs
The sub-aortic patches theory implies that LTR-HSCs are derived from mesodermal cells
contained in these sub aortic structures and that subsequently migrate and mature into LTR-
HSCs in IAHCs before being released into the bloodstream.
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2004). Support for the haemangioblast concept was also provided by EB 
differentiation model: the blast colony forming cell (BL-CFC) arising within EBs 
after 2.5-4.0 days of differentiation has been hypothesised to be the in vitro 
equivalent of the haemangioblast (Choi et al., 1998). BL-CFCs emerge before the 
onset of haematopoiesis within EBs; they express the mesodermal markers Flk-1 and 
Brachyury, and have the potential to form colonies made of haematopoietic and 
endothelial cells after culture in methylcellulose containing vascular endothelial 
growth factor (VEGF) and transfer to liquid medium with cytokines (Choi et al., 
1998; Fehling et al., 2003; Kennedy et al., 1997). An analogous in vivo Flk-
1+Brachyury+ population has been isolated from the posterior region of the primitive 
streak as a transient population in the E7-7.5 embryo (Huber et al., 2004).  
The fact that BL-CFCs arise before the onset of haematopoiesis in EBs 
supports the idea of a common precursor for endothelial and haematopoietic cells. 
However, the mesodermal Flk-1+Brachyury+ immunophenotype and the presence of 
smooth muscle in the differentiated colonies raised the possibility that the cells used 
for secondary culture were a population of uncommitted mesoderm (Choi et al., 
1998; Fehling et al., 2003).  Taken together, these studies do not prove the existence 
of the haemangioblast because it is difficult to be sure that these progenitors are not 
capable of differentiating into some other mesodermal lineages. 
The most convincing in vivo proof of the haemangioblast was obtained in 
zebrafish through the construction of single-cell-resolution fate maps obtained by the 
laser activation of fluorescently labelled cells (Vogeli et al., 2006). This study 
demonstrated the presence of bipotential precursors arising along the ventral 
mesoderm and giving rise to small subsets of haematopoietic (GATA-1+) and 
endothelial (Flk-1+) cells exclusively (Vogeli et al., 2006).  However, assays 
confirming the functionality of Flk-1+ as endothelial, and GATA-1+ as 
haematopoietic, would provide a stronger proof for the existence of the 
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1.4.2.3. Concept of haemogenic endothelium  
 An alternative theory for the origin of haematopoiesis is that haematopoietic 
cells (and perhaps LTR-HSCs) are derived from endothelium that is already 
committed to an haematopoietic fate: the hemogenic endothelium (Jordan, 1917). 
Evidence in favour of this hypothesis came from studies in avian embryos in which 
heterotopic grafts of spanchnopleural lateral plate mesoderm, but not paraxial 
mesoderm, contribute to endothelial cells in the AoV as well as IAHC (Jaffredo et 
al., 1998; Pardanaud et al., 1996). Labelling of endothelial cells with acetylated low-
density lipoprotein (a-LDL) tag or with non-replicative retroviral vector and in vivo 
tracing of their progeny, strongly suggested that the IAHCs are derived from 
precursors in the underlying aortic endothelium (Jaffredo et al., 2000; Jaffredo et al., 
1998). However, the interpretation of these results is problematic as they rely on the 
following assumptions: the endothelial specificity of a-LDL uptake, the identity of 
endothelial cells being Flk-1+CD45- and all haematopoietic cells in the IAHCs being 
Flk-1-CD45+ (Jaffredo et al., 1998).  
 The first functional evidence of a haemogenic endothelium came from an in 
vitro ES cell differentiation model showing that Flk-1+ could give rise to VE-
cadherin+ that could differentiate into functional endothelium and haematopoietic 
cells (Nishikawa et al., 1998a). Analysis of such VE-cadherin+ endothelial cells 
(characterised as CD45-, Ter119-, PECAM-1+, Flk-1+, CD34+ and a-LDL+) isolated 
from E9.5 YS and embryo proper (caudal half of the embryo) could generate 
lymphoid and myeloid progeny as well as fully reconstitute the haematopoietic 
system of conditioned newborn recipients upon intrahepatic injections (Fraser et al., 
2002; Nishikawa et al., 1998b).  
 Recently, live cell imaging of the differentiation of ES cell derived Flk-1+E-
cadherin- mesodermal precursors has shown that endothelial cells (defined by 
morphology, VE-cadherin expression, incorporation of a-LDL and claudin-5 at the 
cell junctions) can give rise to haematopoietic cells that express CD41 prior to CD45 
(also defined by round non-adherent morphology and Mac-1 expression)(Eilken et 
al., 2009). These results confirm the existence of endothelial cells capable of 
haematopoietic commitment as well as the use of CD41 cell surface marker as the 
 
  46 
earliest reliable marker for haematopoietic cells. Similarly, another group also using 
time-lapse photography showed that Tie-2hic-kit+CD41- endothelial cell population 
could acquire the haematopoietic marker CD41 (Lancrin et al., 2009). Based on this 
transient cell population’s lack of Brachyury expression and failure to generate blast 
colonies, they postulate that the haemogenic endothelium is downstream of the 
heamangioblast (Lancrin et al., 2009). Finally, labelling of VE-cadherin expressing 
cells during embryogenesis by crossing an inducible VE-cadherin Cre with 
Rosa26R-lacZ demonstrated that haematopoietic cell in the fetal liver and in the 
adult haematopoietic organs are the progeny of the VE-cadherin labelled cells 
(Zovein et al., 2008). This could be an in vivo proof of the endothelial origin of LTR-
HSCs, but it relies on the assumption that VE-cadherin is exclusively specific to 
endothelial cells. In fact, VE-cadherin is expressed in the earliest population of HSCs 
in the AGM region (North et al., 2002; Taoudi et al., 2005).  
 
1.4.2.4. The mesodermal theories: pre-HSCs 
 So far, various types of long term engrafting cells in the murine embryo have 
been identified using different assays: LTR-HSCs from E10.5 AGM region, neonatal 
repopulating cells from E9 YS and low-level adult repopulating cells in the E8 P-Sp 
(Cumano et al, 2001; Muller et al, 1994; Yoder et al, 1997b). However, it is not clear 
whether these cells are ontogenetically related.  Specifically, it is reasonable to 
assume that early engrafting cells in the E9 YS and E8 P-Sp are pre-HSCs that 
require maturation before acquiring characteristics of LTR-HSCs (Medvinsky and 
Dzierzak, 1999). This idea is supported by a couple of circumstantial lines of 
evidence: first, the conserved expression of c-kit and CD34 among engrafting cells 
during development  (ie, in the E9.5 YS and P-Sp (Yoder et al., 1997a), and LTR-
HSCs in AGM region and placenta (Gekas et al., 2005; Sanchez et al., 1996)); 
second, the ability of the E8.25 YS cells to acquire LTR-HSC activity upon over-
expression of Hoxb4 (Kyba et al., 2002) or after co-culture with the AGM-S3 cell 
line (Matsuoka et al., 2001b). However, the ability of E9 and P-Sp to develop LTR-
HSC potential after experimental manipulation does not necessarily recapitulate the 
events occurring in vivo.  
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Direct evidence for pre-HSC maturation arose from kinetic analysis of the 
CD45+VE-cadherin+ compartment during ex vivo culture (Taoudi et al., 2008). 
Genetically labelled CD45+VE-cadherin+ isolated from the E11.5 AGM give rise to 
the vast majority of the 150 LTR-HSCs obtained during 4 days reaggregate culture 
(Taoudi et al., 2008). Carboxyfluorescein succinimidyl ester (CFSE) retention 
analysis demonstrated that the CD45+VE-cadherin+ cells underwent approximately 6 
divisions during the 4 days culture period (Taoudi et al., 2008). Considering that the 
E11.5 contains 1 CD45+VE-cadherin+ LTR-HSC (Kumaravelu et al., 2002; North et 
al., 2002; Taoudi et al., 2005), it is virtually impossible that proliferation of this 
single cell could account for the 150 LTR-HSCs obtained, so it became clear that 
CD45+VE-cadherin+ pre-HSCs matured into LTR-HSCs during ex vivo culture 
(Taoudi et al., 2008). However, the extent to which maturation and proliferation of 
pre-HSCs and LTR-HSCs contribute to the final pool of LTR-HSCs after 4 days 
culture remains to be determined.  
 
1.4.2.5. The mesodermal theories: sub-aortic patches 
 The observation of mesodermal structures, termed sub-aortic patches (SAP), 
located below the aortic floor in the E10.5-11.5 AGM region have been proposed to 
constitute a pool of pre-HSCs (Bertrand et al., 2005; Manaia et al., 2000). 
Immunostaining, in situ hybridization, and reverse transcriptase polymerase chain 
reaction (RT-PCR) analyses have indicated that SAPs express the haematopoietic 
markers Lmo-2, GATA-3, AA4.1, c-kit, PECAM-1, CD41, and low levels of CD45 
(Bertrand et al., 2005; Manaia et al., 2000). As only IAHCs express similar 
combination of haematopoietic markers, a close developmental link between these 
two structures was assumed. Additionally, the concomitant disappearance of SAP 
and IAHC with the cessation of LTR-HSC production by the AGM region further 
supported the idea that the pre-HSCs or/and LTR-HSCs migrate from SAP to IAHCs 
from which they are released in the peripheral circulation (Bertrand et al., 2005; 
Manaia et al., 2000). Direct functional evidence for such a model has not been 
provided so far and more sophisticated lineage trace systems (such as reaggregate 
culture) may be useful for the accurate tracing of pre-HSCs in the SAPs. 
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1.4.2.6. The primordial germ cells theory 
 The colonisation of the genital ridges at E10.5 by germ cells with totipotent9 
potential have led scientists to hypothesise primordial germ cells (PGCs) as a source 
of LTR-HSCs (Rich, 1995). PGCs are ectoderm-derived, express alkaline 
phosphatase and emerge at the base of the allantois in E6.5 embryos (Ginsburg et al., 
1990). The observation that PGCs can give rise to erythroid lineage cells and 
cobblestone areas indicates that these cells have haematopoietic potential, and 
therefore may harbour the potential for LTR-HSC formation (Rich, 1995). 
Functional evidence supporting this possibility remains to be published.  
 
1.5. Runx1 as a master regulator of haematopoiesis 
Runx1 (also known as AML1, PEBPα2 and CBFA2) is a transcription factor 
involved in many oncogenic chromosomal translocations (Speck and Gilliland, 
2002). The inactivation of Runx1 in murine models has stimulated major scientific 
interest on Runx1 because definitive haematopoiesis is completely ablated in Runx1-
/- embryos, whilst primitive haematopoiesis remains fairly undisturbed (Okuda et al., 
1996; Wang et al., 1996a).  
The Runx family of transcription factors consists of 3 members (Runx1, 
Runx2, and Runx3) that show a high degree of homology within their coding regions 
(Bae, 1993, Ogawa, 1993a). Runx2 is involved in osteogenesis in vivo; deficient 
murine embryos die neonatally, likely owing to an early arrest in osteoblast 
development and a malformed rib cage that prevents normal breathing (Komori et 
al., 1997). Runx3 is predominantly expressed in haematopoietic organs, epidermal 
appendages, developing bones and sensory ganglia; its inactivation in vivo highlights 
its role for the development and survival of dorsal root ganglia neurones (Levanon et 
al., 2002; Levanon et al., 2001a). Interestingly, Runx3 expression overlaps with 
                                                 
9 Totipotency refers to the ability of a single cell to divide and produce all the cell types in an 
organism, including extra-embryonic tissues.  
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Runx1 in the developing haematopoietic system, raising the possibility that cross-
regulation between them plays a role during embryogenesis (Levanon et al., 2001a; 
Spender et al., 2005). 
 
1.5.1. Structure and transcriptional regulation of Runx1 
gene 
1.5.1.1. Regulation of Runx1 transcription 
Mouse Runx1 spans 224 kb gene on chromosome 16 (analogous to 
chromosome 21 in the human), and comprises 7 protein coding exons (Bee et al., 
2009b)(Figure 1.7A). Transcriptional regulation of the human and murine Runx1 is 
under the control of distal (P1) and proximal (P2) promoters that are 128 kb apart 
and differ in their CpG contents (Bee et al., 2009b; Ghozi et al., 1996). Their 
alternative use directs the expression of Runx1 isoforms varying in the N-terminal 
region, and potentially leading to differential gene regulation (Levanon et al., 2001b). 
Among the upstream regulators of Runx1 expression are Runx transcription factors 
themselves as the P1 promoter contains Runx-binding sites (Ghozi et al., 1996; 
Pimanda et al., 2007). For example, Runx1 expression is repressed by Runx3 in B 
cells (Spender et al., 2005). Retinoic acid has also been speculated to act as an 
upstream regulator of Runx1 expression as an increased Runx1 expression was 
observed during retinoic-acid induced differentiation of human leukaemic monocyte 
lymphoma cell line (Tanaka et al., 1995).  
Transcriptional networks regulating Runx1 expression in the development of the 
haematopoietic system have been under scrutiny. Recently, a 23 kb enhancer, located 
in the first intron of Runx1, has been identified as a cis-regulatory element, acting 
during early haematopoiesis and depending on upstream regulators GATA-2 and Ets 
proteins (Nottingham et al., 2007). BMP-4 activity, well known for facilitating 
haematopoietic differentiation of ES cells and HSC activity in human cord blood 
cells culture (Bhatia et al., 1999; Chadwick et al., 2003), can modulate Runx1 








Figure 1.7: Mouse Runx1 genomic locus and alternative splice forms.
A: Runx1 genomic locus under control of distal (P1) and proximal (P2) promoters.
B: Runx1 splice forms: Runx1c, Runx1b, Runx1bΔEx5, 521-41 and Runx1bΔEx5-5.3.
Numbers correspond to exons, white boxes: coding sequences; grey: untranslated regions
(UTRs); striped: predicted coding + UTR.
(adapted from Bee et al, 2009).
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Finally, a recent study showed that SCL directly transactivates Runx1 in the fetal 
liver and YS via the binding of an SCL-Lmo2-GATA2 complex to regions flanking 
the conserved E-boxes of the Runx1 locus (Landry et al., 2008).  
 
1.5.1.2. Structure of the protein and alternative splicing  
The distal (P1) and proximal (P2) promoters direct primary transcripts that 
are alternatively spliced to give a repertoire of mRNA isoforms that are differentially 
expressed in various cell types at different developmental stages (Figure 1.7B). P1 
encodes RUNX1c while P2 encodes RUNX1b and the short isoform RUNX1a 
(Miyoshi et al., 1995). Very little is known about the role of specific isoforms in the 
emergence, maintenance, and expansion of LTR-HSCs. The generation of mice with 
significantly diminished proximal promoter activity on the second allele suggested 
that P1 (Runx1c) activity was sufficient for primitive haematopoiesis whereas P2 
activity (Runx1b) was required for adult definitive haematopoiesis (Pozner et al., 
2007).  Interpretations of these results are limited to the fact that a hypomorphic dose 
of Runx1 was available during development. A recent study focusing on P1 and P2 
transcripts in the YS, AGM, placenta, fetal liver, and adult bone marrow showed that 
primitive erythropoiesis is largely P2 driven (Bee et al., 2009b). Both P1 and P2 act 
with the +23 enhancer to drive the transcription of Runx1 in the YS, AGM, and fetal 
liver at the time of LTR-HSC emergence (Bee et al., 2009a; Bee et al., 2009b). After 
haematopoietic cell migration to the liver, P1 gradually becomes the main 
haematopoietic promoter, as it will remain into adulthood (Bee et al., 2009b). 
Runx proteins are conserved and share a runt DNA-binding domain, 
homologous with the Drosophila pair-rule gene runt  (Kania 1990). A nuclear 
localisation signal (NLS) is located within the Runt domain and immunofluorescent 
labelling experiments have shown that Runx1 localised in the nucleus (Lu et al., 
1995).  
Runx1 functions as a heterodimeric transcription factor composed of Runx1 
(DNA binding unit) and CBFβ, a 128 amino acids protein which allosterically 
enhances the DNA binding affinity of Runx1 (Yan et al., 2004). The requirement of 
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CBFβ for normal Runx1 function is supported by CBFβ knockout mice, which 
display a very similar phenotype to the Runx1 knockout animals (Niki et al., 1997; 
Okuda et al., 1996; Sasaki et al., 1996; Wang et al., 1996a; Wang et al., 1996b). 
Interestingly, CBFβ is mainly located in the cell cytoplasm, suggesting that its 
translocation to the nucleus is another regulatory mechanism of Runx1 function (Lu 
et al., 1995; Tanaka et al., 1997). Additionally, CBFβ also protects Runx1 protein 
from ubiquitin-proteasome-mediated degradation, thus regulating Runx1 turnover 
(Huang et al., 2001). A model of Runx1 cellular localisation and its regulation is 
summarised in Figures 1.8.   
 
1.5.1.3. Runx1-mediated transcriptional activation 
 Upon DNA binding, Runx1/CBFβ acts as an organising factor by recruiting 
various co-factors and interacting with other transcription factors genes (Durst and 
Hiebert, 2004; Lutterbach et al., 2000)(summarised in Figure 1.9A). A number of 
haematopoietic genes are activated by Runx1, including interleukin-3 (IL-3)(Uchida 
et al., 1997), granulocyte-macrophage colony stimulating factor (GM-CSF), 
macrophage colony stimulating factor (M-CSF)(Zhang et al., 1996), CSF-1 receptor 
(Zhang et al., 1994), neutrophil elastase (Nuchprayoon et al., 1994), 
myeloperoxidase (Suzow and Friedman, 1993), or the defensin protein, NP3 









Figure 1.8: Cellular localization of Runx1 and dimerization with CBFβ.
Once synthesized, Runx1 is targeted to the nucleus but it has a poor DNA binding affinity
due to negative regulatory domain for DNA binding (NRDB)n and NRDBc occupying
Runx1 runt domain. CBFβ, which is stored in the cytoplasm, is targeted to the nucleus
where dimerization with Runx1 happens at the runt domain, enhancing Runx1/CBFβ DNA
binding affinity. Runx1/CBFβ then binds to target genes promoters and influence their




Figure 1.9: Models of Runx1-mediated transcriptional activation and repression.
A: Runx1 mediated transcriptional activation. Runx1/CBFβ binds to DNA and recruits co-
activators such as ETS1, Myb, or C/EBP. LEF-1 protein induces DNA bending and
P300/CBP is recruited and mediates interactions with both histone acetyltransferases and
basal transcription complex proteins.
B: Runx1-mediated transcriptional repression. Upon DNA binding, Runx1/CBFβ recruits
co-repressors Groucho and mSin3A and LEF-1 protein induces DNA binding. The
epigenetic state is altered by histones deacetylases (HDACs) and methyltransferases
(SUV39H1 for instance) when they are recruited.
These diagrams are simplified and do not take into account particular situations.
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1.5.1.4. Runx1 mediated transcriptional inactivation  
 Even though Runx1 on its own appears to be a weak transcriptional enhancer, 
it is a potent transcriptional repressor (Durst and Hiebert, 2004). Interactions with 
Groucho, dCtBP, and histone deacetylases (Rpd3 and mSin3A) act in the 
maintenance of repression via three repression domains (RD1, 2, 3)(Figure 
1.9B)(Aronson et al., 1997; Lutterbach et al., 2000; Wheeler et al., 2002).  For 
example, Groucho interacts with Runt proteins at the C-terminal VWRPY amino 
acid sequence located in RD3 (Aronson et al., 1997) whereas recruitment of mSin3A 
and USV39H1, a histone methyltransferase, are via RD1 and RD2 respectively 
(Lutterbach et al., 2000; Reed-Inderbitzin et al., 2006). The most famous 
haematopoietic gene downregulated by Runx1 is the T cell marker CD4 (Durst and 
Hiebert, 2004).  
 
1.5.2. The roles of Runx1 in adult haematopoiesis 
 The roles of Runx1 in adult haematopoiesis have been widely investigated 
because chromosomal translocations leading to impaired function of Runx1 in the 
haematopoietic system are associated with a wide range of disorders (Speck and 
Gilliland, 2002).  
 
1.5.2.1. Runx1 in LTR-HSCs  
 The LTR-HSC enriched fraction lin-c-kit+ express high levels of Runx1 in the 
functional Runx1-IRES-GFP knock-in model, which has no observable 
haematopoietic phenotype (Lorsbach et al., 2004).  
Although Runx1 is essential for embryonic haematopoiesis, its role during 
adult haematopoiesis remained unclear for a long time. To elucidate this issue, 
scientists generated models in which Runx1 can be deleted by Cre-mediated 
recombination (Growney et al., 2005; Ichikawa et al., 2004; Putz et al., 2006). Such 
models showed that Runx1 is not essential for adult haematopoiesis and the null 
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mutation (Runx1Δ/Δ) leads to expansion of the LTR-HSC pool but with a possible 
reduced competitive repopulating activity (Growney et al., 2005; Ichikawa et al., 
2004; Ichikawa et al., 2008; Putz et al., 2006).  
However, the effects of different Runx1 dosages in adult mice are still 
unclear. While the large majority of LTR-HSCs in haploinsufficient animals express 
Runx1, Ichikawa and colleagues report an increase in the number of LTR-HSCs 
whereas Sun and Downing reports a 50% decrease in the number of LTR-HSCs 
(Ichikawa et al., 2008; Sun and Downing, 2004). The reason for this discrepancy is 
most likely due to the fact that Ichikawa’s animals had two Runx1 functional alleles 
until poly(I:C) injection  whereas Sun’s animals were haploinsufficient since 
conception (Ichikawa et al., 2008), indicating that a full dose of Runx1 is necessary 
for establishing a normal LTR-HSCs pool.  
 
1.5.2.2. Runx1 roles in lymphoid lineages  
 The role of Runx1 in the development of T cells is now well documented 
(Collins et al., 2009). In the knock-in reporter mouse, Runx1 is highly expressed in 
CD4-CD8- thymocytes10 and CD4+ peripheral T cells express 2 to 3 times higher 
levels of Runx1 compared to CD8+ T cells (Lorsbach et al., 2004). Runx1 role in 
mature CD4+ T cells is dose-dependent, which is supported by literature 
documenting gene silencing of CD4 by Runx1 (Collins et al., 2009; Durst and 
Hiebert, 2004; Growney et al., 2005). Lineage analyses of the reconstitution obtained 
from Runx1Δ/Δ adults have showed a defect in lymphoid reconstitution (B and T 
cells)(Growney et al., 2005; Ichikawa et al., 2004; Ichikawa et al., 2008; Putz et al., 
2006). The reduced size of thymi and the accumulation of CD4-CD8- thymocytes 
                                                 
10 T-cell lineage choice in the thymus progresses through a series of developmental stages: CD4-CD8- 
(DN) precursors enter the thymus and begin rearranging the T-cell receptor-β chain locus and become 
CD4+CD8+ (DP) and then commit to CD4+ or CD8+ (SP) mature T cell fate (Collins et al, 2009).  
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indicate that Runx1 is required in the early stages of T cell differentiation (Growney 
et al., 2005; Putz et al., 2006).  
 In addition to T cells, there is a severe defect in B cell maturation in Runx1 
null adults and also a defect in reconstituting the B cell compartment of recipients 
(Growney et al., 2005; Ichikawa et al., 2004; Putz et al., 2006).  Runx1 is expressed 
at similar levels during stages of B cell development (North et al., 2004) but very 
little is known about the stage of B cell maturation at which Runx1 is important.  
 
1.5.2.3. Roles of Runx1 in myeloid lineages  
A full deletion (Runx1Δ/Δ) or a haploinsufficient dose, present throughout 
development (Runx1lz/WT) or induced during adulthood (Runx1Δ/WT), results in an 
increased number of committed myeloid progenitors, which can give rise to a 
myeloproliferative phenotype, thrombocytopaenia or splenomegaly (Ichikawa et al., 
2008; Putz et al., 2006; Sun and Downing, 2004).  
  
1.5.2.3.1. Role of Runx1 in megakaryocytes 
It was shown that Runx1 is up-regulated at the early stages of 
megakaryocytic differentiation (Elagib et al., 2003; Lorsbach et al., 2004). Inducible 
Runx1 deletion (Runx1Δ/Δ) results in a rapid and prolonged fivefold drop in peripheral 
blood platelets whereas it has minimal effects on red blood cell and neutrophil 
numbers (Goldfarb, 2009; Growney et al., 2005; Ichikawa et al., 2004). 
Histochemical analysis of Runx1Δ/Δ bone marrow with acetylcholinestase staining 
showed an absence of normal looking megakaryocytes but an increase in small, 
hypolobulated megakaryocyte-like cells showing a marked decrease in ploidy 
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1.5.2.3.2. Role of Runx1 in erythrocytes 
 Runx1 reporter models have clearly shown that Runx1 is down-regulated 
upon erythrocyte differentiation, which can be followed by the differential 
expression of cell surface markers CD71 and Ter119 (Basecke et al., 2002; Kina et 
al., 2000; Lorsbach et al., 2004; North et al., 2004). However, conditional deletion of 
Runx1 does not affect erythroid cell numbers or the potential to reconstitute the 
erythroid compartment (Growney et al., 2005; Putz et al., 2006; Sun and Downing, 
2004), indicating Runx1 is dispensable for erythrocyte maturation.  
 
1.5.2.3.3. Role of Runx1 in monocytes/macrophages 
 In WT and Runx1 haploinsufficient adult bone marrow, the large majority of 
myeloid blast cells, granulocytes and monocytes express Runx1 at various stages of 
maturation (Basecke et al., 2002; North et al., 2004). Runx1Δ/Δ animals can 
reconstitute the granulocytic and monocytic compartments of irradiated recipients, 
indicating that the effect of Runx1 deletion in these myeloid cells is milder compared 
to lymphoid lineages (Growney et al., 2005; Ichikawa et al., 2004). However, the 
increased myeloid cell numbers observed in the spleen and the bone marrow of 
Runx1Δ/Δ adults, together with Runx1 expression in myeloid lineages and Runx1-
mediated activation of the M-CSF promoter, strongly suggest a potential role of 
Runx1 in myeloid development but its stage specific requirement is still to be fully 
investigated (Basecke et al., 2002; Growney et al., 2005; Ichikawa et al., 2004; North 
et al., 2004; Putz et al., 2006).  
 
1.5.3. Roles of Runx1 during embryonic development  
1.5.3.1. Runx1 expression in the developing null or haploinsufficient 
embryo 
 Runx1 expression in the knock-in LacZ reporter mouse model is first 
observed at E7.5, at the neural stage plate, in the endoderm and some extraembryonic 
mesodermal cells (North et al., 1999). At E8.5, strong LacZ expression can be 
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observed in the YS blood islands (both endothelial and haematopoietic cells), in the 
distal portion of the allantois at the junction point with the chorion, in endothelial 
cells of the vitelline artery and in the ventral aspect of the paired dorsal aortae (North 
et al., 1999). LacZ is also expressed in primitive erythrocytes but its expression 
diminishes and disappears by E11.5 (North et al., 1999). At E10.5, the time of LTR-
HSC emergence, Runx1 expression can be observed in the vitelline and umbilical 
arteries, the AGM region, the fetal liver, the placental labyrinth and other sites 
unrelated to haematopoiesis such as the olfactory epithelium, the spinal ganglia, and 
the maxillary processes (North et al., 1999; Rhodes et al., 2008; Simeone et al., 1995; 
Zeigler et al., 2006)(Figure 1.10B). In the E10.5-11.5 AGM region, Runx1 is 
expressed in ventral IAHCs, and particularly endothelial, haematopoietic and 
mesenchymal cells (North et al., 1999; North et al., 2002)(Figure 1.10C and D). Most 
importantly, Runx1 marks LTR-HSCs in the Runx1 haploinsufficient embryo (North 
et al., 2002). 
 
1.5.3.2. Insights from the Runx1 knockout model 
Runx1 deficiency (Runx1-/-) results in a complete block of LTR-HSC 
emergence with no IAHCs in the Ao and vitelline and umbilical arteries (North et al., 
1999; Okada et al., 1998; Okuda et al., 1996; Wang et al., 1996b). Runx1-/- embryos 
develop extensive central nervous haemorrhages and anaemia and die between E11.5 
and E12.5 (Okuda et al., 1996; Samokhvalov et al., 2006; Wang et al., 1996a)(Figure 
1.10A). Extensive cellular necrosis involving endothelial cells in the nervous system 
capillaries has been observed (Wang et al., 1996a).  
No differences in primitive erythrocyte morphology or numbers are observed 
between Runx1-/- embryos and WT age-matched controls (Okuda et al., 1996; Wang 
et al., 1996a). However, primitive erythrocytes in Runx1-/- mice display abnormal 
morphology and a reduced expression of Ter119 and GATA-1 (Yokomizo et al., 
2008).  
In contrast to primitive haematopoiesis, there is a total lack of adult-type 




Figure 1.10: Phenotype of Runx1 deficient E11.5 embryos and Runx1 expression in
embryonic organs.
A: Phenotype of E11.5 Runx1 deficient embryo (Runx1-/-) compared to wild type (WT).
Runx1-/- embryo displays clear central nervous system haemorrhages and liver pallor
(pointed by arrows)(taken from Samokhvalov et al, 2006).
B: Runx1 expression in the E11.5 Runx1 haploinsufficient (Runx1+/-) embryo (in LacZ
knock-in reporter mouse model). Runx1 expression in observed in haematopoietic sites such
as vitelline (v) and umbilical (u) arteries, the AGM (agm) region, and the fetal liver (fl) and
non-haematopoietic sites such as the olfactory epithelium (o), the maxillary processes (m),
spinal ganglia (g) and external genitalia (not seen from this angle)(taken from North et al,
1999).
C: Sections of E10.5 Runx1+/- embryo showing Runx1 expression on the ventral wall of the
dorsal aorta (a) and in haematopoietic cells in the fetal liver (fl)(taken from North et al,
1999).
D: View of the ventral wall of the E10.5 Runx1+/- dorsal aorta showing Runx1 expression in
endothelial cells (closed arrows), para-aortic mesenchyme (open arrows) and circulating
haematopoietic cells (c))(taken from North et al, 1999).
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myeloid, and megakaryocytic cells in the fetal liver, and functionally characterised 
by the absence of haematopoietic progenitors and LTR-HSCs in the E9.5-11.5 YS, P-
Sp/AGM region, and fetal liver (Mukouyama et al., 2000; North et al., 1999; Okuda 
et al., 1996; Wang et al., 1996a). The essential requirement for Runx1 in the 
generation of the adult haematopoietic system was confirmed by the failure of 
Runx1-/- ES cells to contribute to adult haematopoietic system in chimaeric animals 
(Okuda et al., 1996). In addition, further support was obtained from experiments in 
which the rescue of Runx1 expression in Runx1-/- ES cells in vitro, or by conditional 
reactivation of a reversible knockout in vivo restores definitive haematopoietic 
potential (Goyama et al., 2004; Mukouyama et al., 2000; Okuda et al., 2000; 
Samokhvalov et al., 2006).  
 
1.5.3.3. Runx1 effect on LTR-HSC emergence is dose-dependent 
 The study of the LacZ reporter mouse showed that haploinsufficiency results 
in a dramatic change in temporal and spatial distribution of LTR-HSCs (Cai et al., 
2000). The emerging LTR-HSCs in the E10.5 and E11.5 AGM, vitelline and 
umbilical arteries in these animals all express Runx1 but have a heterogenous 
immunophenotype, including haematopoietic (CD45+), endothelial (PECAM-1+, VE-
cadherin+, and Flk1+), and mesenchymal cells (CD45-VE-cadherin-); proportions in 
the haploinsufficient embryo varied from WT controls (North et al., 2002).  
 Additionally, a hemizygous dose of Runx1 results in fewer CFU-Cs in the 
E10.5-11.5 YS and the E9.5-11.5 P-Sp/AGM region and also CFU-S in the YS, 
AGM and fetal liver from E10.5 onwards (Cai et al., 2000; Mukouyama et al., 2000; 
Okuda et al., 1996; Robin et al., 2006; Wang et al., 1996a). Kinetics of LTR-HSCs 
appearance in these embryos demonstrated that LTR-HSCs emerge earlier as they are 
readily detectable in the E10.5 AGM region and the YS (Cai et al., 2000). Explants 
culture confirmed the early emergence of LTR-HSCs in the YS. However, LTR-HSC 
maintenance/expansion in the E10.5 AGM region requires two functional Runx1 
alleles, suggesting a requirement for Runx1 in the AGM microenvironment (Cai et 
al., 2000). Also, both the numbers of IAHCs and LTR-HSCs in the AGM region are 
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Runx1 dose dependent (Cai et al., 2000; North et al., 1999; Robin et al., 2006; 
Yokomizo et al., 2001), providing further circumstantial evidence for a 
developmental link between IAHCs and LTR-HSCs.  
 
1.5.3.4. Runx1 and the emergence of LTR-HSCs  
 The expression of Runx1 in an array of cell types in the E10.5 AGM region, 
as well as the failure of Runx1 deficient embryos to generate LTR-HSCs, has led 
scientists to wonder which specific cell types require Runx1 to allow LTR-HSC 
development. One study reported that LTR-HSCs ancestor cells are marked by 
Runx1 and can be traced back to the E7.5 YS (Samokhvalov et al., 2007). Apart from 
showing that LTR-HSCs ancestors express Runx1 at some stage, this study remains 
controversial because it fails to demonstrate robustly that labelling cannot occur in 
the embryo proper, allantois and placenta. Many other laboratories have also 
attempted to understand which mechanisms controlled by Runx1 are involved in the 
emergence of LTR-HSCs.  The available data supports a model in which Runx1 is 
essential for the transition of haemogenic endothelial cells (see Section 1.4.2.3) to 
haematopoietic commitment, and more particularly LTR-HSCs (Chen et al., 2009; 
North et al., 2002; Yokomizo et al., 2001).  
 The first evidence supporting this model came from the observation that 
Runx1-null endothelial cells (VE-cadherin+ in this case) fail to generate definitive 
haematopoietic lineage cells (Yokomizo et al., 2001). This was further indicated by 
the combined observations that Runx1-null embryos have similar numbers of VE-
cadherin+ compared to WT controls but have virtually no CD45+VE-cadherin+ cells, 
suggesting that there is a failure in haematopoietic commitment at this early stage 
(Fraser et al., 2003; Yokomizo et al., 2001). Additionally, North and colleagues 
reported that endothelial (PECAM-1+ or VE-cadherin+) and mesenchymal cell 
fractions in the E10.5-11.5 AGM region, vitelline and umbilical arteries had some 
LTR-HSC activity (North et al., 2002). However, this study involved Runx1 
haploinsufficient embryos, which have impaired LTR-HSCs kinetics and 
immunophenotype. Additionally, their idea of a Runx1+ endothelial LTR-HSC is 
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based on the lack of CD45 expression, indicating a non-haematopoietic phenotype 
(North et al., 2002). As previously discussed, CD41 is a more accurate early marker 
for haematopoietic cells as it is expressed earlier than CD45, suggesting that VE-
cadherin+CD45-Runx1+ cells might already be haematopoietic (Eilken et al., 2009; 
Ferkowicz et al., 2003; Mikkola et al., 2003a). Finally, a recent study from the same 
lab used a conditional knockout in vivo approach to better define the stage at which 
Runx1 is essential for LTR-HSC emergence (Chen et al., 2009). Runx1 deletion in 
the endothelial compartment, using VE-cadherin Cre recombinase, showed that LTR-
HSCs are much reduced in the E11.5 AGM region of the Runx1Δ/Δ:VE-cadherin Cre 
animals (Chen et al., 2009). This indicates that LTR-HSC development is impaired, 
but with a strong selective pressure exerted on cells that escape excision, accounting 
for the presence of LTR-HSCs (Chen et al., 2009). Similar experiments with Vav-
Cre were carried out and showed that Runx1 excision in the Vav+ compartment does 
not affect the LTR-HSC development. Vav expression is restricted to most 
haematopoietic lineages in vivo (Ogilvy et al., 1999) so it was assumed Vav+ cells 
are already be committed haematopoietic fate.  Based on this assumption, they 
concluded that Runx1 is essential at the endothelial cell level but is dispensable 
afterwards (Chen et al., 2009), pinpointing a stage at which Runx1 is no longer 
required. Lancrin and colleagues came to a similar conclusion using an in vitro ES 
cell model in which they could rescue Runx1 expression and showed that Runx1 is 
not necessary for the establishment of haemogenic endothelium (defined as Tie2+c-
kit+CD41-) but is required for definitive haematopoiesis by this population based on 
colony assay (Lancrin et al., 2009). Even though these studies yielded very 
interesting observations, the criteria by which endothelial cells are defined (Tie2 
expression or VE-cadherin expression only) are not sufficiently robust; thus 
compromising the interpretation that Runx1 is needed for the transition from 
hemogenic endothelial cells to LTR-HSCs.  
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1.6. The ex vivo expansion of LTR-HSCs  
 The failure to generate LTR-HSCs from ES cells in vitro has challenged the 
field of haematopoiesis for years. In contrast, attempts to induce, maintain, and 
expand LTR-HSCs from haematopoietic tissues ex vivo have proven fairly successful 
and have provided major insights into LTR-HSC biology. HSC expansion is defined 
as a symmetrical self-renewal division generating two HSCs whereas HSC 
maintenance involves asymmetrical self-renewal division generating one HSC and a 
more differentiated progeny (Cellot and Sauvageau, 2006). Extensive LTR-HSC 
expansion occurs during ontogeny within the placenta and the fetal liver niche (Ema 
and Nakauchi, 2000; Gekas et al., 2005; Morrison et al., 1995). Studies aiming to 
achieve LTR-HSC expansion in vitro are briefly reviewed in the following sections. 
   
1.6.1. Hoxb4: a potent stimulator of LTR-HSC expansion 
 Insights into the roles of Homeobox (Hox) genes in haematopoiesis emerged 
from over-expression studies. For example, over-expression of Hoxa10, Hoxb3 and 
Hoxb6 in bone marrow cells results in a block in differentiation of B and T cells, 
impaired erythropoiesis and myeloproliferative disorders (Argiropoulos and 
Humphries, 2007). The engineered retroviral over-expression of Hoxb4 in the bone 
marrow transplantation model induces LTR-HSC expansion both in vivo and in vitro 
(Sauvageau et al., 1995). A subsequent study using a similar approach achieved a net 
41 fold ex vivo expansion of LTR-HSC with normal reconstitution of both the 
myeloid and lymphoid compartments without inducing leukaemia (Antonchuk et al., 
2002), placing Hoxb4 as one of the most potent stimulator of LTR-HSC expansion. 
In addition, Hoxb4 over-expressing cells have enhanced regenerative potential; 
meaning transplantation with over-expressing Hoxb4 cells can restore the LTR-HSC 
pool to its normal size compared to around 25% with controls (Antonchuk et al., 
2001; Antonchuk et al., 2002; Sauvageau et al., 1995; Thorsteinsdottir et al., 1999).
 Intriguingly however, the effects of Hoxb4 deficiency on LTR-HSC self-
renewal are fairly elusive, with no disruption of definitive haematopoiesis albeit with 
subtle reductions in HSC and progenitors numbers and a modest impairment of the 
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competitive repopulating ability (Argiropoulos and Humphries, 2007; Bijl et al., 
2006; Brun et al., 2004). More recently, a near-complete Hoxb cluster knockout 
revealed that Hoxb genes are dispensable for normal haematopoiesis as Hoxb 
deficient LTR-HSCs remain competitive and retain their full differentiation potential 
(Bijl et al., 2006). Taken together, these studies highlight the complex network of 
genetic interactions between different categories of Hox genes in LTR-HSCs biology 
and demonstrate their potential overlapping functions (Argiropoulos and Humphries, 
2007; Bijl et al., 2006).  
 
1.6.2. Soluble growth factors as potent inducers of LTR-
HSC expansion  
 Stem cell engineering using retroviral transduction raises the issue of safety 
when it comes to applying this knowledge to the clinic. Many attempts to achieve 
LTR-HSC expansion by modulating the growth factors present in ex vivo culture 
media have been reported. The most successful bone marrow LTR-HSC expansion 
achieved a 30 fold LTR-HSC expansion upon culture in serum free medium 
supplemented with soluble SCF, thrombopoeitin (TPO), Insulin-like growth factor 2 
(IGF-2), fibroblast-growth factor 1 (FGF-1) and angiopoietin like 2 and 3 (Zhang et 
al., 2006). Our group also recently reported a 150-fold LTR-HSCs increase during 4 
days ex vivo culture with SCF, IL-3 and Flt3l (Taoudi et al., 2008). However, this 
increase was due to pre-HSC maturation rather than expansion by symmetrical self-
renewal divisions (Taoudi et al., 2008). 
 Cytokines are secreted proteins that regulate many aspects of LTR-HSC 
functions including quiescence, self-renewal, differentiation, apoptosis and mobility 
(Zhang and Lodish, 2008). It is believed that stromal cells in HSC niches (see 
Section 1.2.1.2) synthesise the appropriate HSC cytokines but little is known about 
which cytokine is produced by which niche stromal cell type (Zhang and Lodish, 
2008). The roles of SCF, IL-3 and Flt3l in the regulation of LTR-HSC 
emergence/maintenance and expansion are discussed. For a more detailed summary 
of cytokine families involved in haematopoiesis, refer to (Zhang and Lodish, 2008). 
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1.6.2.1. Stem cell factor  
 Also known as Steel factor, SCF functions by binding to c-kit, which is 
expressed in LTR-HSCs throughout development (Gekas et al., 2005; Morrison et 
al., 1995; Sanchez et al., 1996; Yoder et al., 1997a). Almost all cytokine 
combinations used for the ex vivo culture of LTR-HSCs include SCF (Zhang and 
Lodish, 2008). 
SCF deficiency results in reduced numbers of LTR-HSCs (assessed by 
numbers of Lin-Thy-1loSca1+ cells in the E13-15 fetal liver) and CFU-S but does not 
affect their proliferation (Ikuta and Weissman, 1992). Interestingly, fetal liver LTR-
HSCs are 6-fold more sensitive to SCF than their adult counterparts, meaning that 50 
ng/mL of SCF is sufficient to maintain fetal liver LTR-HSCs in vitro compared to 
300 ng/mL (and 20 ng/mL of IL-11) required for adult LTR-HSCs (Bowie et al., 
2007a). Taken together, these studies prove that fetal LTR-HSCs are highly sensitive 
to exogenous SCF and that SCF/c-kit-mediated cellular responses might provide an 
explanation for why fetal and adult LTR-HSC display different biological properties.  
 
1.6.2.2. Interleukin-3 
 The effect of IL-3 on adult LTR-HSC function remains controversial, as it 
has been reported both to enhance (Bryder and Jacobsen, 2000) and inhibit (Peters et 
al., 1996; Yonemura et al., 1996) LTR-HSC expansion ex vivo. These discrepancies 
could be due to differences in concentration, presence of other cytokines or serum 
(Robin et al., 2006).  
 Disruption of IL-3 or the IL-3 receptor genes does not affect adult steady 
state haematopoiesis as IL-3 deficient mice have normal blood cell counts, CFU-Cs 
and LTR-HSCs (Lantz et al., 1998; Mach et al., 1998). Exogenous addition of SCF to 
IL-3-/- bone marrow cultures results in fewer mast cells compared to WT cultures 
(Lantz et al., 1998). This defect was rescued by the addition of exogenous IL-3, 
highlighting the synergetic action of IL-3 and SCF (Lantz et al., 1998). Only one 
study to date has investigated the role of IL-3 on the emergence/expansion of LTR-
HSCs during embryonic development (Robin et al., 2006). The numbers of LTR-
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HSCs contained in the E11.5 AGM region, YS and placenta are decreased compared 
to WT controls in the IL-3 haploinsufficient embryos, and undetectable in the IL-3 
knockout animals (Robin et al., 2006). Similar results were obtained in explants of 
IL-3 mutant haematopoietic tissues (Robin et al., 2006). Exogenous addition of IL-3 
mediates proliferation and survival of phenotypically enriched LTR-HSC 
populations (CD34+c-kit+ (Sanchez et al., 1996) and Sca-1+c-kit+ (de Bruijn et al., 
2002)) as well as their early appearances in the E10.5 AGM region and YS (Robin et 
al., 2006). Interestingly however, addition of exogenous IL-3 to explant medium 
yields an unprecedented 35-fold expansion in E11.5 AGM explants, with a similar 
positive effect of IL-3 observed in E11.5 YS and placenta explants (Robin et al., 
2006). Taken together, this study highlights the important positive role of IL-3 in the 
emergence, proliferation and survival of the first LTR-HSCs (Robin et al., 2006).  
 
1.6.2.3. Flt3-ligand 
 Fms-like tyrosine kinase 3 (Flt3, also known as Flk-2) is activated by its 
ligand (Flt3l), which can be released as a soluble homodimeric protein and is 
expressed in cells of the bone marrow microenvironment as well as myeloid and 
lymphoid heamatopoietic cell lines (Gilliland and Griffin, 2002). When soluble Flt3-l 
is administered to mice, haematopoietic progenitors in the bone marrow and the 
spleen expand and HSCs are mobilised into the peripheral blood (Brasel et al., 1996). 
Flt3l deficient animals do not display any overt phenotype, they have normal 
numbers of LTR-HSCs but display reduced numbers of B cell progenitors, dendritic 
cells and natural killer cells in vivo (McKenna et al., 2000; Sitnicka et al., 2002).  
 A recent study focusing on E14.5 fetal liver of Flt3 deficient embryos has 
shown that Flt3 receptor and ligand are dispensable for normal LTR-HSC function, 
both in steady state, and during fetal or posttransplantation expansion (Buza-Vidas et 
al., 2009). While this study implies that fetal liver LTR-HSC expansion is not 
impaired in Flt3l deficient embryos in vivo, no current study has addressed a 
potential role of Flt3l in the emergence of LTR-HSCs at earlier developmental stages 
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(E10.5 at the onset of LTR-HSC emergence) or in other embryonic haematopoietic 
organs (AGM region, YS and placenta).  
 However, the engraftability of bone marrow LTR-HSCs after ex vivo culture, 
and the enhancement of LTR-HSC expansion by the concerted effects of SCF and 
Flt3l, confirm previous studies reporting that Flt3l strongly synergises with other 
haematopoietic growth factors and interleukins (Buza-Vidas et al., 2009; Diehl et al., 
2007; Gilliland and Griffin, 2002). 
Despite a great progress in the past decade, identification and functional 
study of HSC cytokines are still at the primitive stage and many secreted or cell 
surface proteins that affect HSC function remain to be discovered (Zhang and 
Lodish, 2008).   
 
1.7. Summary and project goals  
 While various sites such as the AGM region, the YS, the fetal liver and the 
placenta harbour LTR-HSCs during embryogenesis, the question of the site of the 
first LTR-HSC emergence remains controversial. Functional evidence to date has 
indicated that the E10.5 AGM region is the earliest site with detectable LTR-HSC 
activity and with the capacity to autonomously initiate LTR-HSC expansion 
(Medvinsky and Dzierzak, 1996; Muller et al., 1994).  The unique properties of the 
AGM region to autonomously expand LTR-HSCs have generated a large interest in 
the field of haematopoiesis. However, dissection of mechanisms underlying this 
process has been complicated by the lack of a culture system in which individual 
cells could be manipulated and yet maintain the capacity of the organ to expand 
LTR-HSCs. Recently, the reaggregate culture system was developed in our lab 
(Taoudi et al., 2008).  This system enables the dissociation of the E11.5 AGM region 
prior to culture whilst maintaining its ability to expand LTR-HSCs. The project 
presented here is based on this system and follows three major lines of investigation: 
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1. The E11.5 AGM reaggregate system is capable of ex vivo expanding LTR-HSCs 
from 1 (Kumaravelu et al., 2002) to 150 (Taoudi et al., 2008), a range similar to what 
is observed in vivo (Gekas et al., 2005). Such expansion is achieved in the presence 
of the cytokines IL-3, SCF and Flt3l.  
a) The first goal of this project was to phenotypically characterise the LTR-HSCs 
obtained in reaggregates.  
b) The second goal was to investigate the role of individual cytokines in the LTR-
HSC expansion.  
 
2. The second part of this project was to understand the role of Runx1 in the 
emergence and expansion of LTR-HSCs in the E11.5 AGM region using the 
reaggregate system. In order to address this question, our Runx1EGFP reporter mouse 
model was used.   
a) The first goal was to characterise Runx1 expression in cell populations in the 
adult and the E11.5 embryo to establish whether the transgenic Runx1EGFP allele was 
functional.  
b) The second goal was to identify non-haematopoietic cell populations expressing 
Runx1 and assess their potential to develop into LTR-HSCs using the reaggregate 
culture system.  
 
3. The third part aimed to localise pre-HSCs within the E11.5 AGM region using the 
reaggregate culture system. De Bruijn et al have previously shown that the Ao is the 
site where the first LTR-HSC appear in the E11.5 AGM region (de Bruijn et al., 
2000b). Within the Ao, the majority of LTR-HSCs emerge and are localised to the 
AoV (Taoudi and Medvinsky, 2007).  
a) The first goal was to investigate the possible axio-lateral polarity of LTR-HSC 
development in reaggregates and whether close proximity of Ao and UGR cells 
affected their haematopoietic potential.  
b) The second goal was to assess the presence of cells in the AoD that might be 
competent to mature into LTR-HSCs when exposed to the AGM microenvironment 
(ie, the AoV and UGR).  
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2. Materials and Methods 
Most of the methods described in this section are routinely used in our 
laboratory and were previously described in (Taoudi, 2006). 
2.1. General solutions  
 Dissection solution: room temperature (RT) Dulbecco’s phosphate buffered 
saline (PBS) solution (with Mg2+ and Ca2+ ions; Sigma) containing 7% fetal calf 
serum (FCS) (Gibco, PAA, or Biosera) and 50 units/ml penicillin and streptomycin 
(P/S; Gibco). 
 Flow Cytometry buffer solution: Dulbecco’s PBS (without Mg2+ and Ca2+) 
containing 7% FCS and 50 units/ml P/S. 
 
2.2. Animals  
2.2.1. Animal husbandry 
 C57BL6, CBA, aEGFP (termed GFP) and Runx1EGFP animals were housed 
and bred within the University of Edinburgh animal houses and according to the 
regulations of the Animals Scientific Procedures Act, UK, 1986. Animals were 
provided with a constant supply of water and chow food, and were housed in a 
constant environment with a 14 hours light/10 hours dark cycle (midpoint 12am and 
12pm, and midpoint 7am and 7pm for recipient animals).  
 Litters obtained were left with parents for three weeks postnatally before 
weaning by separating parents and offsprings. Only mice older than 6 weeks were 
used for matings.  
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2.2.2. Timed matings 
 For embryonic tissue collection, time matings were organised to obtain 
embryos at specific stages of gestation. Overnight matings were set up and the 
females were examined for the presence of vaginal plugs the following morning. 
Vaginal plug discovery day was assumed to correspond to E0.5.  
 
2.2.3. Mouse lines 
 Tissues termed wild type (WT) were obtained from C57BL6 animals. For 
lineage tracing experiments, embryos were generated from the pairing of C57BL6 
stud males with C57BL6/aEGFP females. Resulting WT and GFP embryos were 
genotyped under fluorescent light. aEGFP animals (termed GFP) constitutively 
express EGFP (Gilchrist et al., 2003).  
 
2.3. Runx1EGFP line genotyping and backcrossing 
2.3.1. Runx1EGFP mouse line genotyping  
Animal ear samples were taken at weaning by the animal unit staff. To obtain 
DNA, samples were treated with 100µl of lysis buffer containing 10% Tween 20, 
NP40, and 10 mg/ml proteinase K in PCR buffer (Qiagen); and incubated at 55oC 
overnight. Samples were vortexed and proteins denaturated at 95oC for 5 minutes. 
Samples were either used immediately or stored at -20oC.  
Presence of Runx1EGFP allele in genomic DNA was determined by 
polymerase chain reaction (PCR). Mastermix was prepared in clean water (Sigma) 
containing PCR buffer, 10mM dNTPs, 5 units/µl Taq polymerase, 3 primers at 
0.1ρM/µl final concentration, and finally genomic DNA obtained from ear samples 
lysis. Oligonucleotide primers (Table 2.1) were designed by H. Inoue and obtained 




  72 
Table 2.1: Runx1EGFP PCR genotyping primer sequences and genomic locations. H. 
Inoue designed oligonucleotide sequences. Transgenic allele PCR product size is 304 base 
pairs and wild type allele PCR product size is 367 base pairs. Refer to Figure 5.2. EGFP: 














      
primer name  genomic location sequence  
Runx1 forward Runx1 exon 6 5'-CATCGGCATGTCAGCCATGAG-3' 
EGFP forward EGFP 5'-CGGCATCAAGGTGAACTTCAAGAT-3' 
Runx1 reverse Runx1 3'UTR 5'-TCGATGGCGATGGCGCTCAG-3' 
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Samples were run in a T3 thermocycler machine (Biometra) using the 
follwing steps: 1) denaturation at 95oC for 3 minutes, 2) followed by 35 cycles of: 
denaturation at 94oC for 30 seconds, annealing at 60oC for 40 seconds, extension at 
72oC for 3 minutes. Samples were kept at 4oC until examination with a 2% agarose 
gel electrophoresis (30V for 2 hours). DNA was labelled with ethidium bromide and 
pictures were taken with a Geneflash camera (Syngene Bio Imaging). 
 
2.3.2.  Runx1EGFP mouse line backcrossing 
 In order to transfer Runx1EGFP animals on C57Bl6 genetic background, 
Runx1EGFP/WT males were mated with C57Bl6 females. Offspring were genotyped by 
PCR according to the procedure described in Section 2.3.1 and appropriate 
Runx1EGFP/WT males were subsequently mated with C57Bl6 females 8 times before 
the line was assumed to be of C57Bl6 background.  
 
2.4. Embryonic tissue isolation and preparation 
2.4.1. Isolation of embryonic tissue 
 Pregnant females were sacrificed according to schedule 1 method of cervical 
dissociation. The uterus was dissected and embryos were extracted into dissection 
solution. The embryos were then carefully separated from extra-embryonic tissues 
such as YS when appropriate. Developmental stage was scored according to Thelier 
criteria (http://genex.hgu.mrc.ac.uk/intro.html). E11.5 corresponds to stage 19, and 
main morphological characteristics being 41-47 somites pairs, round limb buds and 
not entirely completed eye pigmentation (Figure 3.1A). Embryonic organs of interest 
were dissected in dissection medium using sharpened tungsten needles under 
dissecting microscope (LEICA MZ8 microscope). When required, embryonic 
peripheral blood was placed on ice immediately after isolation.  
 For the lateral sub-dissection of the E11.5 AGM region, UGRs were gently 
cut along the ridges, leaving most para-aortic mesenchymal tissue attached to the Ao 
(Figure 5.1).  
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 For the dorso-ventral subdissection of the E11.5 AGM region, remnants of 
the mesentery (ventral), somites and notochord (dorsal) were left on the AGM to 
easily distingusish AoV and AoD in the dissection dish.  When appropriate, these 
extra aortic tissues were subsequently removed and AoV immediately placed into 
separate dishes (Figure 5.12).  
 
2.4.2. Cellular preparation of embryonic tissues 
To obtain single cell suspensions, embryonic organs were transferred to a 5ml 
polystyrene tube (BD Falcon) containing 450µl of dissection solution supplemented 
with 50µl of 10mg/ml collagenase dispase (Roche). Organs were digested in a 37oC 
gently shaking water bath for 40 minutes. Immediately after, 1ml of dissection 
medium was added and then centrifuged at 1500rpm (GS-6R centrifuge, Beckman) 
for 5 minutes at RT. Cells were gently resuspended in flow cytometry buffer solution 
at RT and immediately placed on ice.  
 
2.5. Adult tissue isolation and preparation 
2.5.1. Isolation of adult tissue 
 Adult animals were all sacrificed according to schedule 1 method of cervical 
dissociation. Spleen and thymus were dissected free of connective tissue and fat and 
immediately placed in flow cytometry buffer solution. Peripheral blood was obtained 
by bleeding from lateral tail vein, and immediately collected into 1ml PBS/EDTA 
(200µg/ml). Bone marrow was obtained by flushing femurs in flow cytometry buffer 
solution with a 26-gauge syringe needle  (BD Microlance).  
 
2.5.2. Cellular preparation of adult tissues 
 Single cell suspensions from adult spleen and thymus were obtained by 
pressing grossly cut organs with a 1ml syringe plunger (BD Plastipak) into round-
bottom 96 well plate (Bibby Sterilin) in the presence of flow cytometry buffer 
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solution. After that, tissues were filtered through a 40µm cell strainer (BD Falcon) to 
get rid of cell clumps.  Bone marrow was mechanically dispersed in flow cytometry 
buffer solution using the 26-gauge syringe needle after flushing. Cells were 
immediately placed on ice.   
 
2.5.3. Erythrocyte depletion in adult tissues 
 Adult blood samples (when appropriate, other haematopoietic cell 
suspensions) were centrifuged at 2000rpm (Biofuge pico from Heraeus Instruments) 
for 3 minutes at RT and pellets were resuspended, well mixed and incubated in dark 
at RT for 15 minutes in 1ml of PharM Lyse solution (BD Bioscience).  
 For recipient’s peripheral blood reconstitution analysis, samples were then 
centrifuged at 2000rpm (Biofuge pico from Heraeus Instruments) for 4 minutes at 
RT before being resuspended in 1ml of flow cytometry buffer solution and being 
processed for flow cytometry analysis.  
 For other tissues and/or analysis, 1ml of flow cytometry buffer was added to 
samples, and then centrifuged at 1500rpm (Labofuge 400R from Heraeus 
Instruments) for 5 minutes at 4oC, resuspended in 1ml of flow cytometry buffer 
solution and stored on ice.  
 
2.6. Flow cytometry 
2.6.1. Staining and flow cytometric analysis of adult and 
embryonic cellular suspensions 
Cell suspensions were obtained as previously described in Sections 2.4.2 and 
2.5.2. Cell numbers were determined using a haemocytometer. Staining procedures 
were performed in 5ml polystyrene tubes (BD Falcon). Samples were centrifuged at 
1500rpm (Labofuge 400R from Heraeus Instruments) for 5 minutes at 4oC and 
resuspended in 100µl of CD16/32 (Table 2.2). After 10 minutes incubation on ice, 
100µl of antibody solution at the appropriate final concentration (Table 2.2) was  
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Table 2.2: Primary antibodies used for flow cytometry and confocal microscopy.   
APC denotes Allophycocyanin; BIO, biotin; FITC, fluorescein isothiocyanate; PE, 




            
Antigen Clone Isotype Working  Conjugate Supplier 
      concentration     
B220 RA3-6B2 Rat IgG2α, κ 2.0 µg/ml PE, BIO, FITC Pharmingen 
c-kit 2B8 Rat IgG2β, κ 2.0 µg/ml PE, BIO Pharmingen 
CD3ε 145-2C11 Hamster IgG1 2.0 µg/ml PE, FITC eBioscience 
CD4 GK1.5 Rat IgG2β, κ 2.0 µg/ml PE, BIO Pharmingen 
CD8α 53-6.7 Rat IgG2α, κ 2.0 µg/ml PE, FITC eBioscience 
CD16/32  93 Rat IgG2β, κ 2.0 µg/ml none eBioscience 
CD19 1D3 Rat IgG2α, κ 2.0 µg/ml PE Pharmingen 
CD34 RAM34 Rat IgG2α, κ 2.0 µg/ml PE, FITC eBioscience 
CD41 MWReg30 Rat IgG1, κ 2.0 µg/ml PE, FITC eBioscience 
CD43 eBioR2/60 Rat IgM 2.0 µg/ml PE eBioscience 
CD45 30-F11 Rat IgG2β, κ 2.0 µg/ml PE, FITC,APC,PerCP Pharmingen 
CD71 R17217 Rat IgG2α, κ 2.0 µg/ml FITC eBioscience 
Gr-1 RB6-8C5 Rat IgG2β, κ 2.0 µg/ml PE, BIO eBioscience 
Ly-5.1 A20 Mouse IgG2α, κ 2.0 µg/ml PE, APC Pharmingen 
Ly-5.2 104 Mouse IgG2α, κ 2.0 µg/ml FITC, APC eBioscience 
Mac-1 M1/70 Rat IgG2β, κ 2.0 µg/ml PE, FITC eBioscience 
PECAM-1 MEC 13.3 Rat IgG2α, κ 2.0 µg/ml PE Pharmingen 
Sca-1 D7 Rat IgG2α, κ 2.0 µg/ml PE Pharmingen 
Ter-119 TER-119 Rat IgG2β, κ 2.0 µg/ml PE Pharmingen 
VE-cadherin 11D4.1 Rat IgG2α, κ 8.0 µg/ml none Pharmingen 
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added to each tube. Cells were then incubated in the dark on ice for 20 to 45 minutes. 
After incubation, 1ml of ice-cold flow cytometry buffer solution was added to each 
sample and cells were centrifuged at 1500rpm (Labofuge 400R from Heraeus 
Instruments) for 5 minutes at 4oC.  When appropriate, supernatant was removed and 
cells were resuspended in 100µl of fluorochrome conjugated streptavidin solution 
(diluted at the appropriate concentration, Table 2.3). Cells were incubated for 15 
minutes in the dark on ice. 1ml of ice-cold flow cytometry buffer solution was added 
and samples were centrifuged at 1500rpm (Labofuge 400R from Heraeus 
Instruments) for 5 minutes at 4oC. Supernatant was gently removed and cells were 
resuspended in 100 to 200µl of 0.25-0.5µg/ml 7-aminoactinomycin D (7-AAD). 
 Flow cytometric analysis was performed using a dual laser FACScalibur (BD 
Bioscience). Fluorescence levels were detected by FL-1, FL-2 and Fl-4 channels 
(Table 2.4). Compensation adjustments were made based on appropriate isotype 
controls and single stains. Viable cells were selected according to their low 7-AAD 
intakes and detected in the FL-3 channel. Cell size and granularity were assessed by 
forward and side scatter profiles respectively. Data acquisition was performed using 
BD CellQuestTM software (BD Bioscience). Data analysis and flow cytometric 
statistical analysis was performed using FlowJo software (Tree Star, Inc).  
 
2.6.2. Fluorescence Activated Cell Sorting of embryonic 
tissues   
 Cell sorting was performed with the help of J.Vrana and S. Monard using a 
MoFlo (DakoCytomation) flow cytometer. Cells were processed and stained as 
described in Section 2.6.1.  After processing, samples were resuspended at a 
concentration no higher than 1x106 cells/ml in 0.25µg/ml 7-AAD. In order to avoid 
cell losses during collection, 5ml polystyrene tubes (BD Falcon) were wetted with 
ice-cold flow cytometry buffer solution and filled with buffer (2.5ml). Throughout 
the cell sorting procedure, cells were maintained at 4oC and the conditions were 
maintained as aseptic as possible. When cell numbers allowed, a purity check of 
collected cell populations was performed.  
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Table 2.3: Secondary reagents and isotype controls antibodies used for flow cytometry. 
7-AAD denotes 7-amino-actinomycin; APC denotes Allophycocyanin; BIO, biotin; FITC, 
fluorescein isothiocyanate; PE, phycoerythrin; n/a, non-applicable. 
 
 
Table 2.4: FACScalibur channels and their corresponding fluorochromes.  
Fluorochromes indicated here were used for flow cytometric analysis and appropriate 
controls were run with each fluorochrome to compensate for fluorescent leakage from one 
channel to another. FITC: fluorescein isothiocyanate, GFP: green fluorescent protein, eGFP: 
enhanced green fluorescent protein, PE: phycoerythrin, 7-AAD: 7-aminoactinomycin D, 
PerCP: peridinin chlorophyll protein; PE-Cy5: phycoerythrin-cyanine5, APC: 
allophycocyanin 
          
Reagent Clone Working  Conjugate Supplier 
    concentration     
7-AAD n/a 0.25-0.5 µg/ml n/a eBioscience 
Hamster IgG1 A19-3 as appropriate PE, FITC Pharmingen 
Mouse IgG2α, κ G155-178 as appropriate PE, FITC, APC Pharmingen 
Rat IgG1, κ R3-34 as appropriate PE, FITC eBioscience 
Rat IgG2α, κ R35-95 as appropriate PE, BIO, FITC, APC Pharmingen 
Rat IgG2β, κ A95-1 as appropriate PE, BIO, FITC, APC Pharmingen 
Rat IgM G35-238 as appropriate PE Pharmingen 
Streptavidin n/a 0.2 µg/ml PE, APC Pharmingen 
TOPRO-3 n/a 1 µM n/a Invitrogen 
channel fluorochromes detected 
FL-1 FITC, Alexa fluor-488, GFP, EGFP 
FL-2 PE 
Fl-3 7-AAD, PerCP, PE-Cy5.5 
Fl-4 APC, TOPRO-3 
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2.7. Tissue culture 
 Tissue culture procedures were carried out in class 2 laminar flow hoods 
(Envair and Nuaire) using aseptic technique by treating all surface areas and items in  
the hood with 70% industrial methylated spirits. Chemicals were prepared in sterile 
conditions.  
 Cells were cultured in 5% CO2 at 37oC in humidified incubators (Heraeus 
Instruments). Solutions were stored at +4oC. Supplementary reagents were prepared 
by the tissue culture core-facility staff and stored at -20oC (except β-mercaptoethanol 
which was stored at +4oC). All solutions and reagents were allowed to warm-up to 
RT prior to use and all media were prepared freshly. 
 Unless otherwise stated Gibco supplied all media and supplementary 
reagents; PeproTech supplied all growth factors.  
 
2.7.1. E11.5 AGM region reaggregation 
 The E11.5 AGM reaggregation technique was carried out as previously 
described (Sheridan et al., 2009; Taoudi et al., 2008); AGM suspensions were 
obtained from pooled embryos, centrifuged at 1500rpm for 5 minutes at 4oC (GS-6R 
centrifuge, Beckman), and resuspended at a concentration of 1 embryo-equivalent 
(e.e) in 15-20µl of culture medium. 200µl pipette tip were then filled with 15-20µl of 
cell suspension and carefully sealed with Parafilm (VWR International). Tips were 
then placed in 25ml tubes (Corning) and centrifuged at 1500rpm (GS-6R centrifuge, 
Beckman) for 5 minutes at 4oC. Cell pellets were then carefully expelled from the tip 
and placed onto Durapore 0.65µm membrane filters (Millipore) at the gas-liquid 
interface of 5ml of culture medium per well in 6 well plates. No more than 4 pellets 
were placed on each membrane filter. 
Reaggregates were cultured in IMDM+ medium (Iscove’s Modified 
Dulbecco’s Medium (IMDM) containing 10-20% FCS; 4mM glutamine; 0.1mM β-
mercaptoethanol; 50 units/ml P/S; 100ng/ml IL-3; 100ng/ml SCF; and 100ng/ml 
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Flt3l). In some cases IL-3, SCF, and Flt3l were not added to the medium (referred as 
IMDM- medium). 
 When appropriate, Durapore 0.65µm membrane filters were rinsed 3 times 
and incubated overnight at 37oC, 5% CO2 in tissue culture grade with P/S. 
Membranes were rinsed again 3 times before being completely dried prior to use. 
 Following 4 to 5 days culture at 37oC, 5% CO2, membrane filters were 
submersed into the culture medium, and reaggregates were collected by gentle 
pipetting. Reaggregates single cell suspensions were used for analysis (see section 
2.4).  
 
2.7.2. E11.5 AGM tissues explant cultures.  
 E11.5 AGM tissues were dissected as described in section 2.4.1. Explant 
cultures were slightly modified from protocols previously described (Kumaravelu et 
al., 2002; Medvinsky and Dzierzak, 1996). E11.5 AGM tissues were submersed in 
the appropriate culture medium and gently put onto Durapore 0.65µm membrane 
filters (sometimes washed, see Section 2.7.1). Membrane filters were placed at the 
liquid gas interface of 5 ml of appropriate medium and cultured for 4 days at 37oC, 
5% CO2. A maximum of 4 AGM explants were put onto each membrane. Explants 
were cultured in Myelo-cult medium (M5300, Stem Cell Technologies) 
supplemented with 1x10-6M hydrocortisone 21-hemisuccinate sodium salt and 50 
units/ml P/S. On occasions, explant cultures were carried out in IMDM- medium. 
 After culture, explants were taken off the membranes and made into single 
cell suspensions (see sections 2.4 and 2.7.1).  
 
2.8. In vitro haematopoietic assay: methylcellulose 
based differentiation 
 Prior to use, methylcellulose based MethoCult medium containing 
erythropoietin, IL-3, IL-6, and SCF (M3434, Stem Cell Technologies) was thawed at 
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RT and 50 units/ml P/S was added. After cell suspensions were added to MethoCult 
at 1/10 dilution, cultures were processed and plated according to manufacturer’s 
instructions (www.stemcell.com).  Haematopoietic colonies were counted and scored 
after 9-11 days of differentiation. The colonies were scored according to described 
standard criteria (Medvinsky et al., 2008; Taoudi, 2006) 
 
2.9. In vivo haematopoietic stem cell assay: 
competitive long-term repopulation assay  
2.9.1. In vivo transplantation  
Cells for the long-term repopulation assay were obtained from either fresh or 
cultured embryonic organs from Ly-5.2/5.2 mice. Appropriate doses of cells were 
resuspended in ice cold 1% FCS/PBS and co-injected along with 2x104 adult carrier 
bone marrow cells from Ly-5.1/5.2 animals. Prior to transplantation, Ly-5.1/5.1 
animals were irradiated. A total dose of 9.5 Gy was split into two doses separated by 
at least 3 hours and delivered by sealed Cs source at a rate of 21.6 rad/min. No more 
than 300µl of cell suspension were injected into each recipient mouse using a 30-
gauge syringe needle (BD Plastipak). All injections were performed in the lateral tail 
vein according to the procedures described by project licence 603715 and the 
regulations of the Animals Scientific Procedures Act, UK, 1986.  
Experiments described in Chapter 3 were performed with F1 (CBA X 
C57Bl6) animals. All other experiments were performed with pure C57Bl6 animals.  
 
2.9.2. Assessment of haematopoietic reconstitution 
 Recipients’ peripheral blood chimerism (PBC) was first assessed 6 weeks 
post-transplantation for short-term repopulation and at least 12 weeks post-
transplantation for long-term repopulation. Blood samples were processed as 
described in Sections 2.5.3 and 2.6.1. Only animals with donor chimerism higher 
than 5% were considered reconstituted.  
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  Multilineage analysis was performed on animals reconstituted for at least 16 
weeks post-transplantation. Bone marrow, spleen, and thymus were isolated, 
processed and depleted of erythrocytes  (see Sections 2.5.2 and 2.5.3) and myeloid 
and lymphoid donor contribution was assessed by flow cytometry (see Section 
2.6.1). 
 
2.10. Confocal microscopy 
2.10.1. Staining for cell surface markers 
2.10.1.1. Embedding and Sectioning 
Fresh or cultured organs were snap-frozen in O.C.T compound (BDH Gurr) 
on dry ice. 10µm thick frozen sections were produced using a LEICA CM1900 
cryostat (Leica) and directly put onto polysine-coated slides (VWR International). 
Sections were air-dried and stored at -20oC. Sections were warmed up at RT and 
fixed with -20oC cold 100% acetone for 2.5 minutes. Sections were air-dried before 
further processing.  
 
2.10.1.2. Immunofluorescent staining 
Sections were first encircled with a PAP pen and rehydrated with PBS 
(containing MgCl and CaCl) for 2 minutes. Dissection solution (no P/S) was used to 
block non-specific antibody binding for 15 minutes at RT. Sections were then 
washed once with PBS before adding fluorochrome-conjugated antibodies 
appropriately diluted in PBS (Table 2.2) and incubated in dark at RT for at least 30 
minutes. After removal of the staining solution, sections were washed 3 times for 5 
minutes with PBS. Cell nuclei were stained with 0.2% 4-6-Diamidino-2-
phenylindole (DAPI)(Molecular Probes) in the dark at RT for 10 minutes, followed 
by quick 3 times washing with PBS and a very quick rinse with distilled H2O before 
air-drying. Finally sections were mounted using a small drop of VECTORSHIELD 
hard-set medium (Vector Laboratories) and left to harden overnight at +4oC 
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according to the manufacturer’s instructions. Stained sections were studied and 
pictures were taken using an inverted confocal microscope (Leica DM IRE2). Images 
were then processed and prepared using Adobe Photoshop.  
 
2.11. Cytological analysis 
2.11.1. Cytospin preparation 
 Single cytospin chambers were loaded with a polysine-coated slide, and a 
filter card (Thermo), followed by filling with 100µl of the cell suspension. At RT, 
samples were centrifuged at 1000rpm for 5 minutes (Cytospin 3, Shandon), air-dried 
and fixed 100% methanol for 2.5 minutes. Methanol was removed and slides were 
air-dried.  
 
2.11.2. May-Grünwald-Giemsa staining 
 May-Grünwald and Giemsa were freshly prepared in PBS as a 50% solution 
and a 10% solution respectively and filtered through number 1 Whatman filter paper 
(Whatman International Ltd). 
 Slides fixed in methanol were stained first with May-Grünwald solution for 
15 minutes, followed by replacement of primary stain with Giemsa stain for 12 
minutes, all in the dark at RT. Finally, slides were rinsed 3 times briefly, washed for 
5 minutes with distilled H2O, and were air-dried and stored in the dark at RT until 
analysis. Pictures were taken using an upright Vanox AHBT3 microscope (Olympus) 
and Openlab software (Improvision).  
 
2.12. Statistical analysis 
Where treatments comprised 3 or more replicates, differences in mean cell 
numbers, percentages, and CFU-Cs counts between treatments were calculated. 
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Parametric tests were used where possible to assess statistical significance. 
Groups were compared using either 2-sample t-tests, or paired t-tests for paired data. 
In each case, the assumption of similar variances between groups was also tested 
using an F-test, and the data inspected for normality. If these assumptions were not 
met, or the number of replicates was low (<4), non-parametric tests were used 
instead. Unmatched groups were compared using a Mann-Whitney test, while in the 
case of paired data; the Wilcoxon Signed Rank test was used.  
Significance was calculated at the 5% significance level. All statistical analyses 
were performed using Minitab v15 (www.minitab.com).  
In the case of the efficacy of haematopoietic reconstitution in the long-term 
repopulation assay, statistical significance was calculated using 2 x 2 contingency 
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3. The reaggregate culture 
system: characterisation and 
insights into cytokine-mediated 
LTR-HSC expansion 
3.1. Introduction 
 Studies have demonstrated that culturing the E10.5-12.5 AGM region and the 
E12.5 YS as explants at the liquid gas interphase can facilitate LTR-HSC expansion 
(Kumaravelu et al., 2002; Medvinsky and Dzierzak, 1996). An advantage of the 
explant culture system is that it maintains the structural integrity and preserves cell 
interactions that in vivo may be essential for LTR-HSC development. It also enables 
the investigation of the autonomous potential of the organ, independent of 
surrounding tissues. However, the need to culture an intact organ also limits the 
accessibility to specific cell populations, and restricts the manipulation of a 
potentially powerful LTR-HSC niche.  
The reaggregate system (Taoudi et al., 2008), however, enables the 
identification of specific cell populations that play key roles in LTR-HSC 
development from the AGM region; including key niche components. The 
reaggregate culture conditions described in Section 2.7.1 were schematically 
represented in Figure 3.1A and will be referred as standard conditions. After culture, 
single cell suspensions are obtained from reaggregates and used for functional assays 
and flow cytometric analysis (Figure 3.1B). The methylcellulose-based assay is used 
to determine the number of haematopoietic progenitors (CFU-C) and the competitive 









































Figure 3.1: Standardised experimental procedures to generate and analyse
reaggregates.
A: Standard procedure for reaggregate set-up. E11.5 AGM regions are dissected and
dissociated by collagenase dispase treatment. One embryo equivalent of the cell suspension
obtained is centrifuged in a sealed tip. The pellet is placed on a membrane filter at the
liquid-gas interface and cultured at 37oC, 5% CO2 for 4 days in IMDM+.
B: Standard analysis of reaggregates. After culture, reaggregates are collected and
dissociated by collagenase dispase treatment with mechanical disruption. The cell
suspension obtained is used to perform competitive repopulation assays, colony forming
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3.2. Characterisation of the reaggregate culture 
system using standard conditions 
3.2.1.  Basic characterisation of the E11.5 AGM region 
Standard cultures were set up to validate the reproducibility of the system 
(Taoudi, 2006). Flow cytometric analysis in fresh and cultured E11.5 AGM tissue 
was performed (Figure 3.2A). Pan-leucocyte marker CD45 was chosen to mark 
haematopoietic cells, and vascular-endothelial cadherin (VE-cadherin) was chosen to 
mark endothelial cells. The fresh E11.5 AGM contained 222100±64530 total cells of 
which 73060±3700 were viable (Table 3.1). The majority of the tissue (68120±610 
cells) was composed of stromal (non haematopoietic, non endothelial) CD45-VE-
cadherin- cells. The E11.5 AGM region contained 63±22 CD45+VE-cadherin+ cells, 
a population highly enriched for LTR-HSCs (North et al., 2002; Taoudi et al., 2005). 
Finally, 2600±750 cells were CD45+VE-cadherin- (haematopoietic, CD45 single-
positive/CD45SP) and 2420±820 cells were CD45-VE-cadherin+ (endothelial)(Table 
3.1 and Figure 3.2A).  
 
3.2.2. Basic characterisation of haematopoietic populations 
in reaggregates 
After 4 days in culture, reaggregates typically adopt a circular morphology 
(roughly 1mm diameter) with cellular protrusions at the periphery (Figure 3.2B). 
Also, some red blood cells can sometimes be observed (Figure 3.2B). Flow 
cytometric analysis showed that a single reaggregate contained 188000±34120 cells 
of which 124380±18620 cells were viable (Table 3.1). Both the stromal and CD45-
VE-cadherin+ (endothelial) compartments were maintained as a single reaggregate 
contained 110650±14650 cells and 2400±1060 cells respectively (Table 3.1 and 
Figure 3.2A). The DP population was also maintained as there were 100±75 cells but 
with high variation among cultures. Finally, the CD45SP population underwent 




































































































Figure 3.2: Anatomy of reaggregates and haematopoietic expansion during culture in
IMDM+.
A: Flow cytometric analysis of both endothelial (VE-cadherin+) and haematopoietic
(CD45+) cell populations in fresh E11.5 AGM compared to reaggregates. Plots are
representative of 7 and 8 experiments respectively.
B: Representative image of a reaggregate after 4 days culture. Typically, the gross
morphology is circular with a diameter of approximately 1mm and protrusions are observed
at the pheriphery. (scale bar: approximately 0.5 mm)
C: Flow cytometric analysis of erythroid (Ter119) cell population in reaggregates.
Quadrants are based on appropriate isotype control (Appendix 3.1) and values indicate the
percentage of cells.
A
Table 3.1: Cell composition of fresh E11.5 AGM region compared to reaggregates
cultured in IMDM+.
Results obtained by flow cytometry (viability determined by 7-AAD exclusion). Data is
representative of 7 independent experiments in fresh tissue and 8 independent
experiments in reaggregates.
absolute numbers ± standard deviation; DP: CD45+VE-cadherin+ ; DN: CD45-VE-cadherin-
fresh reaggregate fold increase
total cells 222100 ± 64530 188000 ± 34120 0.8
total live cells 73060 ± 3700 124380 ± 18620 1.7
total CD45
+
 cells 2600 ± 750 22070 ± 6080 8.5
total VE-cadherin
+
 cells 2420 ± 820 2400 ± 1060 1.0
total DP cells 63 ± 22 100 ± 75 1.6
total DN cells 68120 ± 610 110650 ± 14650 1.6
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which constitutes an 8.5 fold expansion compared to the fresh tissue (Table 3.1 and 
Figure 3.2A).  
As the haematopoietic compartment underwent considerable expansion, the 
nature of the CD45+ cells was further investigated. Although red blood cells could be 
observed under the microscope (Figure 3.2B), the absence of mature erythrocytes 
was indicated by the absence of CD45-Ter119+ cells (Figure 3.2C; Figure 3.3A). 
However, the presence of few CD45+CD71+Ter119+ suggested that erythropoiesis 
was initiated (Figure 3.3A). The CD71 expression in 46.8±3.9% of CD45+ cells also 
indicated that these haematopoietic cells were still cycling at the end of the culture 
period (Figure 3.3A).  
The expression of LTR-HSC markers such as Sca1, c-kit and CD34 was 
investigated (Figure 3.3A). 43±0.2% of CD45+ cells co-expressed Sca1 and c-kit, a 
classic LTR-HSC immunophenotype (Figure 3.3A). Interestingly, only a very small 
fraction of CD45+ cells expressed CD34 (less than 1%), an embryonic LTR-HSC 
marker (Figure 3.3A)(Ema and Nakauchi, 2000; Sanchez et al., 1996; Yoder et al., 
1997a).  
Cytospin preparations were performed to investigate cell morphology and 
confirm the presence of specific haematopoietic cell types within reaggregates. 
Massive cell clusters were observed in high numbers but without a haematopoietic 
appearance (Figure 3.3B). Cells resembling macrophages and erythroid cells could 
be observed, confirming the flow cytometric observations (Figure 3.2C, Figure 
3.3A,B). In addition, given the high frequency of cells with erythroid characteristics 
(blue cytoplasm and purple nucleus), the majority of these cells could also be blasts 
cells. 
 
3.2.3. The expansion of haematopoietic progenitors during 
reaggregate culture 
As CD45SP haematopoietic cells underwent massive expansion during 
culture, the expansion of haematopoietic progenitors was investigated. To this end, 





























































































































































































Figure 3.3: Characterisation of haematopoietic and non-haematopoietic cell
populations in E11.5 AGM reaggregates cultured in IMDM+.
A: Flow cytometric analysis of haematopoietic (CD45+) and non-haematopoietic (CD45-)
cell populations. Plots are representative of two independent experiments. Quadrants are
based on appropriate isotype control (Appendix 3.1); and values indicate the percentage of
cells.
B: Cytospin preparations from whole reaggregates. Asterix indicate cells with macrophage
like morphology (white globules inside cytoplasm and purple nuclei). Arrows indicate
erythrocyte like cells or blast cells (dark blue cytoplasms and purple nuclei). Other
unidentified cell types are also present in high numbers and example of cell cluster in low
left panel.
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reaggregate culture. Haematopoietic colonies were counted after 9 days in 
methylcellulose culture. Colony type was assessed according to gross morphology 
(initially confirmed with cytopsin until comfortable with gross scoring, (Medvinsky 
et al., 2008; Taoudi, 2006). 
The fresh E11.5 AGM region contained 144±42 CFU-Cs made of 42±19   
CFU-mast, 26±24 BFU-E, 8±7.5 CFU-GM, 60±22 CFU-mac, and 9±6 CFU-GEMM 
(Figure 3.4A). After culture in standard conditions, reaggregates contained 
4425±1025 CFU-Cs made of 1095±700 CFU-mast, 735±380 BFU-E, 410±230 CFU-
GM, 1825±970 CFU-mac, and 360±90 CFU-GEMM (Figure 3.4B). This represents a 
31-fold expansion.  
 
3.2.4. The expansion of LTR-HSCs during reaggregate 
culture 
It was previously demonstrated that the fresh E11.5 AGM contains around 1 
LTR-HSCs (Gekas et al., 2005; Kumaravelu et al., 2002). Using the explant culture 
on α-MEM based medium, it is possible to generate 12 LTR-HSCs after 72 hours 
(Medvinsky and Dzierzak, 1996). To date, a maximum of 34 LTR-HSCs can be 
obtained per explant AGM region by supplementing the culture medium with IL-3 
(Robin et al., 2006).  
To investigate the expansion of the LTR-HSC compartment during 
reeaggregate culture, the in vivo long-term repopulation assay was used (Figure 
3.5A). Limiting dilution analysis was performed to functionally quantify the absolute 
number of LTR-HSC by the end of the culture. To this end, 0.1 dose of reaggregate 
(rd), 0.01rd and 0.005rd were injected into individual adult irradiated recipients and 
peripheral blood chimerism (PBC) was determined at least 12 weeks after 
transplantation. I found that 8 out of 8 mice transplanted with 0.1rd were successfully 
repopulated (78.6% mean PBC); 13 out of 14 mice transplanted with 0.01rd were 
repopulated (23.7% mean PBC) and 9 out of 10 mice transplanted with 0.005rd were 
repopulated (12.3% mean PBC)(Figure 3.5B). As 0.005rd was sufficient to 


























Figure 3.4: Haematopoietic progenitors expansion during reaggregate culture in
IMDM+.
A: Number of CFU-Cs per fresh E11.5 AGM region. Bars indicate standard deviation of
three independent experiments.
B: Number of CFU-Cs per reaggregate cultured in standard conditions. Bars indicate
standard deviation of ten independent experiments (from controls run throughout Chapter 3
experiments).
BFU-E: burst forming unit-erythroid; CFU: colony forming unit; Mast: mast; Mac:
macrophage; GM: granulocyte/macrophage; GEMM: granulocyte/erythroid/macrophage/























Figure 3.5:  Assessment of LTR-HSC numbers in E11.5 AGM reaggregates cultured
in IMDM+.
A: In-vivo competitive long term repopulation assay. Donor cells from Ly5.2 embryos are
cultured and transplanted into irradiated Ly5.1 adult recipients. LTR-HSCs are detected by
peripheral blood chimerism assessed by flow cytometry using anti Ly5.1 and Ly5.2
antibodies, at least 12 weeks post-transplantation .
B: LTR-HSC limiting dilution analysis in reaggregates. Each point represents a single
recipient mouse. Recipients were considered reconstituted when their peripheral blood
chimerism exceeded 5% at least 12 weeks after transplantation. Cumulative result from two
independent experiments. rd: reaggregate dose
0.1 rd 0.01 rd 0.005 rd
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LTR-HSCs in a single reaggregate, even if limiting dilution was not reached. This is 
consistent with data previously published, revealing that LTR-HSC numbers ranged 
from 98 to 150 in single reaggregates (Taoudi et al., 2008).  
 
3.2.5. Normal LTR-HSC function: multilineage reconstitution 
and secondary transplantation  
Contribution of donor cells into haematopoietic tissues (peripheral blood, 
spleen, bone marrow, and thymus) of recipients reconstituted with 0.01rd was 
checked by flow cytometry. All tissues contained CD45.2 donor cells in high 
proportions (81.7±5.1% in peripheral blood, 67.6±9.2% in spleen, 77.1±4.6% in 
bone marrow, and 84.6±1.2% in thymus)(Figure 3.6A). Blood, spleen and bone 
marrow contained both myeloid cells, marked by Mac1 and Gr1, and lymphoid cells 
marked by B220, CD3 and CD43 (Figure 3.6B). The majority of donor cells in the 
thymus were CD4+CD8+ (65.1±19.1%), an immunophenotype that corresponds to the 
immature T cell population (Figure 3.6B).  
The AGM-derived LTR-HSCs were subject to secondary transplantations. 
Two reconstituted primary recipients were sacrificed and 1/10 of their whole bone 
marrow (paired femurs and tibias) was transplanted into each secondary recipients. 
Secondary recipient PBC was analysed at least 12 weeks post-transplant and 
multilineage analysis was performed (Figure 3.7). The primary recipients chosen for 
the experiment had PBC of 82.5% and 30.2% on the day of the secondary 
transplantation (Figure3.7A). At least 16 weeks post-transplantation, individual 
secondary recipients displayed 74% and 64.8% and 16.7% PBC (Figure 3.7A). The 
blood of secondary recipients demonstrated successful serial reconstitution of the 































































































































































































































































































































































Blood Spleen Bone marrow Thymus
B
Figure 3.6: Multilineage haematopoietic reconstitution by E11.5 AGM reaggregates
cultured in IMDM+
A: Long term donor-derived reconstitution in major haematopoietic organs (peripheral
blood, spleen, bone marrow, and thymus).
B:  Long-term multilineage (myelo-lymphoid) analysis of donor derived cells in all major
haematopoietic organs (peripheral blood, spleen, bone marrow, and thymus). Events gated
on donor derived cells.
Representative example of analysis performed on six mice reconstituted by reaggregates.
Quadrants are based on appropriate isotype control (Appendix 3.2) and values indicate




















































































































Figure 3.7: Secondary transplantations and multilineage haematopoietic
reconstitution of secondary recipients.
A: Secondary transplantation of bone marrow cells from reconstituted primary recipients.
1/10 of whole bone marrow (paired femurs and tibias) from each of two primary recipients
(reconstituted by reaggregates cultured in IMDM+) was transplanted individually into
irradiated secondary recipients. Peripheral blood chimerism in secondary recipients  was
analyzed at least 12 weeks after transplantation; matching symbols represent secondary
recipients and their corresponding primary recipients.
B: Long term multilineage (myelo-lymphoid) analysis of donor derived cells in the
peripheral blood of secondary recipients. Representative example of analysis of three
secondary recipients. Quadrants are based on appropriate isotype control (Appendix 3.2);
values indicate percentages of cells. Events gated on donor derived cells.
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3.2.6. LTR-HSC phenotype in reaggregates  
To determine the immunophenotype of LTR-HSCs generated in reaggregates, 
FACS was performed and cell populations of interest were transplanted into recipient 
mice.  
Previous experiments demonstrated that all LTR-HSCs are contained in the 
CD45+ compartment (Taoudi et al., 2008). The endothelial marker CD31 (also 
known as PECAM-1), the early haematopoietic marker CD41, the haematopoietic 
progenitor marker CD48, and the LTR-HSC markers Sca1 and c-kit were used to 
further characterise the LTR-HSCs population.  
Analysis of CD31 expression showed that 1.66% of viable cells were 
CD45+CD31high, 18.5% were CD45+CD31medium, and 3.54% were CD45+PECAMlow 
(Figure 3.8A). When, 0.05rd of these three populations were transplanted into 
recipient mice, only CD45+CD31medium cells successfully reconstituted mice (3 out of 
5, mean PBC: 23%)(Figure 3.8A’), indicating that LTR-HSCs are contained in the 
CD45+CD31medium cell population.  Previous data looking at the co-expression of the 
endothelial markers VE-cadherin and CD31 revealed that the endothelial cells reside 
in the CD31high population (Taoudi et al., 2008; Taoudi and Medvinsky, 2007), 
demonstrating that reaggregate LTR-HSCs differ from the endothelium. 
The CD45+ cell population was then further divided using a LTR-HSC 
marker c-kit and an early haematopoietic marker CD41: 31.2% of the CD45+ 
population was c-kit+CD41-, 1.65% was c-kit+CD41+, 0.35% was c-kit-CD41+, and 
60% was c-kit-CD41- (Figure 3.8B). When 0.05rd of each of these four populations 
were transplanted into recipient mice, the majority of LTR-HSC activity was found 
within c-kit+CD41+ and c-kit+CD41- populations:  1 out of 5 mice was reconstituted 
at low level with c-kit+CD41+ cells (9.77% PBC), and 5 out of 8 mice were 
reconstituted with c-kit+CD41- cells (mean PBC: 35.2%)(Figure 3.8B’), indicating 
that most HSCs in reaggregates are c-kit+CD41-. FACS purity analysis of c-
kit+CD41+ population (84.6% purity with little contamination from c-kit-CD41- cells) 













































































































































































































































































































































































Figure 3.8: LTR-HSC phenotyping in E11.5 AGM reaggregates cultured in IMDM+.
A, A’: LTR-HSC phenotyping using CD31 marker. A: isotype control (left) and
representative staining pattern of reaggregates (right). A’: peripheral blood chimerism of
recipients transplanted with CD45+ cells sorted on the basis of different CD31 expression
levels. Result from 1 experiment.
B, B’: LTR-HSC phenotyping using c-kit and CD41 markers. B: isotype control (left) and
representative staining pattern of reaggregates CD45+ population (right). B’: peripherall
blood chimerism of recipients transplanted with CD45+ cells sorted on the basis of different
c-kit and CD41 expression. Cumulative result of 2 experiments.
C, C’: LTR-HSC phenotyping using c-kit and sca1 markers. C: isotype control (left) and
representative staining pattern of reaggregates CD45+ population (right). C’: peripheral
blood chimerism of recipients transplanted with CD45+ cells sorted on the basis of different
c-kit and sca1 expression. Cumulative result of 2 experiments.
D, D’: LTR-HSC phenotyping using CD48 marker. D: isotype control (left) and
representative staining pattern of reaggregates (right). D’: peripheral blood chimerism of
recipients transplanted with CD45+ cells sorted on the basis of different CD48 expression
levels. Result from 1 experiment.
All gates were based on displayed isotype control and values indicate percentages of cells.
Recipients were considered reconstituted when their peripheral blood chimerism exceeded
5% at least 12 weeks post-transplantation. Dots represent individual recipient mice. rd:
reaggregate dose; r: recipient; med.: medium
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The CD45+ cell population was also divided using classical LTR-HSC 
markers Sca1 and c-kit: 20.6% of the CD45+ population were c-kit+Sca1-, 11.5% 
were Sca1+ and 61.3% were either c-kit-Sca1- or autofluorescent (Figure 3.8C). 
When 0.05rd were transplanted per recipient, Sca1+ cells achieved reconstitution in 5 
out of 19 mice, whilst Sca1- cells only in 1 out of 8 mice, indicating that the vast 
majority of LTR-HSCs in reaggregates express Sca1 (Figure 3.8C’). The 
reconstitution of a mouse by c-kit-Sca1- cells could hardly be explained by FACS 
contamination (95.4% pure); however, the overlap of positive cells with 
autofluorescent ones (included in the c-kit-Sca1- gate in this case) cannot be 
excluded. Nevertheless, on the basis of previous experiments (Figure 3.8B’) and 
additional data from S. Taoudi, the majority if not all HSCs are c-kit+Sca1+.   
Finally, LTR-HSCs were tested for CD48 expression, a marker of both adult 
and fetal liver haematopoietic progenitors (Kiel et al., 2005; Kim et al., 2006). The 
CD45+ population was subdivided into CD48+ (17.6%) and CD48- (3.66%) fractions 
(Figure 3.8D). All recipient mice transplanted with 0.05rd of CD48- cells were 
reconstituted at high level (mean PBC: 76.6%)(Figure 3.8D’). When transplanted 
with 0.05rd and 0.01rd of CD48+ cells, 5 out of 5 mice (mean PBC: 43.8%) and 1 out 
of 4 mice (18% PBC) were reconstituted respectively (Figure 3.8D’), indicating that 
reaggregate LTR-HSCs are heterogenous for CD48 expression.  
Taken together, these experiments demonstrate that the majority of LTR-
HSCs produced in reaggregates are CD45+CD31mediumc-kit+Sca1+. Interestingly; 
LTR-HSCs were heterogenous for the cell surface markers CD41 and CD48.  
 
3.2.7. Conclusions 
The reaggregate culture system described above is a robust and reproducible 
model system that allows the dissociation of the E11.5 AGM prior to culture whilst 
maintaining its ability to produce LTR-HSCs. During culture, haematopoiesis is 
largely stimulated as 8.5-fold expansion of haematopoietic (CD45+) cells is 
observed. Functional analysis also demonstrated an extensive expansion of 

















































































































































































































































































































































































Figure 3.12: Multilineage haematopoietic reconstitution and secondary
transplantations of LTR-HSCs generated in growth factors free conditions
A: Long-term donor derived reconstitution in major haematopoietic organs of primary
recipient (peripheral blood, spleen, bone marrow, and thymus).
B: Long-term multilineage (myelo-lymphoid) analysis of donor-derived cells in major
haematopoietic organs  of primary recipient (peripheral blood, spleen, bone marrow, and
thymus).
Representative example of analysis from two mice reconstituted with reaggregates cultured
in growth factors free conditions. Quadrants are based on appropriate isotype control
(Appendix 3.2); values indicate percentages of cells.
C: Secondary transplantation of bone marrow cells from a reconstituted primary recipient.
1/10 of whole bone marrow (2 femurs and 2 tibias) from the primary recipient was
transplanted into each secondary recipient; peripheral blood chimerism was analysed at least
12 weeks post-transplantation.
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from E11.5 AGM region while it originally contains one (Kumaravelu et al., 2002; 
Taoudi et al., 2008). 
 
3.3. Refinement of culture conditions for E11.5 
AGM reaggregates 
3.3.1. The role of FCS in IMDM+ for LTR-HSC expansion 
As FCS contains some unknown and variable components between batches, 
an FCS-free culture medium would provide a system less susceptible to biological 
variations and allow more defined studies on molecular pathways involved in LTR-
HSC development. IMDM+ medium contains defined growth factors (IL-3, SCF, 
Flt3l), suggesting that FCS could be dispensable for LTR-HSC expansion. In order to 
investigate this hypothesis, reaggregates were set up and cultured in IMDM+ and 
IMDM+ without FCS (IMDM+ - FCS). 
 
3.3.1.1. Serum free conditions: haematopoietic progenitor expansion 
 The difference in expansion of haematopoietic progenitors was investigated 
in 2 experiments presented individually. In the presence of FCS (IMDM+), there was 
a total of 5300 and 6450 CFU-Cs  (2000 and 1850 CFU-mast, 700 and 1800 BFU-E, 
100 and 800 CFU-GM, 2050 and 1500 CFU-mac, and 450 and 500 CFU-GEMM 
respectively)(Figure 3.9A). In the absence of FCS, there was a total of 2800 and 
1900 CFU-Cs (950 and 800 CFU-mast, 650 and 200 BFU-E, 50 and 50 CFU-GM, 
850 and 600 CFU-mac, 300 and 250 CFU-GEMM respectively)(Figure 3.9A). In 
both experiments, the presence of FCS significantly stimulated the expansion of 
CFU-Cs. 
3.3.1.2. Serum free conditions: LTR-HSC expansion 
The requirement of FCS for LTR-HSC expansion was then investigated by 






























IMDM+ IMDM+ - FCS IMDM+ IMDM+ - FCS
Figure 3.9: Haematopoietic progenitors and LTR-HSC expansion in reaggregates
cultured in serum free conditions
A: Numbers of CFU-Cs per reaggregate cultured in the presence (IMDM+) or
absence (IMDM+ - FCS) of fetal calf serum (FCS). Cumulative result of two independent
experiments (* correspond to the values from experiment 1, others to values from
experiment 2).
BFU-E: burst forming unit-erythroid; CFU: colony forming unit; Mac: macrophage;
GM: granulocyte/macrophage; GEMM: granulocyte/erythroid/macrophage/ megakaryocyte
B: Peripheral blood chimerism of recipients transplanted with 0.01rd of reaggregates
cultured in the presence (IMDM+) or absence (IMDM+ - FCS) of FCS.
Each dot represents a single recipient mouse. Recipients were considered reconstituted
when their peripheral blood chimerism exceeded 5% at least 12 weeks after transplantation.




  104 
post transplantation by flow cytometric analysis. With IMDM+, 7 out of 7 recipients 
were reconstituted at high level (mean PBC: 67.2%)(Figure 3.9B). In IMDM+ -FCS, 
only 2 out of 8 recipients were reconstituted (mean PBC: 40.6%)(Figure 3.9B). Only 
2 out of 8 recipients were reconstituted in serum free condition, compared to 7 out of 
7 with medium containing FCS, indicating fewer LTR-HSCs in the absence of FCS. 
This difference was statistically significant (Fisher’s exact test; p=0.02). However, 
the reconstitution of 2 out of 8 mice in serum free cultures suggested the presence of 
at least 25 LTR-HSCs. This still represents a significant LTR-HSC expansion 
compared to the fresh E11.5 AGM region (Gekas et al., 2005; Kumaravelu et al., 
2002).  
 
3.3.1.3. Serum free conditions: long-term multilineage contribution and 
secondary transplantations. 
 To confirm the normal function of LTR-HSCs generated in serum free 
conditions, long-term multilineage analysis of haematopoietic organs and secondary 
transplantations were performed. High donor cell reconstitution was observed in 
peripheral blood, spleen, and thymus (Figure 3.10A). The donor cells in peripheral 
blood and spleen were of both myeloid (Mac1+ and Gr1+) and lymphoid lineages 
(CD3+ and B220+)(Figure 3.10B). In addition, the majority of donor cells in the 
thymus were immature (CD4+CD8+) T cells (Figure 3.10B). The low reconstitution 
level in bone marrow (3.65%) was multilineage as both myeloid (Mac1+ and Gr1+) 
and lymphoid lineages (CD3+ and B220+) were present (Figure 3.10A, B). However, 
such low reconstitution was not observed in the other recipient analysed (62.8% 
PBC, both myeloid and lymphoid).   
 As 2 of the recipients transplanted with “serum free reaggregates” were 
highly reconstituted, secondary transplantations were performed. One primary 
recipient was sacrificed and 1/10 of its bone marrow (paired femurs and tibias) was 
transplanted into each secondary recipient.  Secondary recipients PBC was analysed 
at least 12 weeks post-transplantation (Figure 3.10C). While the PBC of the primary 
recipient was 35.5%, none of the secondary recipient was reconstituted with donor  
 
  107 
bone marrow cells (Figure 3.10C). This is either due to the low reconstitution level 
of bone marrow in the primary recipient (4.03%) or a genuine defect in LTR-HSCs; 
additional secondary transplantations would be required to discriminate between 
these two options.  
 
3.3.2. The need for growth factors for LTR-HSC expansion 
It was demonstrated that maximal LTR-HSC expansion requires FCS in 
IMDM+. Based on this result, the requirement of the growth factors cocktail for 
LTR-HSC expansion was also investigated. E11.5 AGM reaggregates were cultured 
in IMDM+ or IMDM- (containing FCS but no growth factors) to address this 
question.  
 
3.3.2.1. Growth factor free conditions: haematopoietic progenitor 
expansion 
The difference in CFU-C expansion between cultures in IMDM+ and IMDM- 
was first quantified in 2 experiments presented individually. In IMDM+, reaggregates 
contained a total of 6450 and 5300 CFU-Cs as previously described in section 3.3.2.1 
(Figure 3.9A and Figure 3.11A). When cultured in IMDM-, reaggregates contained a 
total of 150 and 200 CFU-Cs, consisting of 0 and 150 BFU-E, 50 and 0 CFU-mac, 
and 150 and 0 CFU-GEMM (Figure 3.11A). It was concluded that growth factors in 
the medium are strongly required for optimal CFU-C expansion in reaggregates. 
Interestingly, it appeared that the original numbers of CFU-Cs in the fresh E11.5 
AGM region tissue (144±42 CFU-Cs, Figure 3.4) were in a similar range as 
reaggregates cultured in IMDM-, suggesting that FCS might be enough for 


































IMDM+ IMDM- IMDM+ IMDM-
Figure 3.11: Haematopoietic progenitor and LTR-HSC content in reaggregates
cultured in growth factor free conditions
A: Numbers of CFU-Cs per reaggregate cultured in the presence (IMDM+) or absence of
growth factors (IMDM-). Cumulative result of 2 independent experiments (* correspond to
the values from experiment 1, others to values from experiment 2).
BFU-E: burst forming unit-erythroid; CFU: colony forming unit; Mac: macrophage;
GM: granulocyte/macrophage; GEMM: granulocyte/erythroid/macrophage/ megakaryocyte
B: Peripheral blood chimerism of recipients transplanted with 0.01rd of reaggregates
cultured in the presence (IMDM+) or absence of growth factors (IMDM-).
Each point represents a single recipient mouse. Recipients were considered reconstituted
when their peripheral blood chimerism exceeded 5% at least 12 weeks after transplantation.




  109 
3.3.2.2. Growth factor free conditions: LTR-HSC expansion 
The expansion in LTR-HSCs was investigated by transplanting 0.01rd into 
each recipient mouse. In IMDM+, 7 out of 7 mice (100%) were reconstituted at high 
level (mean PBC: 67.2%)(Figure 3.11B). In IMDM-, only 3 out of 9 mice (33%) 
were reconstituted (mean PBC: 37.7%)(Figure 3.11B). Thus, “IMDM- reaggregates” 
contained significantly fewer LTR-HSCs than “IMDM+ reaggregates” (Fisher’s 
exact test, p=0.01).  
 
3.3.2.3. Growth factor free conditions: long-term multilineage analysis 
and secondary transplantations. 
The function of LTR-HSCs was then investigated by multilineage analysis of 
haematopoietic organs and secondary transplantations. Peripheral blood, spleen, and 
bone marrow were reconstituted with donor cells of myeloid (Mac1+ and Gr1+) and 
lymphoid (CD3+ and B220+) lineages (Figure 3.12A, B). Interestingly, the thymus 
was not highly reconstituted and the proportion of T cells (CD4+ and CD8+) derived 
from donor cells was very low (Figure 3.12A, B). This could hardly be explained by 
technical difficulty in isolating thymic tissue in aged mice (due to thymic involution) 
as flow cytometric analysis of the whole tissue showed it contained 71% of 
CD4+CD8+ cells, as expected. Instead, this observation made in both recipients 
analysed suggests that at least one growth factor in the culture is necessary for the 
generation of fully functional LTR-HSCs capable of T-cell maturation.  
To assess the self-renewal potential of LTR-HSCs generated in IMDM-, 
secondary transplantations were performed. The primary recipient, which had 77.2% 
PBC, was sacrificed and 1/10 of its bone marrow (paired femurs and tibias) was 
transplanted into each secondary recipient. None of the secondary recipients were 
reconstituted with donor cells, which was intringuing because the primary recipient 
blood was highly reconstituted (Figure 3.12C). However, the bone marrow 
reconstitution level of the primary recipient, testing additional primary recipients, 


















































































































































































































































































































































































Figure 3.10: Multilineage haematopoietic reconstitution and secondary
transplantations of LTR-HSCs generated in serum free conditions
A: Long-term donor derived reconstitution in major haematopoietic organs  of primary
recipient (peripheral blood, spleen, bone marrow, and thymus).
B: Long-term multilineage (myelo-lymphoid) analysis of donor derived cells in major
haematopoietic organs  of primary recipient (peripheral blood, spleen, bone marrow, and
thymus).
Representative example of analysis from two mice reconstituted with reaggregates cultured
in serum free conditions. Quadrants are based on appropriate isotype control (Appendix 3.2);
values indicate percentages of cells.
C: Secondary transplantation of bone marrow cells from a reconstituted primary recipient.
1/10 of whole bone marrow (paired femurs and tibias) from the primary recipient was
transplanted into each secondary recipient; peripheral blood chimerism was analysed at least
12 weeks post-transplantation.
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3.4. Requirement of individual growth factors for 
optimal haematopoietic development in E11.5 
AGM reaggregates  
3.4.1. The impact of growth factor deprivation on E11.5 
AGM reaggregates haematopoiesis  
Previous studies have demonstrated that all three growth factors used in 
IMDM+ (IL-3, SCF, and Flt3l) are involved in haematopoiesis (see Section 1.6.2). In 
order to investigate whether any one of these factors plays a predominant role in the 
extensive LTR-HSC expansion observed in E11.5 AGM reaggregates, single growth 
factors were omitted from the culture medium.  
 
3.4.1.1. Descriptive analysis: morphology and haematopoietic cells  
After 4 days of culture, images of reaggregates showed no obvious 
morphological differences among different conditions (either size or 
morphology)(Figure 3.13A).  
In addition, cells were counted and flow cytometry was performed with anti-
CD45 antibody to mark haematopoietic cells in two experiments presented 
individually. In IMDM+, there were a total of 140000 and 140300 cells, of which 
19200 and 15200 were CD45+ respectively (Figure 3.13B). Without IL-3, there were 
120000 and 116300 cells in total, of which 5700 and 4200 were CD45+ (Figure 
3.13B). Without SCF, there were 200000 and 121200 cells in total, of which 23200 
and 10850 were CD45+ (Figure 3.13B). Without Flt3l, there were180000 and 89600 
cells in total, of which 16600 and 9500 were CD45+ (Figure 3.13B). Interestingly, 
only the removal of IL-3 resulted in consistently lower numbers of CD45+ cells 
compared to IMDM+ controls but did not compromise the maintenance of the 






















no IL-3 no SCF no Flt3lIMDM+
Figure 3.13: Effect of growth factor deprivation on reaggregates morphology and
haematopoiesis
A: Representative images of reaggregates cultured in media deprived of single growth
factors. All reaggregates had similar morphology (round with peripheral protrusions) with a
rough diameter of 1mm.
B: Haematopoietic cell numbers (CD45+) per reaggregate cultured in media media deprived
of single growth factors. (* correspond to the values from experiment 1, others to values
from experiment 2). Values obtained by flow cytometric analysis (cell viability determined
by 7-AAD uptake).
* * * *
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3.4.1.2. Functional analysis: haematopoietic progenitors  
After 4 days culture, CFU-Cs assays were set up to investigate the impact of 
single growth factor deprivation on the expansion of haematopoietic progenitors. In 
IMDM+, there was a total of 4080±1333 CFU-Cs (1275±518 CFU-mast, 875±492 
BFU-E, 400±318 CFU-GM, 1165±199 CFU-mac, 366±175 CFU-GEMM)(Figure 
3.14A). In the absence of IL-3, there was a total of 470±60 CFU-Cs (186±29 CFU-
mast, 50±86 BFU-E, no CFU-GM, 233±58 CFU-mac, and no CFU-GEMM)(Figure 
3.14A). In the absence of SCF, there was a total of 3030±630 CFU-Cs (967±153 
CFU-mast, 630±208 BFU-E, 400±0 CFU-GM, 800±264 CFU-mac, and 233±58 
CFU-GEMM)(Figure 3.14A). In the absence of Flt3l, there was a total of 2920±320 
CFU-Cs (1050±50 CFU-mast, 386±202 BFU-E, 283±144 CFU-GM, 750±450 CFU-
mac, and 450±304 CFU-GEMM)(Figure 3.14A). Compared to IMDM+ control, only 
the lack of IL-3 resulted in a significantly reduced CFU-C expansion (Paired T-test; 
p=0.001)(SCF deprived: p=0.23; Flt3l deprived: p=0.12).  
 
3.4.1.3. Functional analysis: LTR-HSC expansion 
Repopulation assays were performed to investigate the impact of single 
growth factor deprivation on LTR-HSC expansion. In each experiment, 0.01rd was 
transplanted into individual recipient mice and PBC was determined at least 12 
weeks post-transplantation.  In standard conditions (IMDM+), 11 out of 11 mice 
(100%) were reconstituted at high level (mean PBC: 70.2%)(Figure 3.14B). In the 
absence of IL-3, only 8 out of 12 mice (66%) were successfully reconstituted (mean 
PBC: 59.5%)(Figure 3.14B). In the absence of SCF, 9 out of 11 recipient mice (82%) 
were reconstituted (mean PBC: 48.5%)(Figure 3.14B). In the absence of Flt3l, 5 out 
of 7 mice (71%) were successfully reconstituted (mean PBC: 69.7%)(Figure 3.14B). 
The presence of non-reconstituted mice upon removal of any single growth factor 
indicates fewer LTR-HSCs than in IMDM+ control, suggesting that all three factors 
are required for maximal LTR-HSC expansion. Nevertheless, the large proportion of 
reconstituted animals in each condition indicates a significant LTR-HSC expansion, 





























no SCF no Flt3l





(100%) (67%) (82%) (71%)
no IL-3
Figure 3.14: Haematopoietic progenitors and LTR-HSCs expansion in reaggregates
cultured in media deprived of single growth factors.
A: Number of CFU-Cs contained per reaggregate cultured in media deprived of a single
growth factor. Bars indicate standard deviation from 3 independent experiments.
BFU-E: burst forming unit-erythroid; CFU: colony forming unit; Mac: macrophage;
GM: granulocyte/macrophage; GEMM: granulocyte/erythroid/macrophage/ megakaryocyte
B: Peripheral blood chimerism of recipients transplanted with 0.01dose of reaggregates
cultured in media deprived of a single growth factor.
Each point represents a single recipient mouse. Recipients were considered reconstituted
when their peripheral blood chimerism exceeded 5% at least 12 weeks after transplantation.
Cumulative result of 3 independent experiments.
IMDM+
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HSC expansion. Whilst only the removal of IL-3 generated significantly fewer 
reconstituted mice (Fisher’s exact test, p=0.03) compared to IMDM+ control (SCF 
deprived: p=0.4; Flt3l deprived: p=0.13), the removal of other growth factors 
resulted in similar percentages of reconstituted mice. In order to appropriately 
quantify the absolute number of LTR-HSCs in each condition, limiting dilution 
experiments would be required and increasing the numbers of recipients would 
strengthen the statistical analysis. 
 
3.4.1.4. Normal function of LTR-HSCs: multilineage analysis and 
secondary transplantations 
To confirm that LTR-HSCs generated in each condition were fully functional, 
multilineage analysis and secondary transplantations were performed. Previous data 
showed that LTR-HSCs generated in IMDM+ are fully functional (Figures 3.6 and 
3.7). In other conditions, the contribution of donor cells to myeloid and lymphoid 
lineages in haematopoietic tissues (blood, spleen, bone marrow and thymus) was 
assessed by flow cytometry at least 12 weeks post-transplant except for “no SCF” 
condition due to the lack of available animal. In the absence of IL-3 and Flt3l, 
peripheral blood, spleen, bone marrow and thymus were reconstituted with donor 
cells (Figure 3.15A, B). Donor derived lymphoid cells (CD3+, CD43+ and B220+) 
were observed in blood, spleen and bone marrow in both conditions (Figure 3.15A’, 
B’). Myeloid cells (Mac1+ and Gr1+) were also observed in these tissues in both 
conditions (Figure 3.15A’, B’). Donor derived cells in the thymus contributed to T 
cells populations (CD4+ and CD8+)(Figure 3.15A’, B’). Low numbers of Mac+ cells 
in the spleen of mice transplanted with cells cultured without IL-3 or without Flt3l 
was not observed in other analysed recipients, so LTR-HSCs generated without IL-3 
or without Flt3l may provide multilineage contribution to recipient haematopoietic 
tissues.  
Secondary transplantations were performed in each condition to identify any 
potential LTR-HSC defect. One primary recipient from each condition was sacrificed 
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Figure 3.15: Multilineage haematopoietic reconstitution by LTR-HSCs generated in
media deprived of single growth factors.
A, A’: Long-term multilineage analysis of  recipient mice reconstituted with reaggregatess
cultured in the absence of IL-3.  A: Donor derived reconstitution in major haematopoietic
organs (peripheral blood, spleen, bone marrow, and thymus). A’:  Multilineage (myelo-
lymphoid) contribution in major haematopoietic organs (peripheral blood, spleen, bone
marrow, and thymus) of recipients. Events gated on donor derived cells.
B, B’: Long-term multilineage analysis of recipient mice reconstituted with reaggregatess
cultured in the absence of Flt3l.  B: Donor derived reconstitution in major haematopoietic
organs (peripheral blood, spleen, bone marrow, and thymus). B’:  Multilineage (myelo-
lymphoid) contribution in major haematopoietic organs (peripheral blood, spleen, bone
marrow, and thymus) of recipients. Events gated on donor derived cells.
Representative example of analysis from two mice reconstituted with reaggregates cultured
in single growth factor deprived conditions. Quadrants are based on appropriate isotype
control (Appendix 3.2); values indicate percentages of cells. Analysis of primary recipients

























































































































































































































































































































































Figure 3.16: Secondary transplantations of LTR-HSCs generated in media deprived
of single growth factors
A, A’: Secondary transplantation and multilineage reconstitution in peripheral blood of
secondary recipients transplanted with bone marrow originally reconstituted with
reaggregates cultured in the absence of IL-3. A: Secondary transplantation of bone
marrow cells from reconstituted primary recipient. A’: Long-term multilineage (myelo-
lymphoid) contribution in secondary recipients peripheral blood.
B, B’: Secondary transplantation and multilineage reconstitution in peripheral blood of
secondary recipients transplanted with bone marrow originally reconstituted with
reaggregates cultured in the absence of SCF. B: Secondary transplantation of bone
marrow cells from reconstituted primary recipient. B’: Long-term multilineage (myelo-
lymphoid) contribution in secondary recipients peripheral blood.
C, C’: Secondary transplantation and multilineage reconstitution in peripheral blood of
secondary recipients transplanted with bone marrow originally reconstituted with
reaggregates cultured in the absence of Flt3l. C: Secondary transplantation of bone
marrow cells from reconstituted primary recipient. C’: Long-term multilineage (myelo-
lymphoid) contribution in secondary recipients peripheral blood.
A, B, C: 1/10 of whole bone marrow (2 femurs and 2 tibias) from a primary recipient was
transplanted into each secondary recipient; peripheral blood chimerism was analysed at
least 12 weeks  post-transplantation.
A’, B’, C’: Representative example of analysis from two reconstituted secondary
recipients. Quadrants are based on appropriate isotype control (Appendix 3.2); values
indicate percentages of cells. Events gated on donor derived cells.
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each secondary recipients and PBC was determined at least 12 weeks post transplant.  
Without IL-3, the primary recipient had a PBC of 84.7% and 4 out of 4 secondary 
recipients were reconstituted at high level (mean PBC: 86%)(Figure 3.16A). Both 
myeloid (Mac1+ and Gr1+) and lymphoid (CD3+ and B220+) compartments were 
repopulated (Figure 3.16A’). Without SCF, the primary recipient had 82.3% PBC 
and 3 out of 3 secondary recipients were reconstituted at a lower level compared to 
the primary recipient (mean PBC: 54.5%)(Figure 3.16B). Both myeloid (Mac1+ and 
Gr1+) and lymphoid (CD3+ and B220+) lineages in the blood were repopulated 
(Figure 3.16B’).  Without Flt3l, the primary recipient used had a PBC of 87% and 4 
out of 4 secondary recipients were reconstituted at high level (mean PBC: 
88.9%)(Figure 3.16C). Both myeloid (Mac1+ and Gr1+) and lymphoid (CD3+ and 
B220+) lineages in the blood were reconstituted (Figure 3.16C’).  
 
3.4.1.5. Conclusions 
All growth factors (IL-3, SCF and Flt3l) are required to achieve maximal 
LTR-HSC expansion in reaggregate culture. However, the LTR-HSCs generated in 
the absence of single growth factors were capable of multilineage reconstitution in 
various haematopoietic organs and successfully reconstituted secondary recipients.  
 
3.4.2. Influence of individual growth factor on 
haematopoiesis in E11.5 AGM reaggregates 
In order to understand the roles of individual growth factors in the expansion 
of haematopoietic cells (CD45+), progenitors (CFU-Cs) and LTR-HSCs, 
reaggregates were cultured with individual cytokines and analysed after 4 days  
reaggregate culture.  
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3.4.2.1. Descriptive analysis: morphology and cell numbers 
Gross morphological study of reaggregates from each condition revealed no 
obvious differences as reaggregates were of similar size and had cell protrusions at 
their periphery (Figure 3.17A). In standard conditions (IMDM+), one reaggregate 
contained 198800±33170 cells, of which 16840±4920 were CD45+ (Figure 3.17B). 
When cultured in IL-3 only, one reaggregate contained 191820±36010 cells of which 
8000±2790 were CD45+ (Figure 3.17B). When cultured in SCF only, one reaggregate 
contained 154000±32240 cells of which 2040±760 cells CD45+ (Figure 3.17B). 
When cultured in Flt3l only, one reaggregate contained 199210±35230 cells of 
which 2340±500 were CD45+ (Figure 3.17B). Every condition generated a 
significantly lower number of CD45+ cells compared to IMDM+ control (Paired T-
test; IL-3: p=0.008; SCF: p=0.002; Flt3l: 0.002), indicating that optimal 
haematopoietic cell expansion occurs from a synergetic response of at least two 
growth factors.  
 
3.4.2.2. Functional analysis: expansion of haematopoietic progenitors 
After 4 days, progenitor content per reaggregate was assessed by CFU-C 
assay. In IMDM+, there were 4620±990 CFU-Cs (1620±333 CFU-mast, 550±50 
BFU-E, 600±50 CFU-GM, 1517±562 CFU-mac, and 333±104 CFU-GEMM)(Figure 
3.18A). In the presence of IL-3, there were 2730±310 CFU-Cs (1030±176 CFU-
mast, 383±161 BFU-E, 333±58 CFU-GM, 833±29 CFU-mac, 150±132 CFU-
GEMM)(Figure 3.18A). In the presence of SCF, there were a total of 670±300 CFU-
Cs (333±208 CFU-mast, 100±87 BFU-E, 33±58 CFU-GM, 133±76 CFU-mac, 
70±115 CFU-GEMM)(Figure 3.18A). In the presence of Flt3l, there were a total of 
280±30 CFU-Cs (130±58 CFU-mast, 33±29 BFU-E and 117±29 CFU-mac)(Figure 
3.18A). Statistical analysis demonstrated that significantly fewer CFU-Cs were 
generated in all conditions (Paired T-test, IL-3: p=0.03; SCF: p=0.002; Flt3l: 
p=0.01), once again indicating that optimal CFU-C expansion occurs through 
combined effects of at least 2 growth factors. 
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Figure 3.17: Influence of single growth factors on reaggregate morphology and
haematopoiesis.
A: Morphology of reaggregates cultured in single growth factor media. All reaggregates had
similar morphology (round with cell protrusions) with a diameter of approximately 1mm.
B: Haematopoietic cell numbers (CD45+) contained per reaggregate cultured in single



































(71%) (35%) (24%) (10%)
Figure 3.18: Haematopoietic progenitors and LTR-HSC expansion in reaggregates
cultured in single growth factor media.
A: Numbers of CFU-Cs per reaggregate cultured in media containing a single growth factor.
Bars indicate standard deviation of 3 independent experiments. BFU-E: burst forming unit-
erythroid; CFU: colony forming unit; Mac: macrophage; GM:: granulocyte/macrophage;
GEMM: granulocyte/erythroid/macrophage/ megakaryocyte
B: Peripheral blood chimerism of recipients transplanted with 0.01dose of reaggregates
cultured in media containing a single growth factor.
Each point represents a single recipient mouse. Recipients were considered reconstituted
when their peripheral blood chimerism exceeded 5% at least 12 weeks after transplantation.
Cumulative result of 3 independent experiments.
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3.4.2.3. Functional analysis: expansion of LTR-HSCs 
 Repopulation assays were performed to assess LTR-HSC expansion in each 
condition. In control experiments (IMDM+), 12 out of 17 mice (71%) injected with 
0.01 rd each were reconstituted (mean PBC: 40.9%)(Figure 3.18B). This level of 
repopulation was lower than expected, most probably due to biological variations. In 
the presence of IL-3, 8 out of 22 mice (36%) were successfully reconstituted (mean 
PBC: 37.5%)(Figure 3.18B). This result approximates findings previously reported 
(Robin et al., 2006). In the presence of SCF, 6 out of 20 mice (30%) were 
reconstituted (mean PBC: 33.9%) and in Flt3l, 2 out of 20 mice (10%) were 
reconstituted (mean PBC: 27.8%)(Figure 3.18B). Compared to IMDM+ control, all 
conditions contained significantly lower proportion of reconstituted recipients 
(Fisher’s exact test; IL-3: p=0.05; SCF: p=0.02; Flt3l: p=0.0004). Thus, the presence 
of a single growth factor cannot on its own account for the extensive LTR-HSC 
expansion observed in reaggregates, but rather results from a combined effect of at 
least two growth factors.  
 
3.4.2.4. Normal function of LTR-HSCs: multilineage analysis and 
secondary transplantations 
The function of LTR-HSCs from each condition was assessed by multilineage 
analysis and secondary transplantations. Multilineage analysis of peripheral blood, 
spleen, bone marrow and thymus was performed by flow cytometry on reconstituted 
recipients at least 12 weeks post-transplant. In all conditions, donor derived cells of 
myeloid (Mac1+ and Gr1+) and lymphoid (CD3+, B220+, CD4+ and CD8+) lineages 
were detected in all tissues (Figure 3.19A’, B’, and C’).  
For secondary transplantations, primary recipients were sacrificed and 1/10 of 
their whole bone marrow (paired femurs and tibias) was transplanted into secondary 
recipients. In the presence of IL-3, the primary recipient (75% PBC) bone marrow 
cells successfully reconstituted 4 out of 4 secondary recipients (mean PBC: 
37.2%)(Figure 3.20A). In the presence of SCF only, the primary recipient (85.8% 
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Figure 3.19: Multilineage haematopoietic reconstitution by reaggregates cultured in
the presence of single growth factors.
A, A’: Long-term multilineage analysis of recipient mice reconstituted with reaggregates
cultured in the presence of IL-3.  A: Donor derived reconstitution major haematopoietic
organs (peripheral blood, spleen, bone marrow, and thymus). A’:  Multilineage (myelo-
lymphoid) contribution in major haematopoietic organs (peripheral blood, spleen, bone
marrow, and thymus) of recipients. Events gated on donor derived cells.
B, B’: Long-term multilineage analysis of recipient mice reconstituted with reaggregates
cultured in the presence of SCF.  B: Donor derived reconstitution major haematopoietic
organs (peripheral blood, spleen, bone marrow, and thymus). B’:  Multilineage (myelo-
lymphoid) contribution in major haematopoietic organs (peripheral blood, spleen, bone
marrow, and thymus) of recipients. Events gated on donor derived cells.
C, C’: Long-term multilineage analysis of recipient mice reconstituted with reaggregates
cultured in the presence of Flt3l.  C: Donor derived reconstitution major haematopoietic
organs (peripheral blood, spleen, bone marrow, and thymus). C’:  Multilineage (myelo-
lymphoid) contribution in major haematopoietic organs (peripheral blood, spleen, bone
marrow, and thymus) of recipients. Events gated on donor derived cells.
Representative example of analysis from two mice reconstituted with reaggregates cultured
in single growth factor conditions. Quadrants are based on appropriate isotype control
























































































































































































































































































































































Figure 3.20: Secondary transplantations of LTR-HSCs generated in the presence of
single growth factor.
A, A’: Secondary transplantation and multilineage reconstitution of secondary recipients
transplanted with bone marrow originally reconstituted with reaggregates cultured in the
presence IL-3. A: Secondary transplantation of bone marrow cells obtained from
reconstituted primary recipient. A’: Long-term multilineage (myelo-lymphoid) contribution
in secondary recipients peripheral blood.
B, B’: Secondary transplantation and multilineage reconstitution of secondary recipients
transplanted with bone marrow originally reconstituted with reaggregates cultured in the
presence of SCF. B: Secondary transplantation of bone marrow cells obtained from
reconstituted primary recipient. B’: Long-term multilineage (myelo-lymphoid) contribution
in secondary recipients peripheral blood.
C, C’: Secondary transplantation and multilineage reconstitution of secondary recipients
transplanted with bone marrow originally reconstituted with reaggregates cultured in the
presence of Flt3l. C: Secondary transplantation of bone marrow cells obtained from
reconstituted primary recipient. C’: Long-term multilineage (myelo-lymphoid) contribution
in secondary recipients peripheral blood.
A, B, C: 1/10 of whole bone marrow (paired femurs and tibias) from the primary recipient
was transplanted into each secondary recipient; peripheral blood chimerism was analysed at
least 12 weeks post-transplantation.
A’, B’, C’: Representative example of analysis from two mice reconstituted with
reaggregates cultured in single growth factor conditions. Quadrants are based on appropriate
isotype control (Appendix 3.2); values indicate percentages of cells. Events gated on donor
derived cells.
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(mean PBC: 49.2%)(Figure 3.20B). In the presence of Flt3l only, the primary 
recipient (42.2% PBC) bone marrow cells reconstituted 4 out of 4 secondary 
recipients at relatively low level (mean PBC: 7.10%)(Figure 3.20C). In all 
conditions, donor-derived cells of both myeloid (Mac1+ and Gr1+) and lymphoid 
(CD3+ and B220+) lineages were observed (Figure 3.20A’, B’, and C’). These results 
indicate that the LTR-HSCs generated in the presence of single growth factors are 




 The results presented in this section confirm that at least 2 growth factors in 
IMDM+ are required for maximal LTR-HSC expansion. However, reaggregates 
cultured in IL-3 only generated higher numbers of CD45+ cells, CFU-Cs and LTR-
HSCs compared to other conditions, raising the possibility that IL-3 might be the 
most potent factor in the IMDM+.  
 
3.5. Discussion 
The reaggregate culture system is a robust and reliable model for the study of 
LTR-HSC development in the E11.5 AGM as it allows the dissociation of the tissue 
prior to culture, giving access to specific cell populations, whilst maintaining the 
tissue’s intrinsic ability to generate LTR-HSCs. Herein, culture conditions were 
tested and it was concluded that the extensive haematopoietic cell, precursors, and 
stem cell expansion during culture was due to the concerted effects of IL-3, SCF, 
Flt3l, and FCS.  
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3.5.1. The reaggregate culture system, in vitro model of in 
vivo LTR-HSC development? 
At E11.5 the entire embryo contains from 3 to 10 LTR-HSCs, a number 
which rises to 70 to 150 by E12.5 (Gekas et al., 2005; Kumaravelu et al., 2002). The 
LTR-HSC expansion in reaggregates (approximately 146 LTR-HSCs) appears 
similar to the one that naturally occurs in vivo (Taoudi et al., 2008), implying it 
might recapitulate biological processes  that occur during development.  
An interesting aspect of the reaggregate culture is the 
CD45+cKit+Sca1+PECAMmedCD34- immunophenotype of the LTR-HSCs produced, 
which is similar to adult LTR-HSCs rather than AGM LTR-HSCs (Baumann et al., 
2004; Osawa et al., 1996; Taoudi et al., 2005; Uchida and Weissman, 1992). The 
lack of CD34 expression indicates that the fetal liver stage might have been by-
passed (Matsuoka et al., 2001a; Taoudi et al., 2005). However, the heterogeneity for 
CD48 expression was intriguing. Additional experiments using a different anti-CD48 
antibody clone would be required to confirm the LTR-HSC heterogeneity for CD48 
expression since data previously published demonstrated that neither adult nor fetal 
(in E12.5 fetal liver, placenta, E9.5 YS and E11.5 AGM region) expressed CD48 
(Kiel et al., 2005; Kim et al., 2006; McKinney-Freeman et al., 2009). The most likely 
explanation is that the ex vivo culture altered LTR-HSC phenotype. Such 
phenomenon is observed in reaggregates because, contrary to the fresh tissue, LTR-
HSCs no longer express CD34 after reaggregate culture (Noda et al., 2008; Sanchez 
et al., 1996; Taoudi et al., 2008). Interestingly, similarly to reaggregate LTR-HSCs, 
HSCs obtained upon cultured of ES-cells treated with ectopic Cdx4 and HoxB4 do 
not express CD34 and are heterogenous for CD48 (McKinney-Freeman et al., 2009). 
 
3.5.2. The requirement for growth factors in reaggregate 
culture 
Various culture conditions were tested to identify the factors that might be of 
importance for LTR-HSC expansion in reaggregates.  
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Interestingly, some LTR-HSC expansion was retained upon removal of FCS 
(approximately 23 LTR-HSCs). This is promising for the future study of molecular 
pathways involved in LTR-HSC emergence, as they require stringent defined culture 
conditions. Some LTR-HSC expansion was also retained upon removal of all growth 
factors (IMDM-)(approximately 33 LTR-HSCs), indicating that FCS is sufficient to 
support limited LTR-HSC expansion. However, it is important to note that FCS 
batch variations could potentially trigger results different to the ones reported here.  
The roles of individual cytokines (IL-3, SCF, and Flt3l) in LTR-HSC 
expansion were investigated. These well-studied haematopoietic cytokines are 
commonly used for LTR-HSC culture, and their roles in various aspects of 
haematopoiesis have been extensively reported (see Section 1.6.2). The removal of 
single growth factors showed that none was dispensable for optimal LTR-HSC 
expansion in E11.5 AGM reaggregates.  
When reaggregates were cultured in the presence of single growth factors, 
there were significantly fewer LTR-HSC compared to control and to numbers 
obtained in the presence of 2 growth factors. This indicates that the concerted action 
of at least growth factors enhances LTR-HSC expansion. Approximately 35 LTR-
HSCs were obtained when reaggregates were cultured in IL-3, a result comparable to 
that observed in E11.5 AGM explants (Robin et al., 2006). Apart from cultures with 
IL-3 only, the numbers of LTR-HSC in other conditions are comparable to the one 
obtained in IMDM- (approximately between 10 and 25 LTR-HSCs). Thus, SCF and 
Flt3l on their own are not sufficient to support extensive LTR-HSC expansion. 
Altogether, these observations supported the conclusion that growth factors act in a 
synergistic way. This result was expected because previous studies have reported that 
Flt3l strongly synergises with other haematopoietic growth factors, including SCF, 
and interleukins (Buza-Vidas et al., 2009; Diehl et al., 2007; Gilliland and Griffin, 
2002).  
Although various growth factor combinations yielded different numbers of 
LTR-HSCs, successful multilineage contribution and secondary transplantations was 
achieved in each condition, demonstrating that LTR-HSCs were fully functional.  
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Most of LTR-HSC numbers in this study were estimated based on the 
proportion of reconstituted animals in each condition. Limiting dilution analyses will 
be required to determine the exact numbers of LTR-HSCs in each condition, thus 
defining more accurately the roles of each cytokine in reaggregate culture. Each 
cytokine might act on different processes involved in LTR-HSC development. As it 
has been shown that (although proliferation may also be important) the extensive 
LTR-HSC expansion observed in reaggregates is the result of pre-HSC maturation 
(Taoudi et al., 2008), future studies will aim to understand which individual cytokine 
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4. Characterisation of Runx1 
expression in the Runx1EGFP 
reporter mouse model 
4.1. Introduction 
 The second part of this study focused on the role of Runx1 in the emergence 
of LTR-HSCs in the E11.5 AGM region and investigating Runx1 expression in pre-
HSC populations. 
Although current theory states that Runx1 transcription factor is required for 
the transition from endothelial to haematopoietic fate, its precise role remains unclear 
(see Section 1.5.3). 
Various Runx1 reporter mouse models were generated to track Runx1 
expression and better understand its roles in haematopoiesis. The Runx1-LacZ 
reporter mouse contains LacZ sequences fused to the 3’ coding sequence of the 
Runx1 locus and generates a non-functional allele (Runx1lz)(North et al., 1999). 
Haploinsufficient dose of Runx1 results in fewer CFU-Cs and CFU-S11 in the YS, 
fetal liver and AGM region (Cai et al., 2000; Mukouyama et al., 2000; Wang et al., 
1996a), and in deviation of spatial and temporal LTR-HSC development (Cai et al., 
2000). To avoid haploinsufficiency, another Runx1 reporter mouse model was 
generated by introducing Runx1 cDNA linked to green fluorescent protein (GFP) via 
internal ribosome entry site (IRES) sequences within the endogenous Runx1 locus 
(Runx1GFP)(Lorsbach et al., 2004). Although Runx1 protein is functional, this mouse 
expresses only one major Runx1 isoform, Runx1b.  In addition, the presence of an 
active selection marker here may interfer with expression of nearby genes or Runx1 
itself. Also, important regulatory elements within the Runx1 3’UTR are not active in 
this model.  
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 To avoid these potential problems, A. Suleman in our laboratory produced a 
Runx1 mouse reporter line in which an IRES-EGFP sequence was introduced after 
exon 6 of the Runx1 locus (Figure 4.1A).  The insertion of IRES-EGFP does not 
replace any genomic sequence and leaves both the Runx1 promoters and the 3’UTR 
regulatory sequences intact, allowing normal regulation of Runx1 expression. In 
addition, EGFP was chosen as the reporter protein because it is significantly brighter 
than WT GFP owing to a double amino-acid substitution of FL64,65ST (Yang et al., 
1996). This allows more sensitive detection of Runx1 expression levels.  
By introducing only a subtle modification within the targeted Runx1 locus, 
Runx1EGFP reporter mice should provide an accurate model for studying the temporal 
and spatial expression pattern of Runx1 in the embryo and the adult. It is also useful 
for purification of various Runx1+ populations for ex vivo assays.  
The first goal of this study was to perform extensive descriptive and 
functional analysis of the Runx1EGFP/EGFP line to determine if these animals display 
any detectable phenotype. The second goal was to identify which cell populations 
express Runx1 in both the adult haematopoietic system and in the E11.5 AGM. 
 
4.2. Genotyping of the Runx1EGFP mice 
As targeting experiments were performed on the 129 genetic background, the 
Runx1EGFP mouse line was backcrossed for 8 generations to transfer the line to the 
pure C57 Bl/6 genetic background (see Section 2.3.2) and allow in vivo 
transplantations into C57 Bl/6 recipient mice.  
 For genotyping animals, PCR primers were designed by H. Inoue in our 
laboratory and consisted of: two forward primers, one within Runx1 exon 6 and 
another one within the IRES-EGFP sequence, and a reverse primer located within the 
Runx1 3’UTR (Figure 4.1A; sequences provided in Table 2.1). Resulting PCR 
products were 367bp for the Runx1WT allele and 304bp for the Runx1EGFP allele. 
Sizes of PCR products were determined by agarose gel electrophoresis in comparison 
with migration of 1KB ladder. DNA controls (both Runx1WT and Runx1EGFP) and  
A
B
exon 6 3’ UTR


























Figure 4.1: Runx1EGFP mouse line PCR genotyping design.
A: Schematic representation of Runx1WT and Runx1EGFP alleles with primer sets (arrows)
used for genotyping and sizes of the resulting PCR fragments.
B: Representative example of PCR genotyping performed on offspring from Runx1EGFP/WT X
Runx1EGFP/WT cross. Each lane corresponds to an individual animal; upper fragment
corresponds to Runx1WT (367bp) and lower fragment corresponds to Runx1EGFP (304bp).
Fragment sizes were determined based on 1KB ladder migration. H2O controls were run in
every case to detect cases of contamination. Black: Runx1WT/WT, Blue: Runx1EGFP/WT, Pink:
Runx1EGFP/EGFP.
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water control were run along with samples (Figure 4.1B). The black, blue, and pink 
genotypes in future figures refer to Runx1WT/WT, Runx1EGFP/WT, and Runx1EGFP/EGFP 
animals respectively.  
 All experiments in this study were performed with Runx1WT/WT age matched 
controls. Unless otherwise stated, all adult and embryonic Runx1 expression analyses 
presented here were performed on a mixed genetic background.  
 
4.3. Mendelian inheritance pattern of the Runx1EGFP 
mouse line 
 Runx1EGFP mice were expected to have a phenotype comparable with 
Runx1WT animals, due to only minor modification introduced into the Runx1 locus.  
No obvious morphological defects were observed in Runx1EGFP/EGFP adults 
and E11.5 embryos. Runx1EGFP mice were born in expected Mendelian ratio (Table 
4.1). Crosses of Runx1EGFP/WT males and Runx1EGFP/WT females produced 25% of 
Runx1WT/WT, 48% of Runx1EGFP/WT, and 28% of Runx1EGFP/EGFP of offsprings 
(expected ratio is 25% of Runx1WT/WT, 50% of Runx1EGFP/WT, and 25% of 
Runx1EGFP/EGFP).  
To rule out the possibility that a proportion of transgenic animals preferably 
die before birth, E11.5 embryos from Runx1EGFP/WT x Runx1EGFP/WT crosses were 
analysed. Out of a total of 36 embryos, 28% were Runx1WT/WT, 50% were 
Runx1EGFP/WT, and 22% were Runx1EGFP/EGFP (Table 4.1), roughly coinciding with 
predicted Mendelian ratio. Slightly low percentage of Runx1EGFP/EGFP embryos (22%) 
can be explained by the low numbers of litters. No breeding impairment was 
observed when the mouse line was maintained as a homozygous Runx1EGFP/EGFP 




Table 4.1: Runx1EGFP mouse line breed in Mendelian proportions.
Total numbers and the relative percentage of offspring with different genotypes
(Runx1WT/WT, Runx1EGFP/WT, Runx1EGFP/EGFP) obtained from Runx1EGFP/WT X Runx1EGFP/WT
cross. Animal numbers were obtained by genotyping both adult and E11.5 animals.







adult animals 25 48 28
% of total 25% (25%) 48% (50%) 28% (25%)
E11.5 animals 10 18 8
embryos % of total 28% (25%) 50% (50%) 22% (25%)
Table 4.2: Cellularity of adult haematopoietic organs of Runx1EGFP/EGFP animals
compared to Runx1WT/WT animals.
Haematopoietic organs were obtained from aged-matched individual adult males. Cell
counts were performed using Newbauer haemocytometer.








bone marrow 235 ± 48 209 ± 14
spleen 992 ± 99 1076 ± 171
thymus 762 ± 204 680 ± 143
 
  139 
4.4. Absence of detectable phenotype in the 
Runx1EGFP mice 
4.4.1. Cellularity of Runx1EGFP/EGFP adult haematopoietic 
organs 
 The cellularity of major adult haematopoietic organs (bone marrow, spleen, 
and thymus) was compared between Runx1WT/WT and Runx1EGFP/EGFP males. Of 
importance, transgenic animals were all age matched and on pure C57 Bl/6 
background. Runx1WT/WT and Runx1EGFP/EGFP adult bone marrows (count made from 
paired femurs and tibias) contained a total of 235±48 x105 cells and 209±14 x105 
cells respectively (Table 4.2). Statistical analysis using a paired T-test revealed no 
significant difference between Runx1WT/WT and Runx1EGFP/EGFP bone marrows (p = 
0.129). 
Runx1WT/WT and Runx1EGFP/EGFP adult spleens contained a total of 992±99 
x105 cells and 1076±171 x105 cells respectively (Table 4.2). Paired T-test revealed 
no significant difference between Runx1WT/WT and Runx1EGFP/EGFP spleens (p = 
0.301). 
Runx1WT/WT and Runx1EGFP/EGFP adult thymi contained a total of 762±204 
x105 cells and 680±203 x105 cells respectively (Table 4.2). Paired T-test revealed no 
significant difference between Runx1WT/WT and Runx1EGFP/EGFP thymi (p = 0.115). 
Thus, no difference was observed in the cellularity of major adult 
haematopoietic organs (bone marrow, spleen and thymus) between Runx1WT/WT and 
fully backcrossed Runx1EGFP/EGFP adults.  
 
4.4.2. Heamatopoietic progenitors content in Runx1EGFP/EGFP 
adult bone marrow 
 To further investigate whether Runx1EGFP/EGFP mice on a C57 Bl/6 
background have a haematopoietic phenotype, numbers of CFU-Cs contained in the 
bone marrow of Runx1WT/WT and Runx1EGFP/EGFP adult males were compared. There 
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were 76±5 CFU-Cs per 2x104 Runx1WT/WT bone marrow cells (19±2 CFU-mast, 4±3 
BFU-E, 30±9 CFU-GM, 22±3 CFU-mac, and 1±1 CFU-GEMM)(Figure 4.2). In 
comparison, Runx1EGFP/EGFP bone marrow contained 72±11 CFU-Cs per 2x104 cells 
(18±4 CFU-mast, 5±4 BFU-E, 26±8 CFU-GM, 23±6 CFU-mac, and 1±1 CFU-
GEMM)(Figure 4.2). Paired T-test showed no significant difference in bone marrow 
CFU-Cs numbers between Runx1WT/WT and Runx1EGFP/EGFP animals (p = 0.591).  
 
4.4.3. Cellularity of the Runx1EGFP E11.5 AGM region 
E11.5 AGM regions from Runx1WT/WT, Runx1EGFP/WT, and Runx1EGFP/EGFP 
embryos were dissected and cell counted. These animals looked morphologically 
normal at E11.5, with no obvious defect. Numbers of cells in the E11.5 AGM region 
were summarized in Table 4.3. A paired T-test showed a significant difference 
between Runx1WT/WT and Runx1EGFP/WT AGM total cell numbers (p=0.003). 
Intriguingly, no difference was observed between Runx1WT/WT and Runx1EGFP/EGFP 
animals (paired T-test, p=0.1). However, Wilcoxon signed-rank test showed no 
significant difference between CD45+ cell numbers among genotypes (p≥0.2 in each 
case). Such observation has various explanations. First, some human error is likely 
when performing haemocytometer based cell counts so additional replicates would 
be required for more powerful statistical analysis. Second, the fact that CD45+ cell 
numbers were similar in Runx1WT/WT, Runx1EGFP/WT, and Runx1EGFP/EGFP embryos 
suggests that normal haematopoiesis occurs in transgenic embryos, but perhaps other 
stromal cell types are sensitive and preferentially die during flow cytometry 
processing.  
 
4.4.4. Flow cytometric analysis of Runx1EGFP mice 
Flow cytometric analyses were performed in Runx1EGFP mice to characterise 
populations expressing EGFP in the adult and embryonic haematopoietic systems. To 
pick possible differences and an eventual haematopoietic phenotype, percentages of 
cells falling into each cell population were compared between Runx1WT/WT and 












Figure 4.2: Haematopoietic progenitors contained in adult bone marrow of
Runx1EGFP/EGFP animals compared to Runx1WT/WT animals.
Bars indicate the standard deviation of 4 independent experiments for total CFU-Cs.
BFU-E: burst forming unit-erythroid; CFU: colony forming unit; Mac: macrophage; GM:
granulocyte/macrophage; GEMM: granulocyte/erythroid/macrophage/megakaryocyte.
Table 4.3: Comparison of the cell compositions of Runx1WT/WT, Runx1EGFP/WT, and
Runx1EGFP/EGFP E11.5 AGM regions.
Data is representative of 7 independent experiments for Runx1WT/WT embryos, 3 independent
experiments for Runx1EGFP/WT embryos, and 4 independent experiments for Runx1EGFP/EGFP
embryos.
Data was acquired by flow cytometric analysis; cell viability was determined by 7-AAD








total cells 293530 ± 41490 239440 ± 27400 272990 ± 44900
live cells 94440 ± 25380 89780 ± 20120 86630 ± 18230
CD45
+
 cells 3200 ± 780 3670 ± 570 3460 ± 940
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In the adult haematopoietic system, Wilcoxon signed-rank test showed no 
significant differences in percentages of cells between Runx1WT/WT and Runx1EGFP/WT 
mice in any of the cell populations and tissues tested (p≥0.2 in all gates). Original 
flow cytometry dot plots were provided in Figures 4.4A, 4.5A B C, 4.6A B, 4.7A B, 
4.8A B C D, and 4.9 and percentages of cells were summarized in Figure 4.9. 
In the E11.5 AGM region, Wilcoxon signed-rank test showed no significant 
differences in percentages of cells between Runx1WT/WT and Runx1EGFP/EGFP embryos 
in any of the cell populations tested (p≥0.2 in all gates)(Figure 4.11A, 4.12A, 4.13A, 
and 4.14A, summarized in Figure 4.9). Although not statistically different, 
percentages of cells in haematopoietic cell populations were consistently higher in 
the Runx1EGFP/EGFP embryos compared to Runx1WT/WT embryos. Although results were 
collected from 4 independent experiments, this observation highlights the limitations 
of statistical analysis with low numbers of replicates and the need for additional 
experiments to detect very small but significant differences between Runx1WT/WT and 
Runx1EGFP/EGFP mice.  
 
4.5. Characterisation of Runx1 expression in the 
Runx1EGFP adult mouse 
4.5.1. Runx1 expression in the bone marrow lin-sca1+c-kit+ 
(LSK) fraction 
 LTR-HSCs are phenotypically characterised by the absence of expression of 
mature lineage markers (Weissman et al., 2001). To investigate Runx1 expression in 
the LTR-HSC population and non-committed progenitors of adult bone marrow, flow 
cytometric analysis using a cocktail of lineage specific antibodies (anti-CD3ε, anti-
CD4, anti-CD8, anti-B220, anti-Gr1, anti-Mac1, anti-Ter119) permitted the 
exclusion of mature haematopoietic cells; and Sca1 and c-kit staining allowed 
detection of the LSK fraction, which is highly enriched in LTR-HSCs (Osawa et al., 
1996; Wagers et al., 2002). All flow cytometric analyses within this section were 
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carried out using age-matched Runx1WT/WT and Runx1EGFP/WT adult males on a C57 
Bl/6 background. 
 Adult bone marrow from Runx1WT/WT and Runx1EGFP/WT mice contained 
2.62±0.7% and 2.21±0.6% of lin- cells respectively. Whole population shifts were 
observed in all the lin- populations except Sca1-c-kit- (Figure 4.3B). Conservative 
gating was performed in each histogram to obtain an approximate percentage of cells 
expressing EGFP. The EGFP+ cells represented 35.1±6.8% of the lin-sca1-c-kit- 
population, 77.3±7.1% of the lin-sca1-c-kit+ population, 18.2±21% of the lin-sca1+c-
kit- population, and 75.3±15% of the LSK population (Figure 4.3B). 
The median fluorescence intensity (MFI) shift of the Runx1EGFP/WT mice 
compared to Runx1WT/WT mice was 6.5±0.4 in the lin-sca1-c-kit- population, 21.4±0.9 
in the lin-sca1-c-kit+ population, 6.33±0.2 in the lin-sca1+c-kit- population, and 
11.16±0.9 in the LSK population (Figure 4.3B; Table 4.3).  
 Altogether, these data show that EGFP/Runx1 is expressed in all lin- cell 
fractions of the bone marrow. Fractions with the highest proportion of EGFP+ cells 
as well as the highest EGFP intensity (shown by highest relative MFI) were lin-Sca1-
c-kit+ and LSK. This strongly suggests that adult bone marrow LTR-HSCs express 
high levels of Runx1, confirming findings of the haploinsufficient model (North et 
al., 2004).  
 
4.5.2. Runx1 expression in myeloid lineages in Runx1EGFP/WT 
adult mouse   
4.5.2.1. Runx1 expression in granulocytes and monocytes 
Because Runx1 is involved in many fusion genes associated with myeloid 
leukaemias, it is likely that Runx1 plays a role during myeloid lineages 
differentiation (Speck and Gilliland, 2002). To investigate Runx1 expression in 
granulocytes and monocytes, haematopoietic organs (bone marrow, blood, and 
spleen) were dissected from Runx1EGFP/WT adult mice, stained for the granulocyte and 






















































































































































































Figure 4.3: EGFP expression within adult bone marrow lin-c-kit+Sca1+fraction.
A: Representative lin-sca1+c-kit+ (LSK) stains in adult bone marrow of Runx1EGFP/WT
animals compared to Runx1WT/WT animals. Quadrants were based on appropriate isotype
controls (Appendix 4.1A) and values indicate percentages of cells
B: Histograms showing EGFP expression in sca1-c-kit-, sca1-c-kit+, sca1+c-kit-, and sca1+c-
kit+ fractions. Black: Runx1WT/WT animals; Blue: Runx1EGFP/WT animals. Values indicate
percentages of cells in Runx1EGFP/WT animals.
Cells were stained with a cocktail of antibodies against mature lineage markers (anti-CD3ε,
anti-CD4, anti-CD8, anti-B220, anti-Gr1, anti-Mac1, anti-Ter119), positive cells for those
markers were excluded along with dead cells (uptaking 7-AAD) in the Fl-3 channel.
Plots are representative examples of 3 independent experiments.
R3R1
R2 R4
R1 R2 R3 R4
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Runx1 reporter models (Lorsbach et al., 2004; North et al., 1999), analysis of the 
percentage of EGFP positive cells in our Runx1EGFP mouse was problematic due to 
very small EGFP shifts. As a result, conservative gating was not appropriate. Instead, 
measures of the MFI in Runx1EGFP/WT mice compared to Runx1WT/WT mice were 
presented to report small, yet consistent, population shifts (summarized in Table 4.4). 
Finally, to prove that very small EGFP shifts in the FL-1 channel were not a false 
positive signal due to under-compensation from the FL-2 channel, FL-2 single stains 
performed in Runx1WT/WT tissues were presented in Appendix 4.1.  
 In the adult bone marrow, the MFI shift of the Runx1EGFP/WT mice compared 
to Runx1WT/WT mice was 1.66±0.5 in the Mac1-Gr1- population, 5.08±1.4 in the 
Mac1loGr1- population, 2.95±0.67 in the Mac1hiGr1lo population, and 1.9±0.2 in the 
Mac1hiGr1hi population  (Figure 4.4A; Table 4.4). 
In the peripheral blood, the MFI shift of the Runx1EGFP/WT mice compared to 
Runx1WT/WT mice was 2.09±0.15 in the Mac1-Gr1- population, 2.23±0.3 in the 
Mac1loGr1- population, 2.43±0.7 in the Mac1hiGr1lo population, and 6.1±2.8 in the 
Mac1hiGr1hi population (Figure 4.4B; Table 4.4).  
In the spleen, the MFI shift of the Runx1EGFP/WT mice compared to 
Runx1WT/WT mice was 0.88±0.1 in the Mac1-Gr1- population, 1.52±0.3 in the 
Mac1loGr1- population, 1.7±0.5 in the Mac1hiGr1lo population, and 1.1±0.3 in 
Mac1hiGr1hi population (Figure 4.4C; Table 4.4).  
Mac1loGr1- cell population, which contains monocytes, expressed the highest 
levels of EGFP in bone marrow, as shown by the MFI analysis. As previously 
reported, MFI shifts become smaller upon increasing expression of the Gr1 antigen 
in the bone marrow (Lorsbach et al., 2004). Because Gr1 expression increases in 
maturing myeloid cells, the MFI analysis here suggests that Runx1 expression 
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Figure 4.4: EGFP expression in myeloid cells: granulocytes and macrophages lineages.
A: Representative Mac1 Gr1 stains in adult bone marrow of Runx1EGFP/WT animals
compared to Runx1WT/WT animals and histograms showing EGFP expression in Mac1-Gr1-,
Mac1loGr1lo, Mac1hiGr1lo, and Mac1hiGr1hi fractions in the bone marrow.
B: Representative Mac1 Gr1 stains in adult peripheral blood of Runx1EGFP/WT animals
compared to Runx1WT/WT animals and histograms showing EGFP expression in Mac1-Gr1-,
Mac1loGr1lo, Mac1hiGr1lo, and Mac1hiGr1hi fractions in the peripheral blood.
C: Representative Mac1 Gr1 stains in adult spleen of Runx1EGFP/WT animals compared to
Runx1WT/WT animals and histograms showing EGFP expression in Mac1-Gr1-, Mac1loGr1lo,
Mac1hiGr1lo, and Mac1hiGr1hi fractions in the spleen.
Black: Runx1WT/WT animals; Blue: Runx1EGFP/WT animals. Quadrants on dot plots were based
on appropriate isotype controls (Appendix 4.1B); values indicate percentages of cells. Cell
viability was determined by 7-AAD uptake. In histograms, values indicate percentages of
cells in Runx1EGFP/WT animals.
All plots are representative examples of 3 independent experiments.
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4.5.2.2. Runx1 expression during erythroid differentiation  
 To characterise Runx1 expression in the erythroid lineage, bone marrow and 
spleen cells from Runx1EGFP/WT adult mice were collected and analysed on the basis 
of co-expression of CD45 and Ter119 markers (Kina et al., 2000). Indeed, 
erythrocyte maturation is described by the down regulation of CD45 marker and the 
acquisition of Ter119 marker, and thus processes through the following 
immunophenotypes: CD45hiTer119-, CD45hiTer119+, CD45loTer119+, CD45-Ter119+ 
(Kina et al., 2000). 
In the adult bone marrow, the MFI shift of the Runx1EGFP/WT mice compared 
to Runx1WT/WT mice was 6.11±1.0 in the CD45hiTer119- population, 5.54±0.8 in the 
CD45hiTer119+ population, 1.6±0.5 in the CD45loTer119+ population, and 0.25±0.06 
in the CD45-Ter119+ population (Figure 4.5A; Table 4.4).  
In the adult spleen, the MFI shift of the Runx1EGFP/WT mice compared to 
Runx1WT/WT mice was 2.04±0.3 in the CD45hiTer119- population, 2.03±0.3 in the 
CD45hiTer119+ population, 0±0.1 in the CD45loTer119+ population, and 0±0.04 in 
the CD45-Ter119+ population (Figure 4.5B; Table 4.4).  
Here, Runx1 expression is down regulated during erythrocyte development, 
consistent with previous reports (Lorsbach et al., 2004; North et al., 2004). However, 
additional Ter119 CD71 staining would be needed to describe more precisely the 
patterns of Runx1 expression during specific stages of erythrocyte maturation.  
 
4.5.3. Runx1 expression in lymphoid lineages in 
Runx1EGFP/WT adult mouse   
4.5.3.1. Runx1 expression in T cell lineages  
 Reports have shown that Runx1 is involved at various stages of T cell 
development (Collins et al., 2009). Anti-CD4 and anti-CD8 antibodies are commonly 
used to characterise T cell maturation stages and are also markers for mature helper 
T cells and cytotoxic T cells respectively (Collins et al., 2009). Both were used to 
















































































































































































































































































































































Figure 4.5: EGFP expression in myeloid cells: erythroid lineage.
A: Representative CD45 Ter119 stains in adult bone marrow of Runx1EGFP/WT animals
compared to Runx1WT/WT animals and histograms showing EGFP expression in
CD45+Ter119-, CD45+Ter119+, CD45loTer119+, and CD45-Ter119+ fractions in the bone
marrow.
B: Representative CD45 Ter119 stains in adult spleen of Runx1EGFP/WT animals compared to
Runx1WT/WT animals and histograms showing EGFP expression in CD45+Ter119-,
CD45+Ter119+, CD45loTer119+, and CD45-Ter119+ fractions in the spleen.
Black: Runx1WT/WT animals; Blue: Runx1EGFP/WT animals. Quadrants on dot plots were based
on appropriate isotype controls (Appendix 4.1C); values indicate percentages of cells. Cell
viability was determined by 7-AAD uptake.
In histograms, values indicate percentages of cells for Runx1EGFP/WT animals.
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In the peripheral blood, the MFI shift of the Runx1EGFP/WT mice compared to 
Runx1WT/WT mice was 2.5±0.3 in the CD4-CD8- population, 1.76±0.3 in the 
CD4+CD8- population, and 0.91±0.3 in the CD4-CD8+ population (Figure 4.6A; 
Table 4.4). CD4+CD8+ population was not analysed because its percentage was 
insignificant (Figure 4.6A; Table 4.4). A small subset of autofluorescent cells in the 
CD4-CD8+ and CD4+CD8- cell populations (1.06±1.2% and 1.5±1.2 respectively) 
could be observed (Figure 4.6A).  
In the thymus, the MFI shift of the Runx1EGFP/WT mice compared to 
Runx1WT/WT mice was 3±0.4 in the CD4-CD8- population, 3.0±0.5 in the CD4+CD8- 
population, 1.6±0.1 in the CD4-CD8+ population, and 2.93± 0.3 in the CD4+CD8+ 
population (Figure 4.6B; Table 4.4). 
In addition to CD4 and CD8, populations of mature T cells were analysed for 
EGFP expression using anti-CD3 antibody in adult haematopoietic tissues (bone 
marrow, peripheral blood, spleen and thymus). In the T cell CD3+B220- population 
the MFI shift of the Runx1EGFP/WT mice compared to Runx1WT/WT mice was 1.4±0.3 in 
the bone marrow, 1.67±0.3 in the peripheral blood, 0.62±0.17 in the spleen, and 
1.68±0.1 in the thymus (Figure 4.7A, B, C, D; Table 4.4).  
Altogether, there is very little expression of EGFP in T cell compartment of 
Runx1EGFP/WT adult mouse. As previously reported, populations of mature T cells 
(CD4+CD8-, CD4-CD8+ and CD3+B220-) generally have stronger EGFP expression 
in the thymus compared to other organs (Lorsbach et al., 2004). Analysis also 
showed that the EGFP expression in the thymus was the highest in CD4-CD8- cells, 
in line with the role of Runx1 in the transition from CD4-CD8- to CD4+CD8+ stages 
of T cell maturation (Growney et al., 2005; Putz et al., 2006). Additionally, EGFP 
was stronger in CD4+CD8- cells compared to CD4-CD8+ cells, also consistent with 





















































































































































































































































































































Figure 4.6: EGFP expression in lymphoid cells: T cell lineage.
A: Representative CD4 CD8 stains in adult peripheral blood of Runx1EGFP/WT animals
compared to Runx1WT/WT animals and histograms showing EGFP expression in CD4-CD8-,
CD4-CD8+, and CD4+CD8- fractions in the peripheral blood.
B: Representative CD4 CD8 stains in the adult thymus of Runx1EGFP/WT animals compared
to Runx1WT/WT animals and histograms showing EGFP expression in CD4-CD8-, CD4-
CD8+, and CD4+CD8- fractions in the thymus.
Black: Runx1WT/WTanimals; Blue: Runx1EGFP/WTanimals. Quadrants on dot plots were based
on appropriate isotype controls (Appendix 4.1D); values indicate percentages of cells. Cell
viability was determined by 7-AAD uptake.
In histograms, values indicate percentages of cells for Runx1EGFP/WT animals.
All plots are representative examples of 3 independent experiments.













































































































































































































































































































































































































































































Figure 4.7: EGFP expression in lymphoid cells: T and B cell lineages.
A: Representative CD3 B220 stains in adult bone marrow of Runx1EGFP/WT animals
compared to Runx1WT/WT animals and histograms showing EGFP expression in CD3-B220-,
CD3+B220-, and CD3-B220+ fractions in the bone marrow.
B: Representative CD3 B220 stains in adult peripheral blood of Runx1EGFP/WT animals
compared to Runx1WT/WT animals and histograms showing EGFP expression in CD3-B220-,
CD3+B220-, and CD3-B220+ fractions in the peripheral blood.
C: Representative CD3 B220 stains in the adult spleen of Runx1EGFP/WT animals compared to
Runx1WT/WT animals and histograms showing EGFP expression in CD3-B220-, CD3+B220-,
CD3-B220+, and CD3+B220+ fractions in the spleen.
D: Representative CD3 B220 stains in the adult thymus of Runx1EGFP/WT animals compared
to Runx1WT/WT animals and histograms showing EGFP expression in CD3-B220-,
CD3+B220-, CD3-B220+ fractions in the thymus.
Black: Runx1WT/WT animals; Blue: Runx1EGFP/Wtanimals. Quadrants on dot plots were based
on appropriate isotype controls  (Appendix 4.1E) and values indicate percentages of cells.
Cell viability was determined by 7-AAD uptake.
In histograms, values indicate percentages of cells for Runx1EGFP/WT animals.
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4.5.3.2. Runx1 expression in B cell lineages  
 Involvement of Runx1 in paediatric acute B-lymphocytic leukaemia suggests 
that an important role of Runx1 in B lymphopoiesis (Speck and Gilliland, 2002). 
Thus, the expression of EGFP in B cell subset was analysed in bone marrow, 
peripheral blood, spleen and thymus using an anti-B220 antibody, which marks most 
mature B cells. In addition, anti-CD19 antibody was used to detect mature B cells in 
the bone marrow.  
In the B cell CD3-B220+ population, the MFI shift of the Runx1EGFP/WT mice 
compared to Runx1WT/WT mice was 1.8±0.4 in the bone marrow, 2.29±0.3 in the 
peripheral blood, 0.68±0.1 in the spleen, and 3.42±1.2 in the thymus (Figure 4.7A, B, 
C, D; Table 4.4).  
As B220 expression is not completely restricted to B cells, anti-CD19 in 
combination with anti-B220 were used in the bone marrow, where B cell maturation 
takes place, to analyse EGFP expression in mature B cells (CD19+B220+). The MFI 
shift of the Runx1EGFP/WT mice compared to Runx1WT/WT mice was 2.45±0.5 in the 
CD19loB220+ population, 2.39±0.5 in the CD19-B220+ population, and 2.08±0.4 in 
the CD19+B220+ population (Figure 4.8 and Table 4.4). 
There was no difference in the EGFP expression between immature B cells 
(CD19-B220+) and mature B cells (CD19+B220+). These data compare with 
Runx1lacZ/+ haploinsufficient mice that have no B cell phenotype and no obvious 
difference in Runx1 expression during B-cell differentiation, as appropriately 
assessed with anti-CD43 and anti-B220 stainings (North et al., 2004).  
 
4.6. Characterisation of Runx1 expression in the 
Runx1EGFP embryo 
 Runx1 deficient embryos completely lack definitive haematopoietic 
progenitors (CFU-Cs and CFU-S11) and definitive LTR-HSCs in the YS, fetal liver, 
and AGM region (Cai et al., 2000; Mukouyama et al., 2000; North et al., 1999; North 













































































































































Figure 4.8: EGFP expression in lymphoid cells: B cell lineage.
Representative CD19 B220 stains in adult bone marrow of Runx1EGFP/WT animals compared
to Runx1WT/WT animals and histograms showing EGFP expression in CD19loB220-, CD19-
B220+, and CD19+B220+ fractions in the bone marrow.
Black: Runx1WT/WT animals; Blue: Runx1EGFP/WT animals. Quadrants on dot plots were based
on appropriate isotype controls (Appendix 5.1F) and values indicate percentages of cells.
Cell viability was determined by 7-AAD uptake. In histograms, values indicate percentages
of positive cells for Runx1EGFP/WT animals.




















































































































Figure 4.9: Summary of proportion of cell populations in Runx1WT/WT and
Runx1EGFP/WT adult haematopoietic system .
Black: Runx1WT/WT animals; Blue: Runx1EGFP/WT animals. Values indicate percentages of











































































































mature B cells CD19+B220+ bone marrow 2.08±0.46
Table 4.4: Relative EGFP expression within haematopoietic cell subsets in the
Runx1EGFP/WT adult mouse.
Relative median fluorescent intensity (MFI)(Runx1EGFP/WT MFI – Runx1WT/WT MFI) for
each cell populations with the mentioned phenotype.
SEM: standard error of the mean. Lineage identity is associated with each phenotype and
each organ is color-coded: black: bone marrow; red: peripheral blood; green: spleen;
orange: thymus.
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development, previous analysis performed by A. Suleman in E9.5 and E10.5 
Runx1EGFP embryos did not detect any abnormalities. Here, a more detailed analysis 
focusing on the E11.5 AGM region and using fully backcrossed homozygous 
Runx1EGFP/EGFP animals was performed. 
 
4.6.1. EGFP expression in the E11.5 AGM region: CD34+ cell 
subsets. 
EGFP expression in CD34+/- cell subsets was investigated as CD34 marks 
LTR-HSCs in the E11.5 AGM region (Sanchez et al., 1996). A whole population 
shift was observed in the CD45SP cell fraction of the AGM region, showing that most 
express EGFP (92.6±6.58%)(Figure 4.10B). Values from conservative gating were 
presented since few cells appeared to be CD45+EGFP-. They were gated out although 
it is not possible to rule out that they express very low levels of EGFP; due to major 
overlap between Runx1WT/WT and Runx1EGFP/EGFP plots (Figure 4.10B). The MFI shift 
of the Runx1EGFP/EGFP mice compared to Runx1WT/WT mice was 12.69±1.9 in the 
CD45SP population. Similar gating strategy to the CD45SP population was adopted 
for the CD45+CD34+ population and showed that 71.95±21.6% of cells were EGFP+ 
(Figure 4.10B). The MFI shift of the Runx1EGFP/WT mice compared to Runx1WT/WT 
mice was 25.06±4.1 in the CD45+CD34+ population.  
Histograms were not used for the analysis of CD45- cell populations as no 
detectable EGFP shift was observed, showing that the majority of CD45- cells do not 
express EGFP.  However, overlaying of Runx1WT/WT and Runx1EGFP/EGFP dot plots 
revealed the existence of few EGFP+ cells in CD45- populations (Figure 4.10B). Two 
distinct populations expressing EGFP were observed in the CD45-CD34- cell 
fraction: a EGFPlo fraction that overlaid with WT cells but with higher density 
(suggesting a very low EGFP expression) and a EGFP+ fraction (0.47±0.1%), 
distinctive from WT cells (Figure 4.10B). By using conservative gating, there were 
1.75±0.4% of EGFP+ cells in the CD45-CD34+ population (Figure 4.10B). Of note, 





















































































































































































Figure 4.10: EGFP expression in E11.5 AGM region haematopoietic stem cells
(CD45+CD34+ fraction).
A: Representative CD45 CD34 stains in E11.5 AGM region of Runx1EGFP/EGFPanimals
compared to Runx1WT/WT animals. Quadrants on dot plots were based on appropriate isotype
controls  (Appendix 4.2A).
B: Histograms and dot plots showing analysis EGFP expression in CD45-CD34-, CD45-
CD34+, CD45+CD34-, and CD45+CD34+ cell fractions in the E11.5 AGM region. Values
indicate percentages of cells for Runx1EGFP/EGFP animals.
Black: Runx1WT/WT embryos; Pink: Runx1EGFP/EGFP embryos. All plots display live cells only
(determined by 7-AAD uptake).
All plots are representative examples of 4 independent experiments.
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4.6.2. EGFP expression in the E11.5 AGM region: c-kit+ cell 
subsets.  
EGFP expression in c-kit+/- cell subsets was investigated as c-kit also marks 
LTR-HSCs in the E11.5 AGM region (Sanchez et al., 1996). For the reasons 
previously described, histograms were used to present CD45+ cell fractions and dot 
plots used to describe CD45- cell fractions. EGFP was expressed in 96.67±0.3% of 
CD45SP cells and 83.4±24.9% of CD45+c-kit+ cells (Figure 4.11B). The MFI shift of 
the Runx1EGFP/EGFP embryos compared to Runx1WT/WT embryos was 12.85±1.1 in the 
CD45SP population and was not calculated for the CD45+c-kit+ (Figure 4.11B). 
Indeed, the Runx1WT/WT curve was pushed against the axis, probably due to slight 
over-compensation in this channel.  
In the CD45-c-kit- cell fraction, 0.24±0.1% of cells were EGFP+ (Figure 
4.11B). In the CD45-c-kit+ cell fraction, 0.98±0.2% of cells were EGFP+ (Figure 
4.11B). No population shifts were observed in these two populations when 
histograms of Runx1WT/WT and Runx1EGFP/EGFP were plotted, together indicating that 
only very few non-haematopoietic cells express EGFP.   
 
4.6.3. EGFP expression in the E11.5 AGM region: VE-
cadherin cell subsets 
Because LTR-HSCs in the E11.5 AGM region also have a CD45+VE-
cadherin+ immunophenotype (North et al., 2002; Taoudi et al., 2005), EGFP 
expression was investigated in this cell compartment. The gating strategy was similar 
to that previously described. In the CD45SP cells, 98.20±1.0% of cells were EGFP+ 
and in the CD45+VE-cadherin+ cells, 96.76±1.0 were EGFP+ (Figure 4.12B). The 
MFI shift of the Runx1EGFP/EGFP embryos compared to Runx1WT/WT embryos was 
9.8±2.0 in the CD45SP population and 16.33±8.3 in the CD45+VE-cadherin+ 
























































































































































































Figure 4.11: EGFP expression in E11.5 AGM region haematopoietic stem cells
(CD45+c-kit+ fraction).
A: Representative CD45 c-kit stains in E11.5 AGM region of Runx1EGFP/EGFP animals
compared to Runx1WT/WT animals. Quadrants on dot plots were based on appropriate isotype
controls  (Appendix 4.2B)
B: Histograms and dot plots showing analysis EGFP expression in CD45-c-kit-, CD45-c-kit+,
CD45+c-kit-, and CD45+c-kit+ cell fractions in the E11.5 AGM region. Values indicate
percentages of cells for Runx1EGFP/EGFP animals.
Black: Runx1WT/WT embryos; Pink: Runx1EGFP/EGFP embryos. All plots display live cells only
(determined by 7-AAD uptake).
All plots are representative examples of 4 independent experiments.





























































































































































































Figure 4.12: EGFP expression in E11.5 AGM region haematopoietic stem cells
(CD45+VE-cadherin+).
A: Representative CD45 VE-cadherin stains in E11.5 AGM region of Runx1EGFP/EGFP
animals compared to Runx1WT/WT animals. Quadrants on dot plots were based on appropriate
isotype controls  (Appendix 4.3A)
B: Histograms and dot plots showing analysis EGFP expression in CD45-VE-cadherin-,
CD45-VE-cadherin-, CD45-VE-cadherin+, CD45+VE-cadherin+cell fractions in the E11.5
AGM region. Values indicate percentages of cells for Runx1EGFP/EGFP animals.
Black: Runx1WT/WT embryos; Pink: Runx1EGFP/EGFP embryos. All plots display live cells only
(determined by 7-AAD uptake). EGFP: enhanced green fluorescent protein; WT: wild type







  164 
In the non-haematopoietic fractions, 0.43±0.1% of cells expressed EGFP in 
the CD45-VE-cadherin- fraction, and 0.82±0.05% of cells in the CD45-VE-cadherin+ 
(Figure 4.12B).   
 
4.6.4. EGFP expression in the E11.5 AGM region: pre-LTR-
HSCs type I (CD45+VE-cadherin+CD41lo) 
Here, the aim was to further characterise non-haematopoietic cell subsets 
expressing Runx1. CD45+ cells were excluded using an anti-CD45 PerCP antibody 
(Appendix 4.2C), and anti-VE-cadherin (endothelial) and anti-CD41 (pre-
haematopoietic) antibodies were used.  Such population is of interest to our 
laboratory as it has been shown that CD45-VE-cadherin+CD41lo can develop into 
LTR-HSCs (S. Rybstov, unpublished data). These cells were termed pre-LTR-HSCs 
type I because their phenotype is more primitive (ie: do not express CD45) than the 
pre-LTR-HSCs type II (CD45+VE-cadherin+), which already have a haematopoietic 
phenotype. Analysis below addressed whether pre-HSCs type-I cell population 
express Runx1.  
Because analysis involves CD45- cells only, dot plots were used. As 
previously, histograms were checked and there was no readily noticeable EGFP shift 
in cell populations.  The percentage of EGFP+ cells increased as the level of CD41 
expression increased: 1.0±0.4% in CD45-VE-cadherin-CD41- cells, 13.8±3.2% in 
CD45-VE-cadherin-CD41med cells and 38.9±16.9% in CD45-VE-cadherin-CD41hi 
cells (Figure 4.13B). A similar observation was made in the endothelial cell 
population (VE-cadherin+), with EGFP+ cells representing:  0.26±0.1% in CD45-VE-
cadherin+CD41- population, 13.27±4.1% in CD45-VE-cadherin+CD41med population, 
and 41.2±7.5% in CD45+VE-cadherin+CD41hi population (Figure 4.13B).  
 
4.6.5. EGFP expression in E11.5 AGM reaggregates 
Future experiments with the Runx1EGFP mice will involve sorting of CD45-
EGFP+ cells prior to ex vivo culture to assess whether such cells are enriched for pre-








































































































































Figure 4.13: EGFP expression in E11.5 AGM region in pre haematopoietic stem cells
type I (CD45-VEcadherin+CD41med fraction).
A: Representative VE-cadherin CD41 stains in the non-haematopoietic cells (CD45-) in the
E11.5 AGM region of Runx1EGFP/EGFP animals compared to Runx1WT/WT animals. Quadrants
on dot plots were based on appropriate isotype controls  (Appendix 4.2C)
B: Dot plots showing analysis EGFP expression in CD45-VE-cahderin-CD41-, CD45-VE-
cadherin-CD41med, CD45-VE-cadherin-CD41hi, CD45-VE-cadherin+CD41-, CD45-VE-
cadherin+CD41med, and CD45-VE-cadherin+CD41hi cell fractions in the E11.5 AGM region.
Values indicate percentages of positive cells for Runx1EGFP/EGFP animals.
Black: Runx1WT/WT embryos; Pink: Runx1EGFP/EGFP embryos. All plots display live cells only
(determined by 7-AAD uptake). EGFP: enhanced green fluorescent protein; WT: wild type.
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Runx1EGFP/EGFP E11.5 AGM region performs similarly as Runx1WT/WT embryos and 
also to characterise EGFP+ populations in reaggregates. Wilcoxon signed-rank test 
showed no significant difference cells percentages between Runx1WT/WT and 
Runx1EGFP/EGFP reaggregates  (p≥0.1 in all gates). Similarly to the fresh E11.5 AGM 
region however, the percentage of CD45SP cells was consistently higher in 
Runx1EGFP/EGFP reaggregates (Figure 4.14A). 
When conservative gating was applied, 98.2±1.3% of CD45SP cells were 
EGFP+ (Figure 4.14B). The MFI shift of the Runx1EGFP/EGFP reaggregates compared 
to Runx1WT/WT reaggregates was 10.15±5.8 in the CD45SP population (Figure 4.14B). 
Only 3.01±0.5% of the CD45+VE-cadherin+ population was EGFP+ (Figure 4.14B). 
The collection of more events would allow detection of a possible population shift in 
this population.  
In the non-haematopoietic populations, 0.34±0.07% of CD45-VE-cadherin+ 
cells were EGFP+ (Figure 4.14B). Interestingly, only 0.08±0.04% of CD45-VE-
cadherin- population was EGFP+, which represents a 5 fold decrease compared to the 
fresh tissue (0.43±0.1%, Figure 4.13B, Figure 4.14B). This observation raises the 
question of the fate of these EGFP+ stromal cells, and further experiments will 
determine whether these cells matured into LTR-HSCs during reaggregate culture.  
The strategy will consist of FACS sorting of CD45-EGFP+ cells, and 
reaggregating them with other AGM cell populations to assess their potential for 
developing into LTR-HSCs. Such chimeric reaggregate set-up, however, would be 
limited by the fact that EGFP is restricted to Runx1+ cells, and thus cannot be used as 
a genetic marker to lineage trace cells in culture. To overcome this technical 
limitation, a lineage-trace system taking advantage of the Ly-5.1 and Ly-5.2 system 
was set up. Briefly, as Runx1EGFP/EGFP animals have a Ly-5.2/5.2 genotype, 
Runx1EGFP cells could be reaggregated with Ly-5.2/5.1 or Ly-5.1/5.1 cells and thus 
still be discriminated by flow cytometry. The fact that only CD45+ cells could be 
identified using this system should not be a problem because all reaggregate LTR-
HSCs express CD45 (Taoudi et al., 2008).  The normal behaviour of Ly-5.2/5.1 and 
Ly-5.1/5.1 cells when cultured as reaggregates was tested and proved the validity of 





















































































































































































Figure 4.14: EGFP expression in haematopoietic and endothelial compartments of
Runx1EGFP/EGFP E11.5 AGM reaggregates.
A: Representative CD45 VE-cadherin stains in Runx1EGFP/EGFP and Runx1WT/WT E11.5 AGM
reaggregates of Runx1EGFP/EGFP animals. Quadrants on dot plots were based on appropriate
isotype controls  (Appendix 4.3C).
B: Analysis of EGFP in CD45-VE-cadherin-, CD45-VEcadherin+, CD45+VE-cadherin-,
CD45+VE-cadherin+ cell fractions. Values indicate percentages of cells in Runx1EGFP/EGFP
reaggregates.
Black: Runx1WT/WT reaggregates; Pink: Runx1EGFP/EGFP reaggregates. All plots display live
cells only (determined by 7-AAD uptake). EGFP: enhanced green fluorescent protein; WT:




















































































Figure 4.15: Summary of proportion of cell populations in Runx1WT/WT and
Runx1EGFP/EGFP E11.5 AGM region .
Black: Runx1WT/WT animals; Pink: Runx1EGFP/EGFP animals. Values indicate percentages of
cells (mean±standard deviation of 4 experiments). Cell viability was determined by 7-AAD
uptake.
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were obtained only recently so functional experiments using this lineage-trace 
system for EGFP+ cells are still pending. 
 
4.7. LTR-HSC numbers in the Runx1EGFP E11.5 AGM 
region 
After backcrossing, functional analysis of the Runx1EGFP mice could be 
started. Fresh E11.5 AGM transplantation was carried out to assess whether LTR-
HSC numbers were similar in Runx1EGFP and Runx1WT E11.5 embryos. This 
experiment was important to functionally prove that the Runx1EGFP allele was 
functional, as it was clearly shown that Runx1 dosage had an impact on LTR-HSC 
development (Cai et al., 2000; North et al., 2002).  
 
4.7.1. Functional analysis of LTR-HSCs in Runx1EGFP mice: 
LTR-HSCs numbers 
Upon transplantation of 2 Runx1WT/WT E11.5 AGM regions into each recipient 
mouse, 7 out of 10 recipients were reconstituted by donor cells, 6 of which had a 
PBC higher than 20% (Figure 4.16). When Runx1EGFP/WT AGM regions were 
transplanted, 3 out of 11 recipients were reconstituted and 2 of them had a PBC 
higher than 20% (Figure 4.16). Although the proportions of reconstituted animals 
were 70% and 27% with Runx1WT/WT and Runx1EGFP/WT donor cells respectively 
(Figure 4.16), there was no statistical difference between the two conditions (Fisher’s 
exact test, p=0.08). Limiting dilution experiments will be required to accurately 
determine the numbers of LTR-HSCs in Runx1EGFP/WT embryos. Also, mutlilineage 
characterisation will be required to demonstrate their normal function.  
Additionally, as preliminary experiments indicated that Runx1EGFP/WT E11.5 
AGM contains fewer LTR-HSCs than Runx1WT/WT embryos based on the proportions 
of reconstituted animals, transplantations using Runx1EGFP/EGFP embryos will be 
performed to investigate any effect of Runx1EGFP allele dosage on LTR-HSC 

















Figure 4.16: Functional assessment of LTR-HSCs content in Runx1WT/WT and
Runx1EGFP/WT E11.5 AGM region.
Peripheral blood chimerism of recipients each transplanted with 2 embryos equivalent of
E11.5 AGM cells.
Each point represents a single recipient mouse. Recipients were considered reconstituted
when their peripheral blood chimerism exceeded 5% at least 12 weeks after transplantation.
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4.8. Discussion 
Flow cytometry and functional assays presented here describe the pattern of 
Runx1 expression in Runx1EGFP adult and E11.5 embryos. Although allowing 
detection of small EGFP expression by flow cytometry, our reporter, as others, has 
technical limitations. Firstly, insertion of the reporter gene after Runx1 exon 6 results 
in EGFP expression only when Runx1b and Runx1c isoforms are expressed. 
Secondly, although EGFP is much brighter than GFP, it also has a longer half-life 
than GFP (over 24 hours compared to 9 hours for GFP)(Choi et al., 2005; Li et al., 
1998; Verkhusha et al., 2003). Since the half-life of the Runx1 protein is 3.3 hours 
(Huang et al., 2001), EGFP is detectable in cells that no longer express Runx1.  
Thus, future experiments require the evaluation of the fidelity of the EGFP reporter 
to Runx1 by checking the overlapping expression of EGFP and Runx1 with more 
sensitive techniques such as quantitative PCR. Despite these points, EGFP 
expression reported here coincides with Runx1 expression patterns reported in other 
models so the Runx1EGFP/EGFP mouse should provide an accurate Runx1 reporter, 
correlating closely to the WT situation (Ichikawa et al., 2004; Lorsbach et al., 2004; 
North et al., 1999; North et al., 2002; North et al., 2004). Statistical analysis 
presented here must also be interpreted carefully as few independent experiments 
limit the power of any statistical test. Additional replicates should be performed in 
order to obtain more robust statistical analysis and detect potential subtle differences.  
 
4.8.1. EGFP expression in the Runx1EGFP adult mouse 
Both descriptive (cellularity, flow cytometry) and functional (CFU-Cs) 
analyses in Runx1WT/WT and Runx1EGFP/WT mice showed no detectable phenotype in 
adult animals. However, in vivo transplantations performed at limiting dilution would 
be required to conclude about any adult LTR-HSC phenotype.  
EGFP was highly expressed in LSK cells, which are enriched for LTR-HSCs 
(Osawa et al., 1996; Wagers et al., 2002). In addition, EGFP was expressed in the lin-
Sca1-c-kit-cell fraction, which contains common lymphoid progenitors (lin-sca1loc-
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kitloThy-1-IL7R- immunophenotype)(Kondo et al., 1997) and in the lin-Sca1+c-kit-, 
which contains common myeloid progenitors (Akashi et al., 2000).  
Very small EGFP shifts were observed in mature lymphoid and myeloid 
lineages. As a result, conservative gating was not appropriate for analysis and 
measures of MFI were reported as an indication of small population shifts. The MFI 
values were consistent between experiments and compensation plots of FL-2 single 
stains were provided in Appendix 4.1 in order to rule out any false positive signals. 
The patterns of EGFP expression in the adult haematopoietic system were consistent 
with observations in other mice reporter models (Lorsbach et al., 2004; North et al., 
2004).  
In myeloid lineages, EGFP expression was decreased upon granulocyte 
differentiation as the MFI decreased with increasing levels of Gr1, suggesting a 
down-regulation of Runx1 upon myeloid differentiation (Lorsbach et al., 2004). This 
contrasts with the Runx1 LacZ reporter in which a high proportion of bone marrow 
and peripheral blood Mac1+ and Gr1+ cells express LacZ; but the relevance of such 
observation in our context is limited because myeloid cells numbers are significantly 
increased in Runx1lz mice (North et al., 2004). Also, EGFP was expressed in 
erythroid progenitors but rapidly downregulated upon erythroid differentiation, 
which processes through the following phenotypes: CD45hiTer119-, CD45hiTer119+, 
CD45loTer119+, CD45-Ter119+ (Kina et al., 2000). Other groups observed the same 
Runx1 down-regulation upon erythrocyte maturation (Lorsbach et al., 2004; North et 
al., 2004). Additional Ter119 CD71 staining would be needed to precisely describe 
the patterns Runx1 expression during specific stages of erythrocyte maturation.  
In lymphoid lineages, populations of mature T cells (CD4+CD8-, CD4-CD8+ 
and CD3+B220-) displayed a stronger EGFP expression in the thymus, the site of T 
cells maturation, also consistent with previous observations (Lorsbach et al., 2004). 
In the thymus, EGFP expression was the highest in CD4-CD8- cells, which 
corresponds to the early thymocyte (CD4-CD8-) population. This observation was not 
surprising as previous reports using conditional inactivation of Runx1 in adult mice 
showed a reduction in thymus size and an accumulation of CD4-CD8- thymocytes, 
suggesting that Runx1 plays a role in early T-cell differentiation (Growney et al., 
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2005; Putz et al., 2006). Finally, also consistent with previous observations, EGFP 
was stronger in CD4+CD8- cells compared to CD4-CD8+ cells (Lorsbach et al., 
2004).   
EGFP was expressed at similar levels in immature B cells (CD19-B220+) and 
mature B cells (CD19+B220+). These data compare with Runx1lacZ/+ haploinsufficient 
mice where Runx1 expression is maintained during B-cell differentiation (North et 
al., 2004). Additional staining with anti-CD43 and anti-B220 antibodies would be 
required to assess accurately Runx1 expression during B cell differentiation. 
Interestingly, B cell development is severely impaired in conditionally inactivated 
Runx1 adult mice and LTR-HSC in vivo transplantations fail to reconstitute 
peripheral B and T cells (Ichikawa et al., 2004). The observation that Runx1EGFP/WT 
mice compared with Runx1WT/WT animals indicates that the Runx1EGFP allele is most 
probably functional in the lymphoid compartments.  
 
4.8.2. EGFP expression in the Runx1EGFP E11.5 embryo 
The second part of this study focused on the E11.5 AGM region because a 
focus of the lab is to investigate the role of Runx1 in the emerging LTR-HSCs in the 
E11.5 AGM region. Runx1EGFP/EGFP embryos were used for most analyses because 
adult analyses had shown that EGFP shifts were very small in the Runx1EGFP/WT 
animals.  
It was shown that most CD45+ cells in the E11.5 AGM region express EGFP, 
consistent with other reporter models (North et al., 1999; North et al., 2002). The 
relative EGFP MFI of cell populations that are enriched for LTR-HSCs (CD45+ c-
kit+ CD34+ VE-cadherin+)(North et al., 2002; Sanchez et al., 1996; Taoudi et al., 
2005) were higher than in other haematopoietic cell populations. Interestingly, a 
small sub-population of CD45- cells expressed EGFP. Further characterisation of this 
cell population showed that most of these cells did not have an endothelial phenotype 
based on VE-cadherin expression. Also, some of them express the pre-
haematopoietic marker CD41 at high levels.  This is of interest because CD41 is 
expressed at the onset of definitive haematopoiesis (Ferkowicz et al., 2003; Mikkola 
et al., 2003a; North et al., 2002; Sanchez et al., 1996; Taoudi et al., 2005) and a 
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recent report has demonstrated that CD41 is expressed prior to CD45 on 
haematogenic endothelial cells (Eilken et al., 2009). Additionally, this cell 
population (CD45-VE-cadherin-EGFP+) decreased by 6 fold during reaggregate 
culture. Cell sorting of such EGFP+ cells and their reaggregation with 
complementary AGM cell fractions will assess the potential of these cells to develop 
into LTR-HSCs.   Because the EGFP marker is only restricted to cells expressing 
Runx1, a lineage trace system that consists in setting up Ly-5.2/5.2 and Ly-5.2/5.1 
chimeric reaggregates has been established and should provide a useful system to 
answer whether CD45-VE-cadherin-Runx1+ are pre-LTR-HSC or are an important 
element of the LTR-HSC niche in the AGM microenvironment.  
 
 
4.8.3. LTR-HSCs numbers in the Runx1EGFP E11.5 AGM 
region 
Transplantations of fresh E11.5 AGM region were performed to confirm the 
absence of LTR-HSC phenotype in Runx1EGFP embryos. Surprisingly, the 
Runx1EGFP/WT AGM region appeared to contain fewer LTR-HSCs compared with WT 
animals. If this result is confirmed by limiting dilution experiments, it could have 
two major implications: Runx1EGFP embryos are developmentally retarded and LTR-
HSCs appear slightly later; or Runx1EGFP allele is hypomorphic and there are fewer 
LTR-HSCs with potential functional defects. Future experiments will need to 
investigate if there is any dose-dependent effect of the Runx1EGFP allele by 
transplanting Runx1EGFP/EGFP embryos and will help discriminating between these 
hypotheses. This is important because an abnormal LTR-HSC phenotype during 
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5. The spatial localisation of pre-
HSC in the E11.5 AGM region 
5.1. Introduction 
 The third part of this study focused on localising pre-HSCs in the AGM 
region and identifying potential interactions between sub-compartments of the AGM 
region. I focused on: 1) the axio-lateral polarity of LTR-HSC development and 2) the 
dorso-ventral polarity of LTR-HSC development and the hypothesis that cells in the 
AoD might be competent to become LTR-HSCs when exposed to the appropriate 
microenvironment. 
The E11.5 AGM region harbours and can autonomously expand the first 
LTR-HSCs of the embryo (Medvinsky and Dzierzak, 1996; Muller et al., 1994). 
However, the question of the origin of LTR-HSCs within the AGM region and 
identification of key niche components remains of importance.  
Previous studies have addressed the axio-lateral repartition of haematopoietic 
progenitors (CFU-S8 and CFU-S11) and LTR-HSCs in the E11.5 AGM region (de 
Bruijn et al., 2000a; de Bruijn et al., 2000b; Medvinsky et al., 1996; Taoudi and 
Medvinsky, 2007). Although their numbers are slightly higher in the dorsal aorta 
(Ao), both Ao and the urogenital ridges (UGRs) contain CFU-S8 and CFU-S11 at 
E10.5 (de Bruijn et al., 2000a; Medvinsky et al., 1996). Absolute numbers of CFU-S 
increased at E11.5 and E12.5 in both regions (de Bruijn et al., 2000a; Medvinsky et 
al., 1996). In contrast, LTR-HSCs were exclusively located in the Ao (including 
surrounding mesenchyme) at E11.5 (de Bruijn et al., 2000b; Taoudi and Medvinsky, 
2007). At E12.5 however, LTR-HSCs are still preferentially located in the Ao but 
can be functionally detected in the UGRs, and more precisely in the mesonephroi (de 
Bruijn et al., 2000b). Small numbers of LTR-HSCs can be obtained from E11.5 
UGRs when they are cultured as explants showing either their capacity to 
autonomously initiate LTR-HSC induction/expansion or that they were populated by 
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pre-HSCs from the Ao prior to E11.5 (de Bruijn et al., 2000b). Co-culture of Ao and 
UGRs as explants failed to show any stimulatory or inhibitory action from either 
tissue on each other (de Bruijn et al., 2000b).  
Since reaggregation, in contrast to explant culture, ensures close intercellular 
contacts, this part of my study addressed whether culturing the E11.5 AGM as 
reaggregates would reveal potential enhancing/inhibiting interactions between Ao 
and UGR in LTR-HSC development.  In addition, the presence of IL-3, SCF, and 
Flt3l and longer culture period could possibly influence the outcome of such 
experiments. 
This part of my study also was to understand cellular mechanisms underlying 
dorso-ventral polarization in LTR-HSC development. The ventral domain of the 
E10.5-11.5 Ao (AoV) contains the majority of LTR-HSCs in the fresh tissue and is 
capable of autonomous LTR-HSCs generation (Taoudi and Medvinsky, 2007). I 
tested, using the reaggregate culture system, whether the dorsal domain of the Ao 
(AoD) contains cells capable of developing into LTR-HSCs under the influence of 
the competent AoV microenvironment.  
 
5.2. Axio-lateral polarity of LTR-HSC expansion 
within E11.5 AGM region 
 E11.5 embryos were selected as described in Section 2.4.1, and the AGM 
regions were sub-dissected into UGR and Ao (Figure 5.1). Importantly, UGRs were 
dissected along the ridges so that the para-aortic mesenchyme was left with the Ao. 








AGM dissection AGM sub- dissection
Figure 5.1: Scheme of E11.5 AGM region lateral sub-dissection into dorsal aorta and
urogenital reidges.
Sub-dissection of the E11.5 AGM region into the dorsal aorta and its surrounding
mesenchyme (Ao), and the two urogenital ridges (UGR)(scale bar: 1mm).
Table 5.1: Lateral repartition of cells in the E11.5 AGM region (Ao and UGR).
Data was acquired by flow cytometric analysis; viability determined by 7-AAD uptake.
Absolute numbers ± standard deviation; mean of 4 independent experiments.
DP: CD45+VE-cadherin+; DN: CE45-VE-cadherin-
AGM Ao UGR
total cells 232500 ± 24660  77460 ± 19170 134300 ± 36210
total live cells 113400 ± 28610  47660 ± 10140 59440 ± 11500
total CD45+ cells 3360 ± 780 1270 ± 400 1800 ± 260
total VE cadherin+ cells 1410 ± 440 470 ± 160 970 ± 340
total DP cells 63 ± 38 20 ± 22 15 ± 9
total DN cells 108600 ± 27570 45900 ± 9690  56650 ± 11150
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5.2.1. Axio-lateral characterisation of the fresh E11.5 AGM 
region 
5.2.1.1. Cellular composition of the Ao and UGR 
 The lateral repartition of haematopoietic (CD45+) cells and LTR-HSCs 
(CD45+VE-cadherin+) between Ao and UGR were analysed by flow cytometry. The 
Ao contained 77460±19170 cells, of which 47660±10140 were viable (Table 5.1). 
The UGR contained 134300±36210 cells, of which 59440±11500 were viable (Table 
5.1). There was no polarised repartition of haematopoietic cells between Ao and 
UGR, which contained 1270±400 and 1800±260 CD45SP cells respectively (paired 
T-test, p≥0.2)(Table 5.1). There was also no polarised repartition of the CD45+VE-
cadherin+ cells between Ao and UGR, which contained 20±22 and 15±9 CD45+VE-
cadherin+ cells respectively (paired T-test, p≥0.2)(Table 5.1). Finally, the Ao and 
UGR respectively contained 470±160 and 970±340 CD45-VE-cadherin+ cells and 
45910±9690 and 56650±11150 CD45-VE-cadherin- cells (Table 5.1). 
Of note, the sum of Ao and UGR cells reached the range of the numbers 
found in the whole AGM (Table 5.1) indicating that there was no preferential cell 
death in either the Ao and UGR during flow cytometry processing. 
 
5.2.1.2. Axio-lateral repartition of haematopoietic progenitors in the 
E11.5 AGM region 
 There was no significant difference in haematopoietic progenitors (CFU-Cs) 
between fresh E11.5 Ao and UGR (paired T-test, p=0.09)(Figure 5.2). Ao contained 
84±11 CFU-Cs (17±9 CFU-mast, 10±7 BFU-E, 8±6 CFU-GM, 46±15 CFU-mac, and 
3±1 CFU-GEMM) and the UGR contained 47±24 CFU-Cs (10±7 CFU-mast, 6±6 
BFU-E, 4±4 CFU-GM, 17±27 CFU-mac, and 0 CFU-GEMM)(Figure 5.2). Although 
there were considerable variations within types and numbers of CFU-Cs in the UGR, 
there were consistently more CFU-Cs in the Ao compared to UGR. Interestingly, no 











Figure 5.2: Lateral repartition of haematopoietic progenitors in the E11.5 AGM (Ao
and UGR).
Bars indicate the standard deviation of 4 independent experiments.
BFU-E: burst forming unit-erythroid; CFU: colony forming unit; Mac: macrophage; GM:
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Cumulative numbers of CFU-Cs in Ao and UGRs roughly corresponded to 
the range of CFU-C numbers in the whole AGM (140±30 CFU-Cs: 37±22 CFU-
mast, 15±3 BFU-E, 15±13 CFU-GM, 66±13 CFU-mac, and 7±2 CFU-
GEMM)(Figure 5.2) suggesting that sub-dissection of the AGM does not influence 
development of haematopoietic colonies in culture.  
 
5.2.2. Autonomous haematopoietic potential of E11.5 Ao 
and UGRs in reaggregate cultures  
 As described in Chapter 3, the reaggregate culture system enables efficient 
expansion of LTR-HSCs from 1 to around 150 within 4 days (Kumaravelu et al., 
2002; Taoudi et al., 2008). Ao and UGR reaggregates were set up in IMDM+ to 
examine their autonomous haematopoietic potential. 
 
5.2.2.1. Expansion of haematopoeitc (CD45+) cells in E11.5 Ao and 
UGR reaggregates 
 Ao and UGR reaggregates were similar by size but UGR reaggregates lacked 
peripheral cell protrusions characteristic of AGM reaggregates (Figure 5.3A). There 
was no statistical difference between cell numbers in Ao and UGR reaggregates 
which respectively contained 98840±31170 and 143170±49860 cells (paired T-test, 
p=0.1)(Figure 5.3B). Ao and UGR reaggregates contained 16070±7130 and 
7880±3860 CD45+ cells respectively (Figure 5.3B). Although CD45+ cells were not 
statistically different in Ao and UGR cultures (paired T-test, p≥0.2), Ao reaggregates 
contained more CD45+ cells than UGR reaggregates in 3 out of 4 experiments. 
Cumulatively, haematopoietic cell numbers in Ao and UGR reaggregates in each 
experiment were similar to those in entire AGM reaggregates (Figure 5.3B), 
























Figure 5.3: Haematopoietic potential of Ao and UGR reaggregates.
A: Representative images of AGM, Ao and UGR reaggregates. Ao and UGR reaggregates
had similar morphology and were smaller than their AGM controls counterparts.
B: Haematopoietic cell numbers (CD45+) in AGM, Ao, and UGR reaggregates. Bars
indicate standard deviation of 6 experiments in AGM and Ao reaggregates, and 4
experiments in UGR reaggregates.
Data was acquired by flow cytometric analysis; cell viability was determined by 7-AAD
uptake.
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5.2.2.2. Expansion of haematopoietic progenitors in E11.5 Ao and UGR 
reaggregates   
The expansion of haematopoietic progenitors in Ao and UGR reaggregates 
was assessed by the CFU-C assay. The Ao reaggregates contained 1780±1350 CFU-
Cs (780±568 CFU-mast, 163±213 BFU-E, 25±29 CFU-GM, 725±527 CFU-mac, and 
88±118 CFU-GEMM) while the UGR reaggregates contained 540±540 CFU-Cs 
(300±280 CFU-mast, 25±50 BFU-E, 15±25 CFU-GM, 191±200 CFU-mac, and 0 
CFU-GEMM)(Figure 5.4). Even though Ao reaggregates consistently contained 
more CFU-Cs than UGR reaggregates (n=4), the difference was not significant 
(paired T-test; p=0.216). Interestingly, similar to the fresh tissue, UGR reaggregates 
did not contain CFU-GEMM.  
AGM reaggregates controls for each of these experiments contained 
4190±1280 CFU-Cs (1725±674 CFU-mast, 450±311 BFU-E, 275±263 CFU-GM, 
1500±734 CFU-mac, and 240±165 CFU-GEMM)(Figure 5.4). In each of the four 
experimental replicates, CFU-C number in AGM reaggregates was significantly 
higher than the cumulative numbers obtained from Ao and UGR reaggregates; 
suggesting a stimulatory interaction between Ao and UGR. 
 
5.2.2.3. Expansion of LTR-HSC in E11.5 Ao and UGR reaggregates  
  In vivo transplantations experiments were set up to answer the following 
questions: 1) do Ao and UGR have the autonomous potential to expand LTR-HSCs 
when cultured as reaggregates in IMDM+?  2) If so, is number of LTR-HSCs 
generated in Ao and UGR reaggregates cumulatively similar to those generated in 
AGM reaggregates? 
Transplantation of AGM reaggregates (0.01rd/recipient) resulted in 
repopulation of 23 out of 27 recipients (85%)(mean PBC: 58.4±27 %)(Figure 5.5A). 
The same dose of Ao reaggregates resulted in repopulation of only 10 out 22 
recipient mice (45%)(mean PBC: 32.3±17 %)(Figure 5.5A). A higher dose of Ao 















Figure 5.4: Haematopoietic progenitor expansion in Ao and UGR reaggregates.
Bars indicate the standard deviation of 4 independent experiments.
BFU-E: burst forming unit-erythroid; CFU: colony forming unit; Mac: macrophage; GM:









































Figure 5.5: Autonomous LTR-HSCs expansion potential of the Ao and UGR as
reaggregates.
A: Peripheral blood chimerism of recipients transplanted with Ao reaggregates. Data is
cumulative of 6 independent experiments.
B: Peripheral blood chimerism of recipients transplanted with UGR reaggregates. Data is
cumulative of 4 independent experiments. Each point represents a single recipient mouse.
Recipients were considered reconstituted when their peripheral blood chimerism exceeded
5% at least 12 weeks after transplantation. (rd: dose of reaggregate injected per recipient
mouse)
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(45%)(mean PBC: 75.9±10 %)(Figure 5.5A). The mean PBC in this case was higher 
than with a lower dose, suggesting a higher number of LTR-HSCs. Statistical 
analysis showed that there was a significant difference in reconstitution levels 
between AGM reaggregates and Ao reaggregates (Fisher’s exact test, p=0.01).  
 Similar experiments were set up with UGR reaggregates. Control AGM 
reaggregates (0.01rd/recipient) gave repopulation of 15 out of 19 recipients 
(79%)(mean PBC: 69.9±17.2 %)(Figure 5.5B). The same dose of UGR reaggregates 
gave no repopulation (0 out of 17 recipients) except one recipient with low-level 
reconstitution (3.58%)(Figure 5.5B). A higher dose (0.05rd/recipient) was 
transplanted to potentially detect low numbers of LTR-HSCs. No recipient mice 
were reconstituted (Figure 5.5B), suggesting that the UGR cannot autonomously 
generate detectable LTR-HSCs even in the presence of growth factors. 
 Taken together, these data indicate that only the Ao can autonomously 
generate detectable numbers of LTR-HSCs. However, the data show that AGM 
reaggregates can generate more LTR-HSCs (approximately 85) than the Ao on its 
own (approximately 45). In addition, the mean PBC of recipients transplanted with 
AGM reaggregates was higher than those of recipients transplanted with Ao 
reaggregates. This further indicates that AGM reaggregates produce more LTR-
HSCs than Ao reaggregates. Thus, although UGR reaggregates cannot independently 
facilitate LTR-HSC formation, UGRs could enhance optimal LTR-HSC formation in 
the Ao. Alternatively, Ao could induce formation of LTR-HSCs from the UGRs. 
 
5.2.2.4. Multilineage reconstitution by LTR-HSCs derived from Ao 
reaggregates 
 Multilineage analysis of mice transplanted with Ao reaggregates cells was 
performed by flow cytometry. The presence of donor cells in primary recipients was 
checked 16 weeks post-transplantation in haematopoietic tissues (peripheral blood, 
spleen, bone marrow, and thymus). All tissues contained CD45.2 donor cells in high 
proportions (ranging from 40 to 73% in peripheral blood, 7 to 70% in bone marrow, 
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Figure 5.6: Multilineage haematopoietic reconstitution by LTR-HSCs generated in Ao
reaggregates.
A: Long-term donor derived reconstitution in major haematopoietic organs (peripheral
blood, spleen, bone marrow, and thymus).
B: Long-term multilineage (myelo-lymphoid) contribution in major haematopoietic organs
(peripheral blood, spleen, bone marrow, and thymus) of recipients. Events were gated on
donor cells exclusively.
Representative example of analysis performed on 2 recipients transplanted with 0.05rd
showing high-level reconstitution.
Quadrants are based on appropriate isotype control (Appendix 3.2) and values indicate
percentages of cells. Cell viability was determined by 7-AAD uptake.
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blood, spleen and bone marrow contained myeloid cells (Mac1+ and Gr1+) and 
lymphoid cells (CD3+ T cells, and B220+ and CD43+ B cells)(Figure 5.6B). The 
majority of donor cells in the thymus were immature CD4+CD8+ T cells and mature 
single-positive T cells (CD4+CD8- and CD4-CD8+)(Figure 5.6B). Thus, HSCs 
generated by Ao reaggregates are true multilineage LTR-HSCs.  
 
5.2.3. Spatial origin of LTR-HSCs in E11.5 AGM 
reaggregates: axio-lateral polarity 
The fact that AGM reaggregates produce more LTR-HSCs than Ao 
reaggregates has two possible explanations: UGRs could generate high level 
reconstituting LTR-HSCs when induced by Ao cells; or that UGRs could enhance 
LTR-HSCs production from the Ao. Chimeric reaggregates combining WT and GFP 
cells were set up to distinguish between these two possibilities. The experimental 
strategy was to produce AoGFP with UGRWT chimeric reaggregates to trace Ao and 
UGR cells during culture (Figure 5.7A). To exclude a potential influence of 
constitutive GFP expression, reciprocal experiments in which chimeric AoWT and 
UGRGFP reaggregates were produced (Figure 5.7A). In addition, basic 
characterisation of E11.5 AGMGFP was performed to confirm constitutive GFP 
expression in the tissue (Appendix 5.1; Gilchrist et al., 2003). No significant 
difference in cell numbers between GFP and WT E11.5 AGM regions were observed 
(Appendix 5.1A). Interestingly, 1.44±0.4 % of viable cells were GFP- (Appendix 
5.1A). GFP reaggregates were also set up. Although 1.34% of cells in GFP 
reaggregates were GFP-, all CD45+ cells were GFP+ (Appendix 5.1B). Analysis of a 
reconstituted recipient showed that more than 98% of leucocytes in the peripheral 
blood were GFP+. This analysis confirmed the validity of using GFP mice in cell fate 













Figure 5.7: Experimental design to trace the origin of LTR-HSCs in the E11.5 AGM
region.
A: Generation of chimeric reaggregates to trace pre-HSCs in the E11.5 AGM region:
organs are laterally sub-dissected in both WT and GFP embryos and chimeric reaggregates
are produced with Ao and UGR from the 2 genotypes. After 4 days in culture, LTR-HSCs
are assessed by competitive repopulation assay.
B: Representative images of AGM chimeric reaggregates showing no morphological
difference between reciprocal set-ups.
 
  189 
5.2.3.1. Expansion of haematopoietic (CD45+) cells in chimeric 
(Ao/UGR) E11.5 AGM reaggregates 
There were no obvious morphological or size differences between 
AoWT|UGRGFP and AoGFP|UGRWT reaggregates (Figure 5.7B). Fluorescent images of 
these reaggregates showed preferable concentration of Ao cells in the centre of the 
reaggregates (Figure 5.7B). More accurate analysis by confocal microscopy is 
required to investigate the spatial segregation of Ao and UGR derived cells.  
There was no statistical difference in cell numbers between reciprocal 
reaggregate set-ups (AoWT|UGRGFP: 199500±51030 cells and AoGFP|UGRWT: 
194330±19120 cells)(Wilcoxon signed rank test, p≥0.2). Respective contribution of 
Ao and UGR to the viable cell population was assessed by flow cytometry. Wilcoxon 
signed rank test showed no significant differences between reciprocate set ups (p≥0.2 
for both Ao and UGR): in AoWT|UGRGFP and AoGFP|UGRWT set ups, UGR generated 
78200±15480 and 82670±14810 cells respectively; and Ao generated 58850±17980 
and 53570±12200 cells respectively (Figure 5.8A).  
Wilcoxon signed rank test showed no significant difference between the 
numbers of haematopoietic  (CD45+) cells in reciprocate set-ups (p≥0.2): 
AoWT|UGRGFP and AoGFP|UGRWT reaggregates contained 21700±5300 and 
20000±5510 CD45+ cells respectively (Figure 5.8B). In AoWT|UGRGFP and 
AoGFP|UGRWT reaggregates, Ao generated 15370±3390 cells and 13800±4290 
CD45+ cells respectively (Figure 5.8B). In AoWT|UGRGFP and AoGFP|UGRWT 
reaggregates, UGRs generated 6340±2540 and 6170±1260 CD45+ cells respectively 
(Figure 5.8B). Respective contributions of Ao and UGRs to CD45+ cells were not 
significantly different between reciprocate set-ups (Wilcoxon signed rank test, p= 
0.58 for UGR, and p=0.85 for Ao). 
Taken together, these data indicate that similar cell contributions from Ao 
and UGR are obtained in AoWT|UGRGFP and AoGFP|UGRWT reaggregates. In both 
cases, the majority (around 70%) of CD45+ cells in reaggregates are Ao-derived and 






































Figure 5.8: Respective contribution of Ao and UGR to the haematopoietic cell
compartment of E11.5 AGM chimeric reaggregates.
A: Live cells numbers and respective contribution of Ao and UGR.
B: Haematopoietic cell (CD45+) numbers and respective contribution of Ao and UGR.
Bars indicate the standard deviation of 4 independent experiments.
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When compared with the fresh tissue, Ao and UGR cells respectively 
underwent between 1.2 and 1.3 fold expansion during reaggregate culture. However, 
CD45+ cells from Ao underwent 12-fold expansion while CD45+ cells from UGR 
underwent 3-fold expansion. Thus, the haematopoietic potential of the Ao, judged by 
the number of CD45+ cells produced, is significantly greater than the UGR. 
 
5.2.3.2. CFU-C expansion potential of chimeric (Ao/UGR) E11.5 AGM 
reaggregates 
 There was no difference in CFU-Cs numbers between AoWT|UGRGFP and 
AoGFP|UGRWT set-ups (Wilcoxon signed rank test, p=0.85)(Figure 5.9). 
AoWT|UGRGFP and AoGFP|UGRWT reaggregates respectively contained 4190±1280 
CFU-Cs (1725±674 CFU-mast, 450±311 BFU-E, 275±263 CFU-GM, 1500±734 
CFU-mac, and 240±165 CFU-GEMM) and 3940±840 CFU-Cs (1775±685 CFU-
mast, 312±165 BFU-E, 265±209 CFU-GM, 1387±522 CFU-mac, and 200±168 
CFU-GEMM)(Figure 5.9).  
 Unfortunately, the respective contribution of the Ao and UGR to CFU-Cs 
could not be reliably assessed for several reasons. First, there was a high amount of 
autofluorescence background in methylcellulose colonies (based on WT colonies 
controls), making the evaluation unreliable. In addition, some mature haematopoietic 
cells express low levels of GFP (own observation and S. Gordon-Keylock, personal 
communication), which are hard to detect by microscopy. To overcome this problem, 
FACS could be attempted but the very low numbers of cells in some individual 
colonies (around 100 in some cases) was unsuitable for flow cytometry processing. 
As a result, several attempts to determine the origin of individual CFU-C colonies 



















Figure 5.9: Haematopoietic progenitors expansion in E11.5 AGM chimeric
reaggregates.
Bars indicate the standard deviation of 4 independent experiments.
BFU-E: burst forming unit-erythroid; CFU: colony forming unit; Mac: macrophage; GM:
granulocyte/macrophage; GEMM: granulocyte/erythroid/macrophage/megakaryocyte; ee:
embryo equivalent
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5.2.3.3. The axio-lateral polarity of LTR-HSC development  
 The respective contribution of Ao and UGR into the chimeric reaggregates 
LTR-HSCs compartment was assessed using GFP expression. Transplantation of 
0.01dose of chimeric AoWT|UGRGFP reaggregates resulted in reconstitution of 19 out 
of 27 recipients (70%)(mean PBC: 62±22 %)(Figure 5.10). Transplantation of 
0.01dose of AoGFP|UGRWT reaggregates resulted in reconstitution of 8 out of 15 
recipients (54%)(mean PBC: 53±37 %)(Figure 5.10). Although it appeared that 
AoWT|UGRGFP contained more LTR-HSCs than AoGFP|UGRWT based on the 
proportion of reconstituted recipients, this was not statistically significant (Fisher’s 
exact test, p=0.3).  
 Respective contribution of Ao and UGR to recipient’s peripheral blood was 
analysed based on GFP expression. The large majority of high level of blood 
chimerism was derived from Ao, both in AoWT|UGRGFP and AoGFP|UGRWT set-ups 
(Figure 5.10). In contrast, UGR only contributed to low level chimerism in 2 out of 
19 recipients (9% and 3.7%) tranplanted AoWT|UGRGFP reaggregates (Figure 5.10). 
However, most recipients reconstituted with AoGFP|UGRWT reaggregates cells had 
low (between 0.9 and 4.7%) but yet detectable contribution by UGR-derived cells 
(Figure 5.10). It is conceivable that some low WT donor contribution was due to 
down-regulating GFP in Ao-derived blood cells. Quantitative PCR would be required 
to properly establish this. However, given that LTR-HSCs are considered to be high 
level repopulating cells, we can safely conclude that in AGM reaggregates, LTR-
HSCs originate from the Ao. Combined with the conclusion that higher numbers of 
LTR-HSCs are produced in AGM reaggregates compared to Ao reaggregates, these 
data demonstrate that LTR-HSCs production from the Ao is significantly enhanced 
by the presence of UGRs in the reaggregates.  
 
5.2.4. Supportive effect of the UGR on LTR-HSC expansion 
The better LTR-HSC production in AGM reaggregates could either be due to 
the presence of the UGRs providing a positive effect on Ao or to the size of the 


















Figure 5.10: Lateral polarity of LTR-HSC expansion in E11.5 AGM chimeric
reaggregates.
Peripheral blood chimerism of recipients transplanted with 0.01 dose of E11.5 AGM
chimeric reaggregates.
Data is cumulative of 6 independent experiments for AoWT|UGRGFP, and 4 independent
experiments for AoGFP|UGRWT.
Only reconstituted mice are displayed; percentages correspond to the proportion of
reconstituted recipients. Each bar represents a single recipient mouse. Recipients were
considered reconstituted when their peripheral blood chimerism exceeded 5% at least 12
weeks after transplantation.
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reaggregates made with 2 Ao (Ao|Ao) were set up along with AGM controls and Ao 
reaggregates.  
Only LTR-HSC data were analysed for these experiments.  When 0.01 dose 
of AGM reaggregate was transplanted into single recipient mice, 8 out of 8 mice 
(100%) were reconstituted (mean PBC: 36.3%)(Figure 5.11). In similar conditions, 
only 3 out of 5 mice (60%) were reconstituted when transplanted with Ao 
reaggregate cells (mean PBC: 37.1%); and 3 out of 6 mice (50%) were reconstituted 
when transplanted with Ao|Ao reaggregates (mean PBC: 21%)(Figure 5.11). When 
transplanted with 0.05 doses of reaggregates, 3 out of 6 mice (50%) were 
reconstituted with Ao reaggregate cells (mean PBC of 79.6%) and 4 out of 6 mice 
(67%) were reconstituted with Ao|Ao reaggregates (mean PBC: 34.6%)(Figure 5.11). 
These data show that doubling of the numbers of Ao cells in reaggregates generates 
approximately the same LTR-HSCs numbers (≈60 in both Ao and Ao|Ao 
reaggregates in contrast to at least 100 in AGM reaggregates).  
Furthermore, because comparable numbers of LTR-HSCs were obtained from 
a single Ao and two Ao, suggests the performance of a single Ao is decreased when 
exposed to additional Ao cells. Altogether, these results confirm that co-culture with 
UGR cells specifically enhances LTR-HSCs formation from Ao. Additional 
experiments would be required in order to obtain more accurate numbers of LTR-
HSCs generated by the Ao.  
 
5.3. Dorso-ventral polarity of LTR-HSC 
development within E11.5 AGM region 
Our laboratory has demonstrated that LTR-HSCs in the E11.5 AGM region 
are almost exclusively located in the AoV and that only this site has the autonomous 
potential of expanding LTR-HSCs when cultured as explants (Taoudi and 
Medvinsky, 2007).  
Here, I focused on the haematopoietic potential of the AoD and aimed to 




















Figure 5.11: Supportive effect of the UGR on LTR-HSCs expansion from the Ao.
Reaggregation of large numbers of Ao cells (Ao|Ao, 2 embryo equivalent per reaggregate)
compared to E11.5 AGM region (Ao|UGR) reaggregates.
Data are cumulative of 2 independent experiments.
Each point represents a single recipient mouse. Recipients were considered reconstituted
when their peripheral blood chimerism exceeded 5% at least 12 weeks after transplantation.
(rd: dose of reaggregate injected per recipient mouse)
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Two major approaches were undertaken to address this issue: 1) does the pesence of 
the notochord and adjoining somites inhibit LTR-HSCs formation in the AoD? 2) 
Can LTR-HSCs be induced from AoD when exposed to AoV/UGR and the 
combination of IL-3, SCF, and Flt3l?  
 
5.3.1. Dorso-ventral dissections of the E11.5 AGM region 
 Previously, the dorsal tissue (DT)(containing notochord and partly somites) 
was left attached to the AoD in order to facilitate the dissections and to keep a 
landmark for the dorso-ventral orientation of the Ao. To test whether DT influences 
the AoD haematopoietic potential, DT was dissected from the AGM region prior to 
AoD-AoV sub-dissection. 
 Figure 5.12 shows dorso-ventral dissections and highlights that DT can be 
removed from the AGM prior to sub-dissection of the Ao (Figure 5.12A and B). 
Confocal microscopy confirmed that the endothelial lining of the AoD and AoV, 
marked by CD31 staining, was not disrupted during sub-dissections (Figure 5.12C). 




5.3.2. Dorso-ventral distribution of cell populations in the 
fresh E11.5 AGM region 
5.3.2.1. Dorso-ventral distribution of haematopoietic (CD45+) and 
endothelial (VE-cadherin+) cells 
 E11.5 AGM regions were sub-dissected and analysed by flow cytometry. DT 
was also isolated and analysed. Wilcoxon singed rank test showed no significant 
difference in cell numbers between AoD and AoV, containing 49330±11010 and 
66330±8000 total cells respectively, and 35570±8250 and 38750±3110 viable cells 













Figure 5.12: Scheme of E11.5 AGM region dorso-ventral subdissection into dorsal and
ventral aspects of the dorsal aorta
A: Dissection of the E11.5 AGM region and removal of the dorsal tissue (DT) containing
notochord and somite remnants. Bars: 1mm
B: Sub-dissection of the AGM region into urogenital ridges (UGR) and dorsal (AoD) and
ventral (AoV) domains of the dorsal aorta. Bars: 1mm
C: Confocal miscroscopy of AoD and AoD shows intact endothelial lining of the dorsal
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haematopoietic (CD45+) cells was observed: AoD and AoV contained 880±260 and 
1380±190 CD45+ cells respectively (Wilcoxon signed rank test, p=0.18)(Table 5.2). 
Although not significantly different, numbers of CD45+VE-cadherin+ cells (enriched 
for LTR-HSCs) were consistently higher in the AoV compared to AoD (AoD: 22±11 
CD45+VE-cadherin+ cells, AoV: 35±11 CD45+VE-cadherin+ cells; Table 5.2) 
(Wilcoxon signed rank test, p=0.18). Interestingly, DT contained 1600±190 of 
CD45+ cells, comparable to what is obtained in the AoD and AoV (Table 5.2). There 
were 8±2 CD45+VE-cadherin+ cells in DT (Table 5.2).  
Altogether, these data confirm published data that there is no significant 
dorso-ventral polarisation of haematopoietic cells in the E11.5 AGM region (Taoudi 
et al., 2008). Furthermore, the DT did not differ in this respect to the AoV and AoD. 
This raises the question of the haematopoietic potential of the DT and its potential to 
influence haematopoiesis from the AoD.  
 
5.3.2.2. Dorso-ventral distribution of EGFP+ cells in Runx1EGFP/WT 
embryos 
In Runx1 haploinsufficient mice, Runx1 expression is restricted to the AoV 
(North et al., 1999). This observation was based on histological sections and the 
dorso-ventral polarity of Runx1 expression in the E11.5 AGM region has yet to be 
quantified and characterised.  Runx1WT/WT and Runx1EGFP/WT E11.5 AGM regions 
were sub-dissected into AoV, AoD, and UGRs, and analysed by flow cytometry 
according to the strategy described in Chapter 4.  
In the UGRs, 96.9±1.7% of CD45SP cells were EGFP+ and 89.3±1.7 of 
CD45+VE-cadherin+ cells were EGFP+ (Figure 5.13B). The MFI shift of the 
Runx1EGFP/WT embryos compared to Runx1WT/WT embryos was 11.1±0.7 in the CD45SP 
population and 13.9±0.8 in the CD45+VE-cadherin+ population (Figure 5.13B). In 
the non-haematopoietic fractions, 0.60±0.1% of cells expressed EGFP in the CD45-
VE-cadherin- fraction, and 0.80±0.2% of cells in the CD45-VE-cadherin+ (Figure 
5.13B).  
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In the AoD, 93.5±2.3% of CD45SP cells were EGFP+ and 97.6±2.3% of 
CD45+VE-cadherin+ cells were EGFP+ (Figure 5.13B). The MFI shift of the 
Runx1EGFP/WT embryos compared to Runx1WT/WT embryos was 9.6±0.8 in the CD45SP 
population and 21.0±4.8 in the CD45+VE-cadherin+ population (Figure 5.13B). In 
the non-haematopoietic fractions, 0.19±0.06% of cells expressed EGFP in the CD45-
VE-cadherin- fraction, and 1.37±0.1% of cells in the CD45-VE-cadherin+ (Figure 
5.13B).  
In the AoV, 96.7±0.4% of CD45SP cells were EGFP+ and 98.0±1.5 of 
CD45+VE-cadherin+ cells were EGFP+ (Figure 5.13B). The MFI shift of the 
Runx1EGFP/WT embryos compared to Runx1WT/WT embryos was 11.3±1.1 in the CD45SP 
population and 23.2±1.8 in the CD45+VE-cadherin+ population (Figure 5.13B). In 
the non-haematopoietic fractions, 1.22±0.2% of cells expressed EGFP in the CD45-
VE-cadherin- fraction, and 0.71±0.2% of cells in the CD45-VE-cadherin+ (Figure 
5.13B).  
The MFI shift of the Runx1EGFP/WT embryos compared to Runx1WT/WT embryos 
was lower in the UGR than in aortic region (AoD and AoV). The presence of few 
CD45-EGFP+ cells in UGRs, AoD, and AoV indicates that such cells are not 
segregated to a particular location. Interestingly however, a larger proportion of these 
CD45-EGFP+ cells were located in the AoV, giving additional incentive to 
investigate the fate of such cells. These results also confirm that most CD45+ cells 
express EGFP/Runx1 (Sections 4.5.1, 4.5.3, 4.5.4, 4.5.5), independently of their 
location in the AGM region. Combining cell numbers with flow cytometric analysis 
indicates that Runx1 positive cells are equally distributed in the AoV and AoD. This 
contradicts previous report in which Runx1 expression was concentrated in the AoV 
in haploinsufficient Runx1lz/+ mice (de Bruijn et al., 2002; North et al., 1999). Such 
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Figure 5.13: EGFP expression in haematopoietic and endothelial compartments of
Runx1EGFP/WT E11.5 UGR, AoD, and AoV.
A: Representative CD45 VE-cadherin stains in E11.5 UGRs of Runx1EGFP/WT animals
compared to Runx1WT/WT animals and analysis of EGFP in CD45-VE-cadherin-, CD45-
VEcadherin+, CD45+VE-cadherin-, CD45+VE-cadherin+ cell fractions. Quadrants on dot
plots were based on appropriate isotype controls  (Appendix 4.3B).
B: Representative CD45 VE-cadherin stains in E11.5 AoD of Runx1EGFP/WT animals
compared to Runx1WT/WT animals and analysis of EGFP in CD45-VE-cadherin-, CD45-
VEcadherin+, CD45+VE-cadherin-, CD45+VE-cadherin+ cell fractions.
C: Representative CD45 VE-cadherin stains in E11.5 AoV of Runx1EGFP/WT animals
compared to Runx1WT/WT animals and analysis of EGFP in CD45-VE-cadherin-, CD45-
VEcadherin+, CD45+VE-cadherin-, CD45+VE-cadherin+ cell fractions.
EGFP: enhanced green fluorescent protein; WT: wild type; UGR: urogenital ridges; AoD:
dorsal domain of the dorsal aorta; AoV: ventral domain of the dorsal aorta.
Black: Runx1WT/WT animals; Blue: Runx1EGFP/Wtanimals. Quadrants on dot plots were based
on appropriate isotype controls  (Appendix 4.3B) and values indicate percentages of cells.
Cell viability was determined by 7-AAD uptake.
In histograms, values indicate percentages of cells for Runx1EGFP/WT animals.
All plots are representative examples of 3 independent experiments.
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5.3.3. Dorso-ventral distribution of haematopoietic 
progenitors (CFU-Cs) in the fresh E11.5 AGM region.  
 The fresh AoD contained 20±7.0 CFU-Cs (4±3.0 CFU-mast, 4±1.5 BFU-E, 
1±0.7 CFU-GM, 10±3.4 CFU-mac, and 1±0.5 CFU-GEMM) and AoV contained 
42±11.8 CFU-Cs (14±2.5 CFU-mast, 6±2.5 BFU-E, 4±2.6 CFU-GM, 17±5.0 CFU-
mac, and 2±1.5 CFU-GEMM), suggesting that there was a dorso-ventral gradient of 
CFU-Cs (Wilcoxon signed rank test, p=0.18)(Figure 5.14). Similarly to AoD, DT 
contained 22±11 CFU-Cs (7±4.5 CFU-mast, 2±0.3 BFU-E, 1±2.2 CFU-GM, 12±5.1 
CFU-mac, and 0 CFU-GEMM)(Figure 5.14). When DT and AoD were not separated 
(DAoD), there were a total of 50±17.2 CFU-Cs (17±4.8 CFU-mast, 7±4.5 BFU-E, 
4±2.5 CFU-GM, 21±9.7 CFU-mac, and 1±0.8 CFU-GEMM). This corresponded 
approximately to the sum of AoD and DT CFU-Cs, indicating that the presence of 
DT had no influence on haematopoietic colony formation during methylcellulose 
culture (Figure 5.14).  
 Similarly, the sum of fresh AGM (138±29.3 CFU-Cs in this case) and DT 
CFU-Cs roughly corresponded to DAGM CFU-C number (159±20 CFU-Cs: 51±7.4 
CFU-mast, 30±7.6 BFU-E, 21±17.7 CFU-GM, 51±4.6 CFU-mac, and 6±3 CFU-
GEMM), confirming that DT does not influence colony formation in methylcellulose 
cultures (Figure 5.14). 
 
5.3.4. The influence of dorsal tissue on AoD haematopoiesis 
5.3.4.1. Influence of dorsal tissue on AoD haematopoietic cells 
outcome during explant culture. 
To test whether DT influences AoD haematopoiesis during ex vivo culture, 
explants of AGM, DAGM, AoD and DAoD were set up in IMDM- (IMDM based 
medium with 20% serum but without IL-3, SCF, or Flt3l) and Myelocult medium 











AGMDAGM AoDDAoD AoV UGRdT
Figure 5.14: Dorso-ventral segregation of haematopoietic progenitors in fresh E11.5
AoV, AoD, and dorsal tissue.
Bars indicate the standard deviation of 3 independent experiments.
BFU-E: burst forming unit-erythroid; CFU: colony forming unit; Mac: macrophage; GM:
granulocyte/macrophage; GEMM: granulocyte/erythroid/macrophage/megakaryocyte; ee:
embryo equivalent.
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After 4 days in IMDM- medium, DAGM and AGM explants contained 
7990±2095 and 6610±1820 CD45+ cells respectively (Figure 5.15A). DAoD and 
AoD explants contained 1830±840 and 970±570 CD45+ cells respectively, which 
was not significantly different (Wilcoxon signed rank test, p=0.18)(Figure 5.15A). 
AoV explants contained 1700±555 CD45+ cells (Figure 5.15A). There was no 
significant difference in CD45+ cell numbers between AoD and AoV explants 
(Wilcoxon signed rank test, p=0.18). 
After 4 days in Myelocult medium, AGM explants contained 5770±1840 
CD45+ cells (Figure 5.15B). DAoD and AoD explants contained 900±300 and 
310±120 CD45+ cells respectively (Figure 5.15A’ and B’). AoV explants contained 
840±360 CD45+ cells (Figure 5.15B). Similarly to IMDM- medium explants, there 
were no significant differences in CD45+ cell numbers between AoD and DAoD 
explants and between AoD and AoV explants (Wilcoxon signed rank test, p=0.18 in 
both cases). 
When compared to the fresh tissue, there was no expansion of CD45+ cells 
during culture in IMDM- (x1.0 fold expansion for AoD, and x1.2 fold expansion for 
AoV). Interestingly, there were consistently more CD45+ cells in DAoD explants 
compared to AoD explants, indicating that DT does not have inhibitory influence of 
AoD haematopoietic cells. However, DT explants are required to understand its 
autonomous haematopoietic potential. 
 
5.3.4.2. The influence of dorsal tissue on AoD haematopoietic 
progenitors. 
The expansion of CFU-Cs in explant cultures was also assessed. When 
cultured in IMDM-, DAGM and AGM explants contained similar numbers of CFU-
Cs: 250±30 and 290±80 CFU-Cs respectively  (Wilcoxon signed rank test, 
p=0.79)(Figure 5.16A). There was also no statistical difference between DAoD and 
AoD explants which contained 39±14 and 50±33 CFU-Cs respectively (Wilcoxon 
signed rank test, p=0.78)(Figure 5.16A). AoV explants contained 64±39 CFU-Cs 






























Figure 5.15: Influence of dorsal tissue on autonomous haematopoietic cell expansion in
E11.5 AGM, AoV, and AoD explants.
A: Haematopoietic cell numbers in explants cultured in IMDM- for 4 days.
B: Haematopoietic cell numbers in explants cultured in Myelocult for 4 days.
Bars indicate the standard deviation of 3 independent experiments
Black: cultures in IMDM-; Grey: cultures in Myelocult



























Figure 5.16: Influence of dorsal tissue on autonomous haematopoietic progenitors
expansion in E11.5 AGM, AoV, and AoD explants.
A: CFU-C numbers contained in E11.5 DAGM, AGM, DAoD, AoD, and AoV explants
cultured in IMDM- for 4 days.
B: CFU-C numbers contained in E11.5 AGM, DAoD, AoD, and AoV explants cultured in
Myelocult medium for 4 days.
Bars indicate the standard deviation of 3 independent experiments.
BFU-E: burst forming unit-erythroid; CFU: colony forming unit; Mac: macrophage; GM:
granulocyte/macrophage; GEMM: granulocyte/erythroid/macrophage/megakaryocyte; ee:
embryo equivalent. N.D.: not done.
IMDM- Myelocult
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explants were consistently higher than those in DAoD and AoD explants (Wilcoxon 
signed rank test, p=0.18). 
However, when Myelocult medium was used, a clear dorso-ventral repartition 
of CFU-Cs was observed as DAoD and AoD explants both contained 2 CFU-Cs 
whereas AoV explants contained 31±10 CFU-Cs (Figure 5.16B). AGM explants 
contained 310±22 CFU-Cs (Figure 5.16B). These observations were in line with 
previous data (Taoudi and Medvinsky, 2007). 
AoD explants have a tendency to give lower numbers of CFU-Cs than AoV 
explants in both IMDM- and Myelocult media.  Such tendency was accentuated in 
Myelocult medium, which might be likely to have inhibitory effects on the 
production of CFU-Cs by AoD.  
 
5.3.4.3. Influence of dorsal tissue on LTR-HSC expansion using 
explant cultures 
LTR-HSC content in explants was assessed by competitive long-term in vivo 
repopulation assay. When E11.5 AGM explants cultured in IMDM- medium for 4 
days were transplanted (0.3 ee/recipient), 7 out of 13 recipients (54%) were 
reconstituted (mean PBC: 56.9%)(Figure 5.17A). However, DAGM in the same 
conditions showed significantly reduced LTR-HSC activity: only 1 out 9 recipient 
mice (11%) was reconstituted at high level (87.4%)(Fisher’s exact test, 
p=0.03)(Figure 5.17). Although control AGM explants showed slightly lower LTR-
HSC activity than expected (S. Taoudi, personal communication), there was a clear 
indication that the presence of DT inhibited LTR-HSC development in the AGM.  
When cultured in Myelocult medium, AGM explants (0.3 ee/recipient) 
reconstituted 8 out of 9 recipients to similar levels as previously reported in this 
tissue (Figure 5.17B)(Taoudi and Medvinsky, 2007).  
Unfortunately, none of the mice transplanted with AoV or AoD explants (0.3 
ee/recipient) were reconstituted. These experiments were performed when 






































Figure 5.17: Influence of dorsal tissue on LTR-HSCs expansion in E11.5 AGM, AoV,
and AoD explants.
Peripheral blood chimerism of recipients transplanted with 0.3 embryo equivalents of
explant cells.
A: LTR-HSCs expansion in explants cultured in IMDM- for 4 days.
B: LTR-HSCs expansion in explants cultured in Myelocult for 4 days.
Each point represents a single recipient mouse. Recipients were considered reconstituted
when their peripheral blood chimerism exceeded 5% at least 12 weeks after
transplantation. Percentage represents the proportion of reconstituted animals. Cumulative
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could explain this intriguing result. Alternatively, this could be due to the longer 
culture period. Thus, these experiments should be repeated and higher doses of cells 
should be transplanted to ensure LTR-HSC detection. 
 
5.3.4.4. Analysis of multilineage reconstitution of mice transplanted 
with IMDM- AGM explant cultures  
Multilineage analysis of LTR-HSCs was performed at least 16 weeks post-
transplantation (Figure 5.18). Peripheral blood, spleen, bone marrow, and thymus 
were analysed. All tissues contained CD45.2 donor cells in high proportions (ranging 
from 76 to 81% in peripheral blood, 44 to 72% in the bone marrow, 62 to 71% in the 
spleen, and 96 to 99% in the thymus)(Figure 5.18A). Peripheral blood, spleen and 
bone marrow contained both myeloid (Mac1+ and Gr1+) and lymphoid populations 
(CD3+ T cells, and B220+ and CD43+ B cells)(Figure 5.18B). The majority of donor 
cells in the thymus were immature double positive  (CD4+CD8+) T cells and mature 
single positive (CD4+CD8- and CD4-CD8+) T cells (Figure 5.18B). Thus, LTR-HSCs 
produced in IMDM- were functional. Multilineage reconstitution from E11.5 AGM 
explants cultured in Myelocult was previously published (Medvinsky and Dzierzak, 
1996). 
 
5.3.5. Dorso-ventral polarity in generation of LTR-HSCs in 
the E11.5 AGM region 
Although AoD contains very few LTR-HSCs, there is no evidence of the 
production of LTR-HSCs by AoD when cultured as explant in either IMDM- or 
Myelocult (Figure 5.17; (Taoudi and Medvinsky, 2007). However, it is conceivable 
that AoD contains cells competent to form LTR-HSCs under the influence of AoV 
and/or UGRs or growth factors.  
To test these hypotheses, E11.5 AGM regions from WT and GFP embryos 
(constitutively expressing GFP, Appendix 5.1, Gilchrist et al., 2003) were sub-
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Figure 5.18: Long-term multilineage haematopoietic reconstitution by LTR-HSCs
generated from E11.5 AGM explants cultured in IMDM-.
A: Donor derived reconstitution in major haematopoietic organs (peripheral blood, spleen,
bone marrow, and thymus) in recipients reconstituted with IMDM- explants cells.
B: Multilineage (myelo-lymphoid) contribution in major haematopoietic organs (peripheral
blood, spleen, bone marrow, and thymus) of recipients reconstituted with IMDM- explants
cells. Events were gated on donor cells exclusively.
Data were collected in high-level reconstituted recipients injected with 0.3 embryo
equivalent of explant cells. Plots are representative of 2 recipient mice. Cell viability was
determined by 7-AAD uptake. Quadrants are based on appropriate isotype control
(Appendix 3.2) and values indicate percentages of cells.
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and cultured in IMDM+ (Figure 5.19). DT was always left with AoD in reaggregates 
experiments.  
 
5.3.5.1. Haematopoietic development from AoD in chimeric 
reaggregates 
The contribution of AoD to chimeric reaggregates haematopoietic (CD45+) 
cells was assessed. Reaggregates were cultured in IMDM+ for 4 and 5 days to 
investigate the potential dynamics of LTR-HSC emergence from AoD. Two 
independent experiments were performed in each condition and presented 
individually as their outcomes varied.  
In 4 days chimeric AGM reaggregates, AoD-derived cells represented 26% 
and 21% of the viable cells in the 2 independent experiments (Figure 5.20A). Similar 
AoD contributions were obtained in 5 days chimeric reaggregates (26% and 
24%)(Figure 5.20A). In 4 days chimeric Ao reaggregates, AoD-derived cells 
represented 47% and 53% of the viable cells in the 2 independent experiments 
(Figure 5.20A). Similar AoD contributions were obtained in 5 days chimeric 
reaggregates (51% and 43%) (Figure 5.20A).  
AoD-derived haematopoietic (CD45+) cell numbers were also assessed. 5 
days AGM chimeric reaggregates contained more AoD-derived CD45+ cells 
compared to 4 days chimeric AGM reaggregates: 10670 and 7070 after 5 days 
(representing 44% and 40% of CD45+ cells) and 5810 and 4960 after 4 days 
(representing 34 % and 21% of CD45+ cells)(Figure 5.20B). In chimeric Ao 
reaggregates, numbers of AoD-derived CD45+ cells were similar after 4 and 5 days 
culture: 8890 and 16570 after 4 days (representing 44% and 58% of CD45+ cells) 
and 8800 and 8600 after 5 days (representing 43% and 44% of CD45+ cells)(Figure 
5.20B).  
Taken together, these data show that there is no obvious difference in CD45+ 
cell numbers between AGM and Ao chimeric reaggregates. In both AGM and Ao 
chimeric reaggregates, AoD underwent a gross 4-fold CD45+ cell expansion 


















Figure 5.19: Experimental design to trace pre-HSCs in E11.5 AGM chimeric
reaggregates.
Schematic representation of experimental design for chimeric reaggregates set-ups: WT and
GFP AGM regions were sub-dissected into UGRs, AoD and AoV and cells from the 2



































4 days 5 days 4 days 5 days 
A
B
Figure 5.20:  Haematopoietic expansion potential of AoD in E11.5 AGM region
chimeric reaggregates.
A: AoD contribution to live cell numbers contained in 4 and 5 days chimeric reaggregates.
B: AoD contribution to haematopoietic (CD45+) cell numbers contained in 4 and 5 days
chimeric reaggregates.
Black: AoD; Grey: other (AoV and UGR when appropriate). Data is cumulative of 2
independent experiments, * mark experiment 2.
* * * *
* * * *
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expansion of haematopoietic cells from AoD. AoD reaggregates would be required 
to conclude on the potential enhancing effects of AoV on haematopoietic cell 
expansion. 
 
5.3.5.2. AoD contribution into the LTR-HSC compartment in E11.5 AGM 
chimeric reaggregates 
After 4 or 5 days of culture, chimeric reaggregates were transplanted into 
recipients (0.1 rd/recipient).  
When transplanted with 4 days AGM chimeric reaggregates, 6 out of 6 mice 
(100%) were reconstituted (mean PBC: 78.6%)(Figure 5.21A). AoD contribution in 
these recipients was assessed using the GFP genetic marker. AoD contribution to 
recipient’s PBC was observed in 1 out of 2 experiments (stars in Figure 5.21A) and 
was on average smaller compared to AoV: 12% of the total PBC was AoD-derived 
(Figure 5.21A). When transplanted with 4 days Ao chimeric reaggregates, 4 out of 6 
recipient mice (67%) were reconstituted (mean PBC: 20.2%) and AoD contribution 
represented 7.6% of the recipients’ PBC (Figure 5.21A).  
Similar analysis was performed with 5 days reaggregates. Unpublished data 
showed a plateau in LTR-HSCs numbers in reaggregates after 4 days of culture 
(S.Taoudi, unpublished). It has also been shown that maturation of pre-HSCs into 
LTR-HSCs mainly occurs between 3 and 4 days of culture (Taoudi et al., 2008). In 
view of these data, it was hypothesised that AoD-derived LTR-HSCs may take 
slightly longer to mature. Therefore, additional experiments were performed with 5 
days cultures. 5 days chimeric AGM reaggregates (0.1 rd/recipient) reconstituted 6 
out of 6 recipients (mean PBC: 67.62%) and a similar dose of chimeric Ao 
reaggregate reconstituted 2 out of 6 recipient mice (33%)(mean PBC: 52%)(Figure 
5.21B). In this case, AoD contribution to recipient PBC was observed in the 2 
experiments (Figure 5.21B). In AGM chimeric reaggregates, an average of 38.5% of 
the total PBC was AoD-derived; and in Ao chimeric reaggregates, an average of 9% 
of the total PBC was AoD-derived (Figure 5.21B). The fact that AoD-derived LTR-





















Figure 5.21: AoD contribution to LTR-HSC compartment in E11.5 AGM chimeric
reaggregates.
Peripheral blood chimerism of recipients transplanted with 0.1 dose of reaggregates.
Individual bars correspond to individual recipients.
A: AoD contribution to LTR-HSC compartment in 4 days chimeric reaggregates cultured
for 4 days. Short (6 weeks) and long-term (16 weeks) analysis.
B: AoD contribution to LTR-HSC compartment in 5 days chimeric reaggregates. Short (6
weeks) and long-term (16 weeks) analysis.
Black: AoD; Grey: other (AoV and UGR when appropriate).
Data are cumulative of 2 independent experiments, * mark animals from experiment 2
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out of 2 with 4 days reaggregates) may indicate that AoD-derived LTR-HSCs indeed 
take slightly longer to mature. This hypothesis is supported by the fact that the AoD-
derived chimerism was higher at 5 days than at 4 days (38.5% and 12% in AGM 
reaggregates respectively)(Figure 5.21B). However, additional experiments are 
required to establish whether this observation is a consistent phenomenon.  
Interestingly, comparison of short-term (6 weeks post-transplant) and long-
term (16 weeks-post transplant) showed that AoD-derived chimerism decreased with 
time (Figure 5.21). Reconstitution with 4 days AGM reaggregates showed 20.6% 
AoD-derived chimerism 6 weeks post-transplantation which decreased to 12% 16 
weeks post-transplantation (Figure 5.21A). Similarly, reconstitution with 5 day 
reaggregates gave 45.3% AoD-derived chimerism 6 weeks post-transplantation and 
38.5% 16 weeks post-transplantation (Figure 5.21B). Similar observations were 
made with Ao chimeric reaggregates.  
Thus, these observations show that AoD contains cells which become LTR-
HSCs in appropriate microenvironment, but they seem less competitive than those 
emerging from emerging in the AoV (Taoudi and Medvinsky, 2007). However, 
additional experiments are required to confirm this hypothesis. To assess the 
numbers AoD-derived LTR-HSCs quantitatively; limiting dilution experiments 
would be required.  
 
5.3.5.3. Multilineage contribution of AoD-derived LTR-HSCs from AGM 
chimeric reaggregates  
The multilineage haematopoietic reconstitution of AoD-derived cells in 4 
days AGM and Ao reaggregates cultured was assessed by flow cytometry. More than 
16 weeks post-transplantation, the presence of AoD-derived cells in primary 
recipients was checked by the expression of GFP in haematopoietic tissues 
(peripheral blood, spleen, bone marrow, and thymus). All tissues contained CD45.2 
donor cells in high proportions (ranging from 12 to 90% in the peripheral blood, 
from 2 to 94% in the bone marrow, from 16 to 89% in the spleen, and from 9 to 99% 




















































































































































































































































































































































































































































































































































































































































































































































































































































































Spleen Bon  marrow ThymusBlood
ThymusBo  marrowSpleenBlood
Figure 5.22: Long-term multilineage haematopoietic reconstitution by AoD-derived
LTR-HSCs generated in AGM and Ao chimeric reaggregates.
A: E11.5 AGM chimeric reaggregates donor and AoD derived reconstitution in major
haematopoietic organs (peripheral blood, spleen, bone marrow, and thymus). AoD-derived
contribution was determined based on GFP expression.
A’: Multilineage (myelo-lymphoid) contribution of AoD-derived cells in major
haematopoietic organs (peripheral blood, spleen, bone marrow, and thymus) of recipients.
Events were gated on GFP+ exclusively.
B: E11.5 Ao chimeric reaggregates donor and AoD derived reconstitution in major
haematopoietic organs (peripheral blood, spleen, bone marrow, and thymus). AoD-derived
contribution was determined based on GFP expression.
B’: Multilineage (myelo-lymphoid) contribution of AoD-derived cells in major
haematopoietic organs (peripheral blood, spleen, bone marrow, and thymus) of recipients.
Events were gated on GFP+ exclusively.
Data were collected in high level reconstituted recipients injected with 0.1 dose of
reaggregate each. Plots are representative of 3 recipient mice. Cell viability was determined
by 7-AAD uptake. Quadrants are based on appropriate isotype control (Appendix 3.2) and
values indicate percentages of cells.
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contribution (Figure 5.22A and B). Peripheral blood, spleen and bone marrow 
contained AoD-derived myeloid cells marked by Mac1 and Gr1 and lymphoid cells 
marked by CD3 (T cells), B220 and CD43 (B cells)(Figure 5.22A’ and B’). In the 
thymus, the majority of AoD-derived cells were immature double-positive 
(CD4+CD8+) T cells (Figure 5.22A’ and B’). Thus AoD-derived LTR-HSCs were 
functional, independently on whether AoD was cultured with AoV only (Ao 
reaggregates, Figure 5.22B and B’) or AoV and UGR (AGM reaggregates, Figure 
5.22A and A’).  
 
5.4. Discussion 
5.4.1. Axio-lateral polarity of LTR-HSC development in E11.5 
AGM reaggregates 
 LTR-HSCs localize solely in the Ao of the E11.5 AGM region (de Bruijn et 
al., 2000b; Taoudi and Medvinsky, 2007). However, the presence of LTR-HSCs in 
the E12.5 UGRs and their capacity at E11.5 to induce LTR-HSC formation (de 
Bruijn et al., 2000b) raises the possibilities that either UGR autonomously support 
LTR-HSC formation or pre-HSCs from the Ao have seeded UGRs. Co-culture of Ao 
and UGR as explants does not improve LTR-HSC production from either Ao or 
UGR (de Bruijn et al., 2000b) but does not exclude the possibilities of LTR-HSC 
induction in the Ao by UGRs and vice-versa. Reaggregate culture was used to 
address this question because it allows the production of chimeric “organoids” with 
enhanced cell-cell contacts, whilst maintaining the AGM capacity to produce high 
numbers of LTR-HSCs in response to growth factors. First, I showed that there was 
no axio-lateral polarity in the repartition of haematopoietic cells and progenitors in 
the uncultured E11.5 AGM region as they are evenly distributed between Ao and 
UGRs. Second, I investigated the autonomous haematopoietic potential of the E11.5 
Ao and UGR reaggregates. Contrary to previous observations with explants, the 
E11.5 UGRs in our study were not capable of generating LTR-HSCs while the Ao 
maintained its ability to generate functional LTR-HSCs (from ≈1 to ≈45 in 4 days of 
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culture). This discrepancy could be due to either the mechanical dissociation of 
UGRs in our experiments or due to some contamination with the Ao in previous 
experiments. In my experiments, it was observed that AGM reaggregates 
consistently contained higher LTR-HSC activity than Ao reaggregates. Although 
evaluation of accurate numbers of LTR-HSCs requires limiting dilution experiments, 
these results suggested that both Ao and UGR are required to provide optimal LTR-
HSC expansion in reaggregates.  
 Experiments with E11.5 AGM and Ao chimeric reaggregates were set up in 
order to answer whether the higher LTR-HSC expansion in AGM reaggregates 
compared to Ao reaggregates was due to either 1) stimulatory effects of UGRs on the 
LTR-HSC expansion from the Ao or 2) stimulatory effects of the Ao on LTR-HSC 
formation in the UGR. Tracing of Ao and UGR cells was allowed by using GFP 
expression as a genetic marker. The large majority of the PBC of recipients was Ao-
derived, demonstrating that most pre-HSCs were located in the Ao region. This result 
has two implications: 1) it shows that exposure of the UGR to Ao cells did not 
trigger LTR-HSCs formation from the UGRs; 2) it suggests that UGRs are required 
to support optimal LTR-HSC expansion from Ao in reaggregates. To address the 
latter idea and rule out any “size” effect of the smaller Ao reaggregates, double-sized 
Ao|Ao reaggregates were set up.  Similar LTR-HSC numbers were obtained in Ao 
and Ao|Ao reaggregates. This suggests that UGRs specifically enhance LTR-HSCs 
expansion from a single Ao.  
In addition, my results contradict Myelcult explants data showing that 
juxtaposition of Ao and UGR in explant cultures did not influence LTR-HSC 
development from Ao (de Bruijn et al., 2000b). This discrepancy could have two 
explanations: 1) cell-cell contacts between Ao and UGR cells are required for the 
UGR to stimulate LTR-HSC expansion, or 2) the absence of growth factors in 
Myelocult medium fails to reveal the positive effects of UGR cells on LTR-HSC 
expansion. Near future experiments will address these questions by culturing 
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5.4.2. Dorso-ventral polarity of LTR-HSC development in 
E11.5 AGM reaggregates 
 I have shown that Ao is the site containing the vast majority of pre-HSCs in 
the E11.5 AGM region. The second aspect of this study was to investigate the dorso-
ventral repartition of these pre-HSCs using a similar strategy involving chimeric 
reaggregates.  
In the fresh AGM region, there was no obvious dorso-ventral polarity in the 
repartition of haematopoietic cells and CFU-Cs, confirming previous observations 
(Taoudi and Medvinsky, 2007). More interestingly, there was no dorso-ventral 
polarity of EGFP+ cells in the Ao, implying that AoV and AoD equally express 
Runx1. This argues with the ventral segregation of Runx1 expression in the E11.5 
Ao (North et al., 1999). Although this discrepancy is likely due to a different Runx1 
dose in the murine models used (haploinsufficient in Runx1lz, full dose in 
Runx1EGFP), my observation highlights the AoD as a potential haematopoietic site 
due to its Runx1 expression.    
 In previous experiments DT (containing somites remnants and the notochord) 
was left attached to the AoD. However, surrounding tissues are known to express 
factors, such as sonic hedgehog or VEGF for example, that can influence 
haematopoiesis in the AGM region (Pardanaud and Dieterlen-Lievre, 1999; Peeters 
et al., 2009). In view of these data, the influence of DT on LTR-HSC development 
was investigated in explants cultures. My results suggested that DAGM explants 
contained less LTR-HSCs than AGM explants, thus suggesting that DT has a 
negative influence on LTR-HSC development from the AGM region. Another group 
made a similar conclusion in a recently published paper (Peeters et al., 2009). It will 
be interesting to establish in future if the addition of IL-3, SCF, and Flt3l could by-
pass the inhibitory effects of DT.  
Suboptimal culture conditions at the time (observed by all lab members) most 
likely led to fewer LTR-HSCs in cultures and thus also probably explain the lack of 
reconstitution in AoV explants. The lack of reconstitution from AoD explants even 
when DT was stripped off suggested that AoD cannot generate LTR-HSCs. 
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However, transplantation experiments with higher doses of explants are required to 
detect very low numbers of LTR-HSCs and thus formally conclude on the effect of 
DT on AoD explants. Additionally, preliminary data indicate that DT might have an 
inhibitory effect on the fresh E11.5 AoD but this needs to be confirmed. 
 Evidence so far has shown that LTR-HSC activity is almost exclusively 
located in the E11.5 AoV and the explant culture revealed intrinsic properties of the 
AoV to induce LTR-HSC formation (Taoudi and Medvinsky, 2007). The 
haematopoietic response of AoV when exposed to the AoD or vice versa could not 
be assessed by the explant culture. However, such interactions are present in vivo and 
might play important roles. The reaggregate culture system bypasses such limitations 
and thus was used to assess the possible presence of cells competent to become LTR-
HSCs in the AoD. Chimeric GFP and WT E11.5 AGM and Ao reaggregates were 
cultured in IMDM+ for 4 days and 5 days. Whereas AoD-derived reconstitution was 
observed in 1 out of 2 experiments with 4 days reaggregates, it was observed 
consistently, at high level, in 5 days reaggregates. This suggests that: 1) AoD 
contains pre-HSCs that can mature into LTR-HSCs during reaggregate culture and 2) 
AoD-derived LTR-HSCs might take slightly longer to mature in culture. In addition, 
reconstitution data were similar in 4 and 5 days reaggregates, confirming S.Taoudi’s 
unpublished observations. Interestingly, it also appeared that AoD-derived 
chimerism decreased between short and long term reconstitution analyses, while 
contribution of AoV remained fairly stable. This indicates that AoD-derived LTR-
HSCs have different properties than AoV-derived LTR-HSCs. I also showed that 
AoD-derived LTR-HSCs are functional as they provide multilineage reconstitution in 
recipients. Although these results are promising, further experiments are required to 
generate a set of data that can be analyzed statistically. It will be interesting to 
investigate the numbers and properties of AoD-derived LTR-HSCs by isolating and 
transplanting them. Finally, removal of growth factors will be required to assess 
whether the generation of AoD LTR-HSCs occurs through the exposure of AoV 
microenvironment or the exposure to growth factors. Altogether, the results from this 
study are the first indication that AoD contains cells competent to develop into LTR-
HSC. 
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6. Summary and Perspectives 
6.1. Summary 
This project focused on the reaggregate culture system as a method for 
studying the emergence and expansion of LTR-HSC in the E11.5 AGM region. 
I first demonstrated the reproducibility of this culture system by showing its 
consistent ability for the extensive LTR-HSC expansion. I further characterised E11.5 
AGM reaggregates by showing that the majority of the LTR-HSCs adopted a 
CD45+Sca1+c-kit+CD31med immunophenotype and that IL-3, SCF, and Flt3l are all 
required to achieve maximal LTR-HSC expansion.  
Second, I characterised EGFP expression in the Runx1EGFP adult 
haematopoietic system and in the E11.5 AGM region. The reported pattern of Runx1 
expression in the adult was in agreement with Runx1 reporter models previously 
published (Lorsbach et al., 2004; North et al., 2004). As Runx1 is thought to be 
required for the transition from endothelium to haematopoietic fate, I focused my 
analyses on EGFP expression in LTR-HSC compartment (CD45+c-kit+CD34+VE-
cadherin+) and in non-haematopoietic compartment (CD45-). I identified a population 
of CD45-VE-cadherin- cells that express EGFP in the fresh E11.5 AGM but disappear 
after reaggregate culture. Additionally, preliminary analysis of the LTR-HSC content 
in the E11.5 AGM highlighted the possibility that the transgenic E11.5 AGM region 
contains fewer LTR-HSCs than in the WT.  
In the third part of my project, the use of reaggregate culture system confirmed 
the Ao as the site harbouring the majority of pre-HSC in the E11.5 AGM. Interestingly, 
the close proximity of Ao and UGR cells enhanced the overall LTR-HSC expansion in 
chimeric reaggregates and preliminary data indicated that the UGRs provide support 
for Ao pre-HSC maturation. Additionally, the presence of DT appeared to inhibit LTR-
HSC formation in AGM explant, supporting the idea that dorso-ventral positioning 
information is important for haematopoietic induction. Finally, dorso-ventral analysis 
of the Ao showed that the AoD contains pre-HSCs when cultured in reaggregates. 
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6.2. Ongoing work 
6.2.1. The supportive role of the UGRs for LTR-HSC 
development 
 Preliminary data presented in Chapter 5 indicate that the UGRs provide support 
for LTR-HSC development from the Ao as the culture of multiple Ao did not result in 
the extensive LTR-HSC expansion that is observed with the AGM. Currently, I am 
trying to formally address the role of the UGR in pre-HSC development by setting up 
multiple Ao reaggregates and transplanting the cellular equivalent of 1 Ao. This should 
assess the potential of a single Ao when exposed to UGR, and hopefully confirm that 
UGR have a specific and positive influence.  
 In addition, I am addressing whether the presence of the UGR for maximal 
LTR-HSC expansion is still required in the absence of growth factors. Chapter 3 
demonstrated that a significant LTR-HSC expansion could be achieved without growth 
factors. Because the absence of growth factors should be a situation closer to 
physiological conditions, it will be interesting to understand whether the UGR can 
achieve such positive effects on their own and perhaps will answer why our 
observations differed from what was previously observed (de Bruijn et al., 2000b).  
 Finally, I am also trying to identify the potential factors secreted by the UGRs 
that specifically improve pre-HSC maturation. This is currently assessed by culturing 
Ao as explants and reaggregates in the presence of various exogenous factors. Micro-
array data from S. Rybtsov provided a list of candidate factors that are preferentially 
expressed by the UGR and some candidates are currently being tested. 
 
6.2.2. The haematopoietic potential of AoD 
 Results presented in the second part of Chapter 5 are promising but require 
additional experiments to obtain a larger data set that can be statistically analysed.  
I showed that the presence of dorsal tissue in AGM explants might inhibit LTR-
HSC development. This result is currently being quantitatively assessed and AoD and 
DAoD explants are cultured with and without growth factors. In view of these results, 
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we also are currently trying to reproduce S. Taoudi data by transplanting fresh AoD 
and DAoD to understand whether DT could potentially inhibited AoD engraftment. 
 Additionally, chimeric reaggregates showed that AoD contains pre-HSC that 
could mature when exposed to the AoV microenvironment. My current experiments are 
repeating these experiments in the absence of growth factors to understand whether 
exposure to AoV microenvironment is sufficient to stimulate AoD pre-HSC 
maturation. Near future experiments will also focus on identifying the 
immunophenotype of the pre-HSCs in the AoD.  
 
6.3. Perspectives 
In the future, the reaggregate culture system could prove very useful for 
dissecting developmental processes involved in de-novo LTR-HSC development and 
the data presented in this thesis provide some examples of such applications. For 
example, identifying the immunophenotype of pre-HSCs in the E11.5 AGM region is 
a key to understand the dynamics by which LTR-HSCs emerge in the AGM region 
(Taoudi et al., 2008). Intrinsic proliferative properties of LTR-HSCs in the bone 
marrow have been extensively studied (Bowie et al., 2007b; Bowie et al., 2006; 
Cellot and Sauvageau, 2006; Wilson et al., 2008). However, the processes of LTR-
HSC emergence and pre-HSC maturation are thought to occur exclusively in the 
embryo (Godin and Cumano, 2002). Whilst still subject to controversy, the AGM 
region is the first site harbouring LTR-HSCs during development (Muller et al., 
1994) and has the capacity to support pre-HSC maturation and LTR-HSC expansion 
(Medvinsky and Dzierzak, 1996; Taoudi et al., 2008). While gene inactivation 
studies have shown that such processes are developmentally regulated by various 
genes such as Runx1, SCL, GATA-2, or Lmo-2 for example (Godin and Cumano, 
2002), the exact developmental timepoints and cell types in which such signals are 
required are still unknown. Reaggregate culture system will allow the use of 
transgenic cells and tracing of their developmental potential, and as such will aid 
understanding the processes and stages at which these genes play important roles.  
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Similarly, the reaggregate system also allows identification and manipulation 
of key components of the LTR-HSC niche within the AGM region as shown in 
Chapter 5. Further characterisation of LTR-HSC niche components is of great 
interest in the HSC field because understanding external signals regulating HSC self-
renewal, maintenance, expansion and differentiation is as important as understanding 
the intrinsic properties of HSCs. Studies of niche components in the adult bone 
marrow have highlighted the importance and the complexity of such extrinsic signals 
on LTR-HSCs (Arai et al., 2004; Calvi et al., 2003; Kiel and Morrison, 2008; Nilsson 
et al., 2001; Orford and Scadden, 2008; Warner et al., 2004; Zhang et al., 2003).  In 
the AGM region more precisely, studies with explants and AGM cell lines have 
shown that the AGM microenvironment can support LTR-HSC maintenance, and 
probably induction and expansion (Matsuoka et al., 2001b; Medvinsky and Dzierzak, 
1996; Taoudi et al., 2008; Xu et al., 1998).  A recent study also highlighted the 
importance of dorso-ventral positioning for LTR-HSC expansion in the AGM region 
(Peeters et al., 2009). Importantly, the use of reaggregates in future studies will 
further assess which cells and signals in the AGM microenvironment promote either 
LTR-HSC induction, expansion, or differentiation.  
Most importantly, dissecting biological processes that govern LTR-HSC 
emergence will provide an understanding of how to reproduce such developmental 
mechanisms and induce LTR-HSC formation from alternative sources such as ES 
cells. Despite many attempts to produce LTR-HSCs from ES cells (Tian and 
Kaufman, 2008), no one so far has been able to formally induce and expand LTR-
HSCs. Such scientific advancements will hopefully provide alternative sources of 
LTR-HSCs for the treatments of HSC-related diseases such as leukeamia as well as 


























































































































































































































































Appendix 3.1: E11.5 AGM reaggregate flow cytometry controls.
Single cell suspensions from E11.5 AGM reaggregates were obtained and incubated with
the indicated isotype controls. Antibody stains corresponding to each isotype control are
displayed on the top of each plot.
Cell viability was determined by 7-AAD uptake. Biotin conjugated antibodies were
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Appendix 3.2
Appendix 3.2: Multilineage analysis flow cytometry controls.
Single cell suspensions from organs of primary recipient reconstituted with E11.5 AGM
reaggregate cells were obtained and incubated with the indicated isotype controls. Antibody
stains corresponding to each isotype control are displayed on the top of each plot.
Cell viability was determined by 7-AAD uptake. Biotin conjugated antibodies were
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Appendix 4.1: Adult haematopoietic organs flow cytometry controls.
Single cell suspensions from Runx1WT/WT adult haematopoietic organs were obtained and
incubated with the indicated isotype controls (left of each panel). Single PE stains against
EGFP in Runx1WT/WT organs showing compensation between FL-1 and FL-2 channels (right
of each panel)
A: Adult bone marrow Lin Sca1 c-kit stain flow cytometry controls. Live lin- cells only are
displayed and were gated based on 7-AAD intake and lineage marker exclusion.
B: Adult bone marrow, peripheral blood, and spleen Mac1 Gr1 stain flow cytometry
controls.
C: Adult bone marrow and spleen CD45 Ter119 stain flow cytometry controls.
D: Adult peripheral blood and thymus CD4 CD8 stain flow cytometry controls.
E: Adult bone marrow, peripheral blood, spleen and thymus CD3 B220 stain flow cytometry
controls.
F: Adult bone marrow CD19 B220 stain flow cytometry controls.
Cell viability was determined by 7-AAD uptake. Biotin conjugated antibodies were
















































































































































































































































B  CD45 c-kit
Appendix 4.2
A  CD45 CD34
Appendix 4.2: E11.5 AGM region flow cytometry controls.
Single cell suspensions from Runx1WT/WT adult were obtained and incubated with the
indicated isotype controls (left of each panel). Single PE stains against EGFP in Runx1WT/WT
organs showing compensation between FL-1 and FL-2 channels (right of each panel and
middle of C panel).
A: E11.5 AGM region CD45 CD34 stain flow cytometry controls.
B: E11.5 AGM region CD45 c-kit stain flow cytometry controls.
C: E11.5 AGM region CD45 VE-cadherin CD41stain flow cytometry controls. CD45+ cells
were excluded using anti-CD45 PerCP antibody (right of the panel).
Cell viability was determined by 7-AAD uptake. Biotin conjugated antibodies were

























































































































































































































































Appendix 4.3: E11.5 AGM region CD45 VE-cadherin flow cytometry controls.
Single cell suspensions from Runx1WT/WT adult haematopoietic organs were obtained and
incubated with the indicated isotype controls (left of each panel). Single PE stains against
EGFP in Runx1WT/WT organs showing compensation between FL-1 and FL-2 channels (right
of panels A and C).
A: E11.5 AGM region CD45 VE-cadherin stain flow cytometry controls.
B: E11.5 AGM region sub-compartments (UGR, AoD, and AoV) CD45 VE-cadherin stain
flow cytometry controls.
C: E11.5 AGM reaggregates CD45 VE-cadherin flow cytometry controls.
Cell viability was determined by 7-AAD uptake. Biotin conjugated antibodies were



































donor            ly-5.2/5.2             ly-5.2/5.1              ly-5.1/5.1
(100%)(92%) (58%)
D
Appendix 4.4: Experimental design for a new lineage trace protocol and assessement
of LTR-HSCs expansion potential of Ly-5.1 mice.
A: Control reaggregate system using Ly-5.2/5.2 E11.5 AGM derived donor cells and
transplant into Ly-5.1/5.1 recipient mice.
B: Experimental reaggregates using Ly-5.2/5.1 E11.5 AGM derived donor cells and
transplant into Ly-5.1/5.1 recipient mice.
C: Experimental reaggregates using Ly-5.1/5.1 E11.5 AGM derived donor cells and
transplant into Ly-5.2/5.1 recipient mice.
D: LTR-HSCs expansion in reaggregates generated with Ly-5.2/5.2, Ly-5.2/5.1, and Ly-
5.1/5.1 E11.5 AGM region.
Peripheral blood chimerism of recipients transplanted with 0.01 doses of reaggregates.
Each point represents a single recipient mouse. Recipients were considered reconstituted
when chimerism exceeded 5% at least 12 weeks after transplantation; percentages indicate
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total cells 251081 ± 64147 268664 ± 58812
total live cells 123201 ± 50981 114316 ± 38303
total CD45+ cells 4091 ± 2434 4036 ± 2871




Appendix 5.1: Comparison between E11.5 AGM regions from WT and GFP embryos
and GFP expression in fresh and cultured E11.5 AGM region.
A: Cell composition of E11.5 AGM regions in wild type and aGFP embryos. Data is
representative of 5 independent experiments. Absolute numbers ± standard deviation.
B: Flow cytometric analysis of GFP expression in the endothelial (VE-cadherin+) and
haematopoietic (CD45+) cell fractions of the fresh E11.5 AGM region.
C: Flow cytometric analysis of GFP expression in the endothelial (VE-cadherin+) and
haematopoietic (CD45+) cell fractions of the E11.5 AGM reaggregate.
Black: WT mouse; Green: GFP mouse. Cell viability was determined by 7-AAD uptake. DP:
CD45+VE-cadherin+
dAGM dAoD
total cells 401000 ± 64210 160333 ± 35170
total live cells 189621 ± 63287 116684 ± 22987
total CD45+ cells 5883 ± 3439 1969 ± 170
total VE cadherin+ cells 3012 ± 899 524 ± 42
total DP cells 84 ± 54 30 ± 14
total DN cells 180650 ± 59103 114444 ± 22776
Appendix 5.2
Appendix 5.2: Cell composition of E11.5 fresh dAGM and dAoD.
dAGM and dAoD correspond to AGM and AoD including dorsal tissue (somites remnants
and notochord).
Data is representative of 3-4 independent experiments; absolute numbers ± standard
deviation.
Cell viability was determined by 7-AAD uptake. DP: CD45+VE-cadherin+; DN: CD45-VE-
cadherin-
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